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The established records of the safety of Ormeloxifene along with its favorable 
bioavailability and ability to inhibit rapid cell proliferation in the endometrium during 
embryonic implantation has made it one of the best drug candidates for controlling 
undesirable rapid cell growth such as endometriosis and cancerous tumor conditions. 
Recent studies have confirmed the effectiveness of Ormeloxifene to suppress and inhibit 
epithelial-mesenchymal transition process as evidenced by repression of N-cadherin, slug, 
snail, vimentin, MMPs, β-catenin/TCF-4 transcriptional activity and induce the expression 
of pGSK3b. Recently conducted studies have revealed the dynamic binding of 
ormeloxifene with β-catenin, GSK3b, CDK4, and other downstream EGFR. In this 
communication, a novel Ormeloxifene analogs with inhibitory activities towards epidermal 
growth factor receptor (EGFR) is used to develop a potential drug candidate for the 
treatment of ovarian cancer. Molecular modeling results revealed that the introduction of 
electron withdrawing group at the para position of aromatic at C-3 such as JA-16 increased 
binding affinity in GSK3B binding pocket relative to Ormeloxifene. Substitution of 
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trifluoromethylated moiety on the phenoxy position and incorporation of pyrrolidine side 
chains at C-7 of the benzopyran framework such as JA-15, JA-16, JA-17, and JA-18 
improved the inhibitory activity of the compound in the crystal structure of CDK2 as 
compared to Ormeloxifene. A total of 25 analogs have been synthesized and biologically 
evaluated. Cell proliferation inhibitory assay revealed the ability of JA-15, ORM-Br, and 
JA-28 to inhibit ovarian cancer cell line (A2780) with IC50 of 9µM, 11.2µM, and 17.6µM 
respectively. Cell cycle analysis performed by flow cytometry revealed that JA-15 arrest 
A2780 cells in the G0 – G1 phase. JA-15 showed an increase in the fraction of cells in the 
G0-G1 phase with 61.98% compared to the control with 53.42%. However, JA-28 exhibited 
an increase in the fractions of cells in the G2-M phase with 8.74% relative to 3.52% for 
control. This result indicates that JA-15 has the potential to chemotherapeutic effects 
because it arrests (A2780) ovarian cell cycle in G0-G1 phase. To explore the impact of 
ORM analogs on other cancer cell lines, ORM-Br was tested on cervical cancer cell lines 
(CaSki and SiHa).  Western blot analysis conducted to establish the effect of ORM-Br 
on β-catenin degradation after using translational inhibitor (cycloheximide) showed a 
significant decrease in protein levels of β-catenin in CaSki and SiHa cells relative to 
cycloheximide treatment. The clonogenic assay revealed that ORM-Br suppresses the 
clonogenic potential of CaSki and SiHa cell lines. 
On the other hand, ORM-Br inhibits the migration of cervical cancer cells as predicted by 
agarose bead assay. Boyden chamber and xCELLigence assay revealed that Br-ORM 
inhibits the invasion of cervical cancer (CaSki and SiHa) cells. There was a decrease in the 
expression of nuclear β-catenin in the cytoplasm of cervical cancer cell lines when 
subjected to western blot analysis to detect the protein levels of β-catenin. Cell lysates and 
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western blot analysis conducted for EMT markers and MMPs analysis showed the ability 
of ORM-Br to inhibit the EMT associated markers in both CaSki and SiHa cell lines. The 
knowledge of varying inhibitory activity of JA-15, JA-28, and ORM-Br on multiple 
pathways is a possible lead towards the discovery of potential anticancer agent; we propose 
that ormeloxifene framework can be altered to generate possible drug candidates, which 
can affect multiple targets following multi-faceted drug strategies to combat ovarian 
cancer. 
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Chapter 1 
1 Introduction and Background  
1.1 Drug Discovery and Development  
Before any drug discovery program initiates, there is a disease or clinical conditions 
with no suitable medication available1. Initial research has to be done to generate a 
hypothesis that will result in a biological or therapeutic effect of the disease state. 
Understanding the mechanistic pathway of the disease has led to a dramatic 
improvement in human health, as a result of modern medicine2. Diseases and 
conditions that were thought to be incurable are now treated with highly potent 
medications. However, drug discovery is a long process that involves many 
commitments. It is estimated that about 100,000 drug candidate compounds are 
expected to be screened as wells as numerous clinical trials before a single market drug 
is produced. On the other hand, the cost associated with developing a single drug is 
estimated to be over 1.75 billion dollars3 (Fig 1.1).  
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Figure 1.1. An analysis of the various stages of drug discovery and development process. 
 
The complex processes of drug discovery and development have different steps, tasks, and 
functions. The process can broadly be divided into two major stages. Drug discovery which 
is the first stage involves chemoinformatics, molecular modeling, and chemical synthesis, 
toxicity screening, and clinical studies4. This stage can further be categorized into three 
distinct phases namely: target discovery, lead discovery and lead optimization. Each of 
these stages is designed to establish a scientific link between the biological target and the 
human diseased model intended. The molecular target validation and progression is 
accomplished through the use of molecular probes, designed to identify a series of 
compounds that would alter and modify the activity of the biological target of interest4. 
Once the structurally related compounds with their desired biological activities are 
identified, the lead optimization begins, where many analogs within the lead compound are 
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screened to identify compounds that may progress to the drug development stage. The lead 
optimization (HTS) compounds are then subjected to in vivo studies in various animal 
models and eventually clinical studies to identify their efficacy5.  
Once a single compound is identified, the second primary stage in drug development 
begins, where the compound progress through various studies for its approval by various 
regulatory bodies6(Fig 1.2). 
 
Figure 1.2. The drug discovery and development process. 
 
There is no doubt that the discovery of a new drug has a positive impact on medicine, but 
it is more challenging, time-consuming and is associated with higher cost. 
1.2 Natural products in drug discovery 
Before the existence of modern medicine natural products were the only source of 
medication use by our ancestors to treat wounds and diseases7. Even up to date, some tribes 
in Africa (Akan) chew herbs to relieve pains, wraps herbs on wounds for quick healing, as 
an eye drops to treat various eye diseases and sometimes remove the speck from the eye.  
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Plants, in particular, have played an essential role in traditional medicine system. The 
Egyptian medical papyrus which dates from 1500 BC documents over 700 drugs that 
mostly originated from plants. There was other evidence of the use of approximately 1000 
plant-derived substances in Mesopotamia around 2600 BC of which many are still being 
used today for the treatment of various ailments8.  
Over the centuries, the Chinese Materia Medica (1100 BC,Wu Shi Er Bing Fang, 
containing 52 prescriptions), Shennong Herbal (100 BC, contains about 365 drugs) , the 
Tang Herbal (659 AD; 850 drugs) and the Indian Ayurvedic system dates from about 1000 
BC (Charaka; Sushruta and Samhitas with 341 and 516 drugs respectively) are some of the 
evidence of the extensive use of natural products as drugs9.  
Natural products and their derivatives have been a most active and productive source of 
ingredient in medicines. They have contributed to the development of many drugs for 
various indications and represent a unique and abundant source of therapeutic agents and 
lead structures for new drug discovery.  
According to Alan L Harvey, (2007), up until 1996, about 80% of medicinal products were 
either directly derived from naturally occurring compounds or were inspired by a natural 
product and recent analysis have confirmed that between 1981 and 2002, 28 percent of 868 
new chemical entities were natural products or derived from natural products and another 
24 percent created around a pharmacophore from natural products10. On the other hand, in 
2004, about 70 natural product-related compounds were in clinical trials, and more recent 
analysis confirms the continuing importance of natural products for drug discovery11. 
Based on the recent US prescription data, about 50% most prescribed drugs had a natural 
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product either as drug or as a progenitor in the synthesis or design of the chemical 
agent12(Fig. 1.3).  
 
Figure 1.3 All newly approved drugs 1981−2014; n = 15627 
B = Biological macromolecule, 1997, N = Unaltered natural product, 1997, NB = Botanical 
drug (defined mixture), 2012, ND = Natural product derivative, 1997, S = Synthetic drug, 
1997, S* = Synthetic drug (NP pharmacophore), 1997, V = Vaccine, 2003, S /NM = Mimic 
of natural product, 2003.  
 
 
Despite the challenges and challenging synthetic routes of drugs from natural products, 
technical advancements achieved in the field has helped in the screening and evaluation of 
natural products and has resulted in the improvement of therapeutic efficacy. Also, 
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modifications of active natural products skeletons have led to the discovery of several novel 
agents13. One of these novel agents is Centchroman (ormeloxifene) a selective estrogen 
receptor modulator (SERM), with the ability to suppress cancer cells has become an 
attractive target for the development of future drugs.  
 
 
 
 
1.2.1 Centchroman (Ormeloxifene) 
Ormeloxifene is a nonsteroidal selective estrogen receptor modulator, a class of 
medications which acts on estrogen receptors, was developed by the Central Drug Research 
Institute (CDRI), Lucknow, (India)14. It was introduced 20 years ago as a safe and effective 
oral contraceptive because it is free of the side effects associated with estrogen and 
progestin-based oral contraceptives. It provides an opportunity for effective and efficient 
reversal of fertility once discontinued by the patient. The contraceptive action of 
ormeloxifene mainly depends on its ability to suppress embryonic implantation in the 
uterine wall15. It is marketed in India and some other countries under the trade names saheli, 
central, savista, Novex, and Novex DS.  Ormeloxifene is used as a weekly contraceptive 
which is taken twice per week (30 mg dose) for the first twelve weeks and once every week 
after that. Studies have shown that the standard 60 mg weekly dose can reduce pregnancy 
rate by 38% with about 1-2% failure rate 16. Ormeloxifene with the trade name Savista is 
used to treat dysfunctional uterine bleeding due to its anti-proliferation effect on the uterus 
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which causes endometrial atrophy leading to decrease in uterine bleeding17. Recent reports 
have shown the effectiveness of ormeloxifene in various cancer cell lines and its 
therapeutic effects in other clinical conditions such as dermatitis, uterine fibroid, 
osteoporosis, restenosis, and endometriosis18. Other uses of ormeloxifene are for treatment 
of conditions such as active liver disease, recant history of jaundice and mastalgia19 
 
1.2.1.1 Physical properties of Centchroman (ormeloxifene 
 
Ormeloxifene(1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-chromen-4 
yl)phenoxy)ethyl)pyrrolidine) is a white crystalline solid with molecular weight 457 g/mol 
and has a melting point of 165 -166°C. It is soluble in organic solvents such as Ethyl 
acetate, dichloromethane, chloroform, acetone, methanol, and ethanol, but sparingly 
soluble in water, HCl, NaOH, and isobutanol16. It is a very stable compound under normal 
conditions and can retain its physical characteristics and biological activities for over three 
years when stored in aluminum strips or glass container at room temperature. Previous 
studies have shown that the racemic mixtures of Ormeloxifene can be resolved into D- and 
L- enantiomers with L-isomer showing more receptor binding potency and about two-fold 
higher anti-implantation activity in rat than D and DL- ormeloxifine20 (Fig 1.4) 
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Figure 1.4 Centchroman (Ormeloxifene).                 3D Structure of Ormeloxifene 
 
  
 
1.2.1.2 Chemistry of Centchroman (ormeloxifene) 
Centchroman is antiestrogens of triarylethylene class such as tamoxifen and nafoxidine. 
They show dual behaviors due to the presence of two molecular components in their 
structural framework. Their estrogenic nature is accounted for by a trans-stilbene-like core 
that stimulates diethylstilbestrol, hexestrol, or estradiol and their antiestrogenic property 
are as a result of the presence of ώ-tert-aminoalkoxy) phenyl residue that interferes with 
the initiation of estrogenic activity21. The stereostructure of centchroman –DL has two 
notable conformational structural features and are marketed as racemic mixtures with the 
L-enantiomer being the more potent of the two. Recent structural analysis has predicted 
that the more active L-ormeloxifene has 3R,4R configuration whiles the less active D-
enantiomer has a configuration of 3S,4S (fig 1.5)22.   It has two chain substituents at C-3, 
and C-4 position that is twisted out of a plane from the chroman system and also have 
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distinct chair cyclohexane –like wrinkle at C-2, C-3 and C-4 atoms of chroman system. 
These aryl rings are twisted at 71.5° for C-3 ring and 98.7° for C-4 ring and are more 
extensive than that of other nonsteroidal estrogens like tamoxifen and nafoxidine23. The 
dihedral twist in ormeloxifene can be attributed to the presence of the two aryl substituents 
attached to the tetrahedral centers which are in contrast to the tamoxifen and nafoxidine 
and can form arene double bond conjugation which can enforce ring double bond 
planarity20. 
 
 
 
     
OO
H3C
O
N
CH3
CH3
H
H
(3S,4S)- or d-Centchroman [less active)
OO
H3C
O
N
CH3
CH3
H
H
(3R,4R)- or l-Centchroman [more active)   
Figure 1.5 Enantiomers of l-, and d- Centchroman. 
 
1.2.1.3 Total synthesis of ormeloxifene 
Ormeloxifene (1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-chromen-4 
yl)phenoxy)ethyl)pyrrolidine hydrochloride) was first synthesized by Grignard reaction of  
cis-3-phenyl-4-p-acetoxyphenyl-7-methoxy-3,4-dihydrocoumarin (a) and 
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methylmagnesium iodide with THF as a solvent to produce 2-(3-hydroxy-1-(4-
hydroxyphenyl)-3-methyl-2-phenylbutyl)-5-methoxyphenol (b).  Cyclisation of (b) with 
polyphosphoric acid at a temperature of 75 - 80°C produced 4-(3,4-dihydro-7-methoxy-
2,2-dimethyl-3-phenyl-2H-chromen-4-yl)phenol (c). Condensation of 1-(2-chloroethyl) 
pyrrolidine with potassium carbonate (K2CO3) in acetone at 60 °C yielded 1-(2-(4-
((3R,4R)-3,4-dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-chromen-4-
yl)phenoxy)ethyl)pyrrolidine (d). Further isomerization of (d) with n-butyl lithium in 
dimethyl sulfoxide (DMSO) afforded centchroman (e)24 (Scheme 1.1). There has been 
another alternative and improved synthesis of centchroman over the past years which will 
be elaborated in the next chapter.  
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Scheme 1.1 Total synthesis of centchroman. 
 
1.2.1.4 Resolution of dl-centchroman. 
 
D-Centchroman can be resolved by reacting dl-centchroman with (+)-O, O′-Di-p-toluoyl-
D-tartaric acid ((2S, 3S)-2,3-bis((4-methylbenzoyl)oxy)succinic) acid in dry methanol. 
The mixture is then stirred for 2 hours at room temperature, the solvent is then evaporated 
under reduced pressure and the residue crystallized from methanol to afford d-3,4- trans -
2,2-Dimethyl-3-phenyl-4-[p -(pyrrolidinioethoxy)phenyl]25-7-methoxychroman Di-p-
toluoyl-d-tartrate a colorless crystalline solid.  The d-salt is further extracted with aqueous 
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NaOH (10%) and the organic layer washed with water, dried with anhydrous Na2SO4 and 
concentrated to give d-Centchroman. On the other hand l-Centchroman is resolved by 
adding dl-centchroman and (−)-O, O′-Di-p-toluoyl-L-tartaric acid ( (2R,3R)-2,3-bis((4-
methylbenzoyl)oxy)succinic acid) under similar conditions described above to afford the 
1-3,4-trans-2,2-Dimethyl-3-phenyl-4-[p-(pyrrolidinioethoxy)benzyl]-7-
methoxychromanDi-p-toluoyl-I-tartrate. The L-salt is then extracted with NaOH, and the 
organic layer was washed with water, dried over anhydrous Na2SO4, and concentrated to 
give l- centchroman22.  
 
  
1.2.1.5 Pharmacokinetics and bioavailability of Centchroman. 
Centchroman (ormeloxifene) is a lipophilic drug and possesses both pharmacodynamics 
and pharmacokinetic properties. 26 This drug shows low binding affinity to plasma albumen 
with Kd value of 13.90x 10-6 which is an evidence of its low binding affinity to albumin 
and has no interaction with steroids such as cortisol, testosterone, progesterone, and 
estradiol27. It is clear that centchroman does not compete with steroids to a specific binding 
site and also shows no competition with nonsteroidal agonistics such as diethylstilbestrol 
nor steroidal antagonistic like tamoxifen28.  Studies have demonstrated that the liver 
metabolized centchroman and is quickly excreted from the body through faces29. It has also 
been proved that perfused organs like spleen, liver, and lungs can retain more of this drug 
as compared to the less perfused organs such as muscles and pancreas. 7- Desmethylated 
ormeloxifene, the active metabolite (Scheme 1.2) of centchroman is formed in a matter of 
an hour after a patient has taken the drug and peaks within 24 hours30. A higher 
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concentration of this drug as well as its metabolites can be detected in the spleen, liver, 
lungs, adipose tissues as well as the uterus after administration31. It is factual that 
centchroman and its metabolites accumulate higher in tissues than the plasma and its 
concentration in tissue or plasma is higher compared to its major metabolite30. In human, 
the overall half-life of ormeloxifene and its primary metabolites with either single dose 
administration of 30 mg or 60 mg was detected to be around 168 hours whereas that of rats 
and lower mammals was about 26 hours for 12.5 mg/kg of centchroman32. Studies have 
shown that rats and lower mammals metabolize centchroman faster than humans. The 
maximum serum concentration (Cmax) of centchroman depends on the dose used, for 
instance, 30 mg dose has a Cmax of about 55.53 ± 15.43 ng/ml while 60 mg dose has Cmax 
of 122.57 ± 6.25 ng/ml32.  Also, the Cmax for 30 mg dose (twice a week for 12 weeks) in 
breast cancer patients is 54.98 ± 14.19 ng/ml and 60 mg dose for a month or a year is 135 
± 15.5 ng/ml. The Cmax of Centchroman and its half-life are quite similar in both nursing 
and non–lactating mothers and it is estimated, about 2.5% of the drug is excreted in milk 
but this is less likely to have any physiological effect on a breastfeeding child. No 
significant differences were observed in an amount of drug accumulated or time taken for 
maximum accumulation when multiple repeating doses were administered to adult female 
volunteers33. In rats, a low dosage of centchroman does not affect the hypothalamus-
pituitary-ovarian response, but the opposite occurs at much higher dose34. The above data 
is proof that ormeloxifene is a favorable and safe drug candidate for various health 
problems. 
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1.2.1.6 Structural activity relationship of centchroman 
Anti-implantation, estrogen agnostic, antagonistic and in vitro relative binding affinity 
(RBA) for rat uterine cytosol endoplasmic reticulum (ER) of DL-centchroman has shown 
that when the methoxy group at position C-7 is replaced with a phenolic group improves 
receptor binding affinity35. Therefore, a free OH group at the C-7 position is essential for 
dynamic binding to the estrogen receptor (ER). 7-desmethyl centchroman reported by 
Merck group is also estrogenic24 and has been found to prevent implantation in rats at 0.1 
mg/kg dose between 1-5 days schedule36. Out of the seven metabolites identified in 
centchroman, after its incubation with rat homogenate, 7-desmethyl centchroman was 
found to constitute only about 2.5%. When the piperidine moiety, a characteristic of more 
potent antiestrogens was introduced in the aminoalkoxy side chain, its anti-implantation 
activity did not improve. 
Meanwhile, there was a reduction in relative binding affinity but higher than the methylated 
moiety35.  However, the cis – isoforms show negligible binding affinity35. The receptor 
binding affinity, estrogen antagonistic and anti-implantation activities of centchroman is 
as a result of the pyrrolidinoethoxy side chain at p-4-phenyl position37. The removal of the 
pyrrolidinoethoxy side chain decreases relative binding affinity about tenfold as well as 
losing its anti-implantation activity38. Studies have shown that replacing the pyrrolidine 
residue with diethyl or dimethyl-amino moiety causes a significant decrease in the relative 
binding affinity of the compound as a result of the involvement of hydrocarbon component 
which appears to be in hydrophobic interaction with the receptor38. Transposition of 
pyrrolidinoethoxy moiety to the ortho position on the 4-phenyl ring leads to the total 
decrease relative binding activity or complete loss of receptor activity of centchroman22,39. 
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Replacement of 3-nbutylamino-2-hydroxypropyloxy moiety with tertbutyl-aminoethoxy 
increased the anti-implantation activity of centchroman, 3,4-diaryl coumarins, and 
chromans to 2.5 – 5 fold40. The stereochemistry of  C-3 and C-4 and substitution at C-2 
position offer useful information of stereochemical requirement that influences the optimal 
receptor fit of centchroman39. The relative binding affinity of Centchroman is almost 10-
times greater in C-2 unsubstituted  3,4-trans-chroman and four times greater than 2,3-trans-
2- methylchroman39. A complete loss of receptor affinity was observed when the keto-
group was introduced at the C-2 position in 3,4-diarylchromenes38. Contribution of these 
methyl groups to receptor affinity shows the presence of corresponding hydrophobic 
pocket on receptor fit, though with limited bulk tolerance as evidenced by higher 
diminished receptor affinity of 3,4-trans-2,2-diethylchroman and decrease in anti-
implantation activity by a factor of 20, but its corresponding cis-isomer and its p-4-phenyl 
hydroxy analogs possess no estrogen and anti-implantation activities16.  
Stepwise increase in relative binding activity was observed when α- and β- methyl groups 
were introduced at the C-2 of both cis and trans-3,4-chroman. However, the introduction 
of an additional methyl group resulted in a considerable decrease in receptor binding 
affinity39 and may be as a result of the altered stereochemical relationship between the C-
4 benzene residue and the two methyl moieties of centchroman (Scheme 1.2). 
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Scheme 1.2  Major metabolites of centchroman isolated from rat liver homogenate after 6 
hours incubation. 
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1.2.1.7 Centchroman (ormeloxifene) and hormone-related disorders 
1.2.1.7.1 Abnormal uterine bleeding (AUB)  
Menorrhagia affects about 33% of women at some stage in their life, and its management 
has been a challenging task and available drugs prescribed for this disorder lack consensus 
for medical treatment41. Menorrhagia occurs as a result of uterine abnormalities or large 
fibroid and is sometimes associated with systemic disorders. This condition is sometimes 
called dysfunctional uterine bleeding if the cause of the heavy bleeding is not known41. 
There have been several medical options such as anti-inflammatory drugs, combine 
estrogen and progesterone, Danazol and cyclical combined oral contraceptive pills for the 
treatment of this condition but comes with a high cost and adverse effects42.  
Centchroman is an estrogen antagonistic on uterine and breast tissues, and its effects are 
stimulated on bone, vagina, cardiovascular and the central nervous system. It has been 
revealed that it has no uterine stimulation; it maintains a better function of the brain, lower 
cholesterol level and has no increased risk of breast cancer and prevents bone loss43. The 
effect of centchroman on the management of menorrhagia and endometriosis was observed 
when administered as a contraceptive.   
In recent studies, one hundred women participated in a clinical study; 60 mg of 
ormeloxifene was given to each woman twice a week for three months followed by once a 
week administration for one month. Patients were monitored for six months. Menstrual 
blood loss was observed by a pictorial blood loss assessment chart (PBAC) score as well 
as visual analog scale (VAS)44. The results showed a significant reduction in median PBAC 
score ranging from 252 to 102.8 in patients treated with Ormeloxifene and the presence of 
blood clot reduced from 64 to 12%. On the other hand, the incidence of dysmenorrhea 
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drastically suppressed from 22 to 8% and the mean endometrial thickness was decreased 
from 9.7 to 6.7 mm45. However, there was an increase in PBAC score to 112.7% when 
treatment was stopped after six months but lower than the pretreatment level. There was a 
significant reduction from 64 to 12% in patients with initial passage of clot and massive 
improvement of patients with mild or severe dysmenorrhea (22 to 12%)17. The fact that 
ormeloxifene is a safe and effective therapeutic option for the management of Menorrhagia 
cannot be disputed because of its higher potency and minimal side effects.  
 
1.2.1.7.2 Bone loss (Osteoporosis) 
According to world health organization (WHO), Osteoporosis is a condition where the 
patient spinal bone mineral density (BMD) is less than 2.5 standard deviations below the 
mean of young, average adult of the same gender46. It is a condition of increased concern 
in adults where the bone has been lost to the extent that it is unable to function very well 
to support its regular activities and this may result in the risk of spontaneous or mild trauma 
fractures. This condition is highly observed in postmenopausal women with about 75% 
lifetime risk47. There has been an unmet medical need as a result of yearly increased in the 
number of aged people due to continual increased in life expectancy worldwide. The FDA 
has recently approved many drugs including selective estrogen receptor modulator, Evista, 
that can be used to suppress further bone loss in postmenopausal women, but they are not 
so useful in replacing a significant amount of lost bones48. To treat or prevent osteoporosis 
there has been considerable development of animal models and analytical methods for 
osteoporosis research.  
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It has recently been reported that L-centchroman (Levormeloxifene) is capable of 
preventing bone loss as well as lowering cholesterol level in the rat model and suppress 
uterine stimulation relative to 17 β estradiol49 ‘50. Studies have also shown that L-
centchroman was able to reduce serum cholesterol and biochemical markers of bone 
turnover in postmenopausal women during clinical trials51. On the other hand, 
Ormeloxifene has demonstrated its antiosteoporotic activity as evidenced by 
concentration-dependent inhibitor in PTH –induced resorption of 45Ca from pre-labeled 
chick and rat fetal limb bones with better effect tamoxifen or CDRI-85/287 52.  
1.2.1.7.3 Male infertility 
Administration of 30 mg per day of centchroman in oligospermic men for six weeks 
showed a dramatic increase in sperm count in three individuals with the history of 
infertility. However, there was a decrease in sperm count in one of the patient, while 4 of 
the patients were identified to have lower plasma testosterone with no effect on seminal 
parameters, however, increased in acidic phosphatase and GPC were observed in two of 
the patients 53. Increasing dose of centchroman from 30 to 60 and 120 mg a day (twice a 
week) for six weeks resulted in a significant decreased in sperm count in one of the patients 
during phase II and III of treatment, but the percentage of nonmotile and abnormal 
spermatozoa in all the patients escalated.  No plasma testosterone or seminal acid 
phosphatase, Salic acid, GPC or fructose effect was observed in any of the patients53. The 
epididymal motility and vassal spermatozoa pattern nor testicular histology were not 
affected after up to 10 mg/kg of centchroman was administered throughout the 
spermatogenic cycle in rats. No adverse effect was observed on the testicular tissue in 
cholesterol-clamped rabbits after three weeks of administration of L-centchroman54.   
20 
 
 
 
1.2.1.7.3.1 Regulatory safety studies of centchroman 
1.2.1.7.3.2 Pharmacological effects 
Three months of toxicity studies of centchroman in rats and rhesus monkeys were found to 
be non-toxic. The compound showed no adverse impact on humans during preclinical trial 
up to a dose of 120 mg per day55. Centchroman has a lower ulcerogenic index (0.8) 
compared to phenylbutazone (1.7) and is less likely to cause gastric irritation. Its 
intraperitoneal and oral LD50 is higher compared to phenylbutazone and does not in any 
way produce leucopoenia and eosinopenia as seen in phenylbutazone. Its anti-
inflammation and anti-implantation effect is exerted directly on inflamed tissues and does 
not mediate its weak estrogenic agnostic activity or via pituitary- adrenal axis56. Using 30 
mg weekly dose of centchroman in women for one year did not cause any 
hyperaggregability of platelets.57 The antiaggregatory effects of centchroman are as a result 
of platelet cyclooxygenase inhibition, and it is an evidence of thromboxane–B2 synthesis 
as well as inhibition of in malonaldehyde57’56. No significant effect on thyroid weight, 134I-
uptake, and conversion ratio or excretion rate of 24-hour urinary 17-OH ketosteroids was 
observed when upon five consecutive administration of centchroman to female rhesus 
monkeys58. When the dose of centchroman was increased to 30, 60 and 120 mg/day for six 
weeks in normospermic men, it resulted in decreased in urinary 17 –OH ketosteroids in all 
cases. 53  
1.2.1.7.3.3 Toxicological effect 
Centchroman has shown an excellent therapeutic index, upon 12 months administration in 
rats and rhesus monkey, with no evidence of biochemical, hematological or 
histopathological toxicity. 59 No evidence of congenital abnormalities of fetuses, anomalies 
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or aborting was reported during six weeks of oral administration to rabbits and mice60. DL-
centchroman and its enantiomers possess no mutagenicity, genotoxicity and with a reduced 
toxic effect on known mutagens and no carcinogenic effects have been observed following 
life-term administration to rats61. Ormeloxifene has a few side effects which include 
Delayed menstruation, Nausea, Vomiting, headache and Weight gain62. Also, women with 
the desire of becoming pregnant must discontinue taking the drug.  However, Ormeloxifene 
should not be taken by patients with any of the following problems such as polycystic 
ovarian disease, cervical hyperplasia, the recent history of jaundice or hepatic impairment, 
severe allergic state, TB, renal impairment63.  
1.2.1.7.3.4 Drug-drug interactions  
Oral administration of tetracycline and other non-steroidal anti-inflammation drugs like 
ibuprofen produces no effect on efficacy or terminal half-life of centchroman, but there 
was a significant increase in maximum serum concentration, (Cmax) from 22 to 30 ng/ml 
and decrease tmax from 12 to four hours in rats 
64’16. Similar effects were observed when 
lactic acid bacillus spores were included in the regimen, Cmax increased to 47% and AUC0-
∞ of 34% of centchroman with a drastic reduction in tmax
18. There is, therefore, no known 
drug-drug interaction with centchroman, devoid of side effects and safe for prolonged use.  
1.2.2 Centchroman as an anti-cancer agent 
 The established records of the safety of Ormeloxifene along with its favorable 
bioavailability and ability to inhibit rapid cell proliferation in the endometrium during 
embryonic implantation has made it a potential drug candidate for controlling undesirable 
rapid cell growth such as endometriosis and cancerous tumor conditions65. Previous studies 
have confirmed the effectiveness of Ormeloxifene in preventing and suppressing various 
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cancer cell lines due to its potent estrogen agonist and antagonists functions of the 
reproductive tissues as well as non-reproductive tissues66’67 (Fig.1.6). Investigations have 
revealed that Ormeloxifene induced apoptosis, inhibits Akt/mTOR, signal transducers and 
activators of transcription protein 3 (STAT3) signaling. It can also alter proteins associated 
with cell cycle regulations and DNA damage and inhibits colony forming efficiency of  
Head and neck squamous cell carcinoma (HNSCC) cells68 
 
1.2.3 Ormeloxifene as an anti-breast cancer agent 
Ormeloxifene is known to suppress breast cancer cell migration and invasion in vitro and 
breast cancer metastasis in vivo. In another development, it has been shown that 
Ormeloxifene induces G0/G1 phase cell cycle arrest and cellular apoptosis in human breast 
cancer MDA-MB-231 and MCF-7 cells with IC50 of 10µM and 20µM respectively
69.  On 
the other hand, the migratory and invasion capacity human breast cancer MDA-MB-231 
and mouse mammary cancer 4T1 cells were inhibited upon treatment with ormeloxifene. 
A lower dose of ormeloxifene (< 5M) on breast cancer cells was able to suppress migration 
and invasion of cells while higher dose inhibited cell proliferation and induced apoptosis 
which is evidence that suppression of migration and invasion is independent on cell growth 
or apotosis70. Combination of ormeloxifene with other sensitizing agents such as 
resveratrol and curcumin has also proven to be effective. Combination of these agents 
relatively lowers the concentration of ormeloxifene induced apoptosis in breast cancer 
cells71.  
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1.2.4 Ormeloxifene as anti-head and neck cancer agent  
According to the world health organization, the 6th most common cancer in the world is 
Head and Neck squamous cell carcinoma (HNSCC) with approximately fifty thousand new 
cases diagnosed in the United States alone in 201272. The role of the ER in HNSCC is very 
controversial.  While some previous reports have revealed little to no expression of ER in 
HNSCC because of the controversial role of ER in HNSCC73. Recent investigations have 
shown a significant role for ER in enhancing migration and proliferation of cell in 
HNSCC74. Ormeloxifene has been known to exert its cytotoxicity via ER-dependent and 
ER-independent pathways in cancer cells, and its potential utilization for HNSCC 
treatment has been investigated68.  Dual inhibition of ormeloxifene on Akt and mTOR 
could be a significant therapeutic breakthrough as these signaling pathways are massively 
activated in HNSCC which explains how Akt/mTOR inhibitor effectiveness to overcome 
the effects of feedback loops better than a single inhibitor that selectively targets 
mTOR75’76. It is worth noting that ormeloxifene inhibits multiple HNSCC cell line growth 
by inducing apoptosis through caspase 3 activation.   Treatment with ormeloxifene inhibits 
phosphorylation of Akt which leads to attenuate downstream Akt signaling thereby 
suppressing Akt/mTOR, STAT3 signaling and enhanced p21 and p27 protein expressions 
associated with cell cycle progression77.  These promising in vitro results have shown 
ormeloxifene to be a potential drug candidate for the treatment of HNSCC and warrants 
for further clinical studied. 
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1.2.5 Ormeloxifene as an anti-prostate cancer agent  
The second most common leading cause of cancer death in male is prostate cancer72. ER 
is found in both the stroma and epithelium of the prostate. Studies have revealed estrogen 
as the genesis of prostate cancer. Rising estrogen and decreasing androgen levels in aged 
males triggers prostate cancer, and this is where SERM comes in as a potential treatment 
of prostate cancer where it selectively inhibits ER. There have been several reports where 
tamoxifen, and in combination with other anticancer agents have been used to suppress the 
proliferation of prostate cancer cells78’79. Other SERM such as raloxifene has been reported 
to inhibit prostate cancer cell growth expressing in different levels of ERα and ERβ and 
has efficiently induced apoptosis and inhibited proliferation of prostate cancer cells by 
modulating multiple signaling pathways 80. The use of ormeloxifene as a prostate cancer 
agent has however not been reported, but the initial report has predicted the effectiveness 
of ormeloxifene to arrest androgen-dependent and independent androgen growth of 
prostate cancer cell growth26.   
1.2.6 Ormeloxifene and Chronic Myeloid Leukemia  
Recent studies have revealed that Ormeloxifene induces apoptosis in several leukemia cells 
in a dose-dependent manner especially in K562. 2-DE-gel electrophoresis of K562 cells, 
57% of the cells induced apoptosis when treated with ormeloxifene while 30% of proteins 
belong to cell cycle pathways. Activation of the extracellular signal-regulated kinase 
(ERKs) and further cytochrome C release, leading to mitochondria-mediated caspase-3 
activation are evidence of ormeloxifene-induced apoptosis81. Moreover, Ormeloxifene 
suppresses the proliferation of K562 cells by blocking them in the G0/G1 phase and 
suppressing c-myc promoters via ormeloxifene induced MBP-1 and upregulation of p21 
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expression81. The ability of ormeloxifene to induce apoptosis in K562 cell via 
phosphorylation or ERK and block them in G0/G1 through reciprocal regulation of p21 
and c-myc has been demonstrated81.  
 
 
Figure 1.6  Ormeloxifene efficiently attenuates the growth of multiple types of cancer cells 
Adapted from (Kumar G et al., 2013).  
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1.3 Ovarian Cancer 
Ovarian cancer remains the leading clinical challenge in gynecological oncology. It is 
among the leading cause of death (approximately 140,000 per year) worldwide and 
estimated to be diagnosed in over 220,000 women every year 82. Ovarian cancer is the 
second most frequent malignancy after cancers of the uterine corpus in the United States 
with 20,880 estimated cases each year. About 13,850 women die from ovarian cancer 
annually representing the most common cause of death among women with gynecological 
malignancies83. The lifetime incidence for ovarian cancer is approximately 1.39% ( 1 in 
72) and about 1.04% death risk from ovarian cancer for women living in the united states. 
The higher mortality rate of ovarian cancer is attributed to its late stage of diagnosis as 
approximately 75% of patients present with evidence of metastasis spreads beyond the 
ovaries84.  The median survival rate is as between 24 to 60 month depending on the 
magnitude of residual disease following initial surgery(Fig 1.7)85.   
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Figure 1.7 Survival rates of ovarian cancer in England and Wales (1971-2006) 
 
1.3.1 Classifications of ovarian cancer 
The histological classification of ovarian cancer according to world health organization 
(WHO) is based on the principle of histogenetic of the normal ovary 86. This histogenetic 
classification groups ovarian neoplasms based on their derivation from coelomic surface 
epithelium, germ cells, and mesenchyme (the stroma and the sex cord). Epithelial ovarian 
cancer which is the primary malignant ovarian tumor in adult females and is classified into 
histological categories such as acute, mucinous, endometrioid, clear cell and transitional, 
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squamous, mixed and undifferentiated epithelial tumors87. Lesions that appear in situ in the 
surface epithelium or surface epithelial inclusion glands (SEIG) and preexisting benign 
epithelial ovarian endometriosis and tumors have been described as a possible precursor of 
ovarian surface epithelial lesions.  
1.3.2 Epidemiology   
There has been an increased incident of ovarian cancer in the United States, Europe, and 
Israel with the lowest in Japan and the developing countries88. The incidence of ovarian 
cancer in the united states is higher in Caucasian women than African-American and Asian 
American women88, but there is evidence that the gap is narrowing every year. Compared 
to the native-born women, there is a gradual increased in the cases of ovarian cancer in 
women who migrated from low-risk countries of origin such as Asia to the high-risk 
countries like the United States89.  
1.3.3 Etiology 
1.3.3.1 Family history 
Family history of breast cancer is the most significant risk factor of ovarian cancer. The 
risk of the disease depends on the number of affected relatives as well as their age at 
diagnosis with ovarian or breast cancer25a. Most hereditary ovarian cancer cases occur as a 
result of mutation of BRCA genes, with almost two-thirds of the cases associated with 
BRCA1 gene mutation on chromosome 17q, and the rest linked to BRCA2 mutation found 
on chromosome 13q90. According to U.S. based population studies, the average lifetime 
risk for ovarian cancer is approximately 30% in BRCA1 carriers91. It has been estimated 
that about 5% of all ovarian cancer cases in women under the age of 40 can be associated 
with BRCA1 mutation while 4.4% and 1.1% rate are recorded in women between ages of 
29 
 
 
 
40 to 50 and above 50 years respectively92. However, there is approximately 87% 
cumulative risk of breast cancer in people from high-risk families with BRCA1 at the age 
of 70  91. The risk for ovarian and breast cancers in BRCA2 mutation carriers has been 
reported to be 20% and 84% respectively 93 
1.3.3.2 Reproductive factors 
The concern of ovarian cancer in women is age independent, but late menopause has been 
confirmed to be one of the risk factors of ovarian cancer94. An increased risk of ovarian 
cancer has also been reported in women who have never given birth and therefore infertility 
is one of the significant risk factors for ovarian cancer95. Risk of ovarian cancer and the 
use of infertility drugs has been a considerable concern. There is a significantly increased 
risk of ovarian cancer in women with prolong use of infertility drug as compared to women 
who received a short term treatment96.  
1.3.3.3 Environmental and dietary factors 
 Varieties of factors such as the use of talc in genital hygiene, exposure to radiation, use of 
tobacco, psychotropic medications, the mumps, high-level physical activities97, virus, 
dietary factors, and caffeine consumption, have been associated with ovarian cancer. Other 
studies suggested an excessive use of premenopausal estrogen as the leading risk factor of 
endometrioid ovarian cancer. However, there has not been any proven risk of ovarian 
cancer associated with the use of premenopausal hormone98. Moreover, risk factors such 
as the prior history of pelvic inflammatory disease99, endometriosis and polycystic ovarian 
syndrome100 have been linked to ovarian cancer. 
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1.3.3.4 Pharmacological agents 
The use of oral contraceptive has shown to reduce the risk of ovarian cancer. Studies 
conducted revealed that the use of oral contraceptive by women for 4, 8 and 12 years 
reduces their risk of ovarian cancer by 40%, 53%, and 60%, respectively. Therefore, the 
risk of ovarian cancer decreases with increasing duration of the use of oral contraceptive 
and this protective effect continue to exist even after the patient discontinued use101. Cancer 
and Steroid Hormone studies (CASH) have revealed that women who have never given 
birth and have used an oral contraceptive for five or more years are less prone to ovarian 
cancer risks compared to those who have given birth and have never taken oral 
contraceptives. Prolong use of oral contraceptive (10 years and above) by women with a 
family history of ovarian cancer reduced their risk level below the general population 
baseline102. The use of oral contraceptives for six years or more in women with a high risk 
of BRCA1 and BRCA2 have resulted in about 60% risk reduction103 (Fig 1.8). 
Acetaminophen and synthetic retinoid are the two pharmacological agents believed to 
reduce the risk of ovarian cancer but need to be studied further104.   
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Figure 1.8 Factors Influencing the Risk of ovarian cancer.  
Adapted from Holschneider and Berek, Seminars in Surgical Oncology 2000; 19:3–10 
 
1.3.4 Etiology of ovarian cancer: a proposed mechanism 
The chronic injury and repairs cycle of ovarian surface epithelium (OSE) in connection 
with ovulation can lead to mutation in genes that regulate the OSE growth. A crypt is 
formed on the surface of the ovary lined with epithelial cells; these crypts can break through 
the underlying extracellular matrix during reproductive and premenopausal life and 
become internalized as epithelium line inclusion cyst into the stroma.  Surface epithelial 
cells that are hidden in inclusion cyst in the ovarian stroma during the repair process of 
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OSE are eliminated by apoptosis and as results eliminate the potential sites of ovarian 
tumorigenesis.  However, if the apoptotic elimination process is weekend or damaged, it 
results in the persistence of the inclusion cysts in the stroma leading to exposure of stroma-
derived growth factors, steroids, and intragonadal peptides and cause propagation of 
mutation and proliferation of tumor formation105. 
 Fas/Fas ligand system, a major apoptotic inducer in the immune system is a 48 kDa cell 
membrane protein which is part of tumor necrosis factor (TNF) and a family of nerve 
growth factor (NGF) receptor106. Cells that express Fas can induce apoptosis when they are 
exposed to either Fas ligand or an agonistic monoclonal Fas antibody107. The ovary in 
addition to the immune system, on the other hand, expresses the abundance level of Fas 
mRNA and is active in human and rat ovary108 ‘109. Localization of Fas in the surface of 
epithelial cells section of normal human ovaries has been confirmed, and it has shown to 
express Fas and remain healthy and viable as long as they are prevented from making direct 
contact with the stroma by the underlying connective tissue110. As crypt is internalized and 
inclusion cyst is formed, the barrier becomes disrupted resulting in direct contact formation 
of surface epithelial cells with stromal cells that synthesized Fas ligands. This cell-cell 
contact between the mesenchymal cells with epithelial cells triggers Fas and signal 
transduction pathway induces apoptosis and death of inclusion cyst110. However, the 
persistence of the inclusion cysts in the stroma and onset of tumorigenesis occur when the 
Fas/Fas ligand system fails to operate110.  
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1.3.5 Diagnosis and treatment of ovarian cancer 
1.3.5.1 Diagnosis of ovarian cancer 
The highest fatality rate of ovarian cancer is due to lack of early warning signs, effective 
detection techniques and the successful management of the disease. Many cancer networks 
and health institutions have recommended symptoms that trigger testing for ovarian 
cancer111. Women that show persistent symptoms of loss of appetite, frequent urinating, 
pelvic, abdominal pains, abdominal distension, early satiety, unexpected loss in weight, 
fatigue, change in bowel movement should be tested in the primary care setting and refer 
urgent cases to the secondary care for immediate diagnosis and treatment to enhance 
survival112.  The use of serum markers (such as CEA, CDX2, CA 19-9, AFP, beta-HCG, 
and HE4)   are essential and has improved in the early detection of ovarian cancer. It is 
recommended to conduct sequential testing of serum CA125 followed by abdominopelvic 
ultrasonography if the level of serum CA125 is higher than 35 IU/L and urgently refer 
women diagnosed with ascites and pelvic or abdominal masses for further testing111.  
However, CA125 does not diagnose the early stage of ovarian cancer with high accuracy 
and is prone to false results. As such, the need to identify additional markers is vital to the 
successful management of the disease.  DNA chip technology is used to address this 
problem at the genomic level and provide accessibility to gene expression profiles. The 
studies of changes in proteins that result from pathological lesion such as cancer would, 
however, be the critical source of potential cancer biomarkers113. Sonography screening 
and serum test/imaging, mass spectrometry proteomic approach, the SELDI (surface-
enhanced laser desorption/ ionization)114, and protein chip system appear to be potential 
biomarker discovery and effective tools for ovarian cancer screening (Fig 1.9)115. There is, 
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therefore, a need for a useful tool and techniques to detect early warning signs and 
successful treatment of ovarian cancer 
 
 
Figure 1.9 Floor chart for the diagnosis of ovarian cancer. Adapted from National Institute 
for Health and Care Excellence (NICE) 
 
1.3.5.2 Treatment of ovarian cancer 
The standard treatment of advanced ovarian cancer over the past decades includes surgical 
approaches followed by platinum and alkylating–based chemotherapy116. Manipulation of 
combinations dosages of existing drugs have resulted in marginal gains, but the use of these 
agents in standard therapy has not improved the overall survival of ovarian cancer patients.  
Several clinical controlled trials have predicted the platinum-paclitaxel combination 
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regimen as the initial treatment for advanced ovarian cancer with the responds rate of more 
than 80% and 40-60% complete responses117. However, a number of these patients suffer 
deterioration after a period of improvement (about 18 months)118’119. The disease-free 
period following patients’ responds to the platinum compound is used to group patients 
into different prognoses categories such as platinum-resistant, platinum-sensitive, and 
platinum-refractory diseases. Since the platinum-resistant disease and platinum-refractory 
disease have less than 10-20% response rate to carboplatin, they are further treated with 
other agents such as gemcitabine, liposomal doxorubicin, topotecan, etoposide, and 
hormonal therapies117. The response rate, however, decreases at each subsequent relapse 
leading to drug resistance.   A significant challenge in the treatment of ovarian cancer is 
the failure of current established therapies to treat the disease at the diagnosis stage. Other 
cytotoxic drugs including trabectedin, patupilone, and canfosfamide are recently used to 
overcome drug resistance in ovarian cancer, and the most effective has been the 
combination of trabectedin with doxorubicin120. The agents that currently being used to 
treat ovarian cancer have a different range of mechanical action such as binding to VEGFA 
or VEGF receptors, inhibition of receptor tyrosine kinase activation and downstream 
molecules121.   
1.3.5.2.1 Resistance to chemotherapy  
Resistance to chemotherapy has been a significant threat to the treatment of ovarian cancer. 
This failure in treatment occur in more than 90% of patients with metastatic disease and 
have resulted in many death117. Drug resistance in clinical practice refers to the progressive 
disease that occurs at the dose associated with manageable toxicity. Most of these 
chemotherapeutic agents have very minimal therapeutic index such that small-fold changes 
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in the sensitivity of the patient tumor cells can result in clinical resistant.  Reason for 
chemotherapeutic failure and clinical drug resistance can be categorized into three groups: 
(a) Pharmacokinetic, (b) tumor micro-environmental and (c) and cancer cell specific.  
 
1.3.5.2.1.1 Pharmacokinetic  
It has been established that the fraction of tumor cells killed in many cytotoxic agents is 
proportional to total drug exposure (drug concentration x time of exposure = area under 
the curve (AUC)). Insufficient intratumor drug concentration due to inter-patient 
differences in pharmacokinetic variables in some cases might result in drug resistance. First 
pass metabolism, conversion of prodrugs to active metabolites, renal clearance, hepatic 
drug metabolism, and tumor vascularity are some of the parameters for drug 
resistance122’117. Interpatient variation in drug effect has also been identified as a result of 
a change in gene expression and enzyme polymorphism117. 
1.3.5.2.1.2 Tumor microenvironment 
Tumor microenvironment has been known to modulate tumor cell drug sensitivity while 
hypoxia has been identified to trigger radioresistance, chemoresistance implications123, and 
might be related to cell arrest at G0 phase following hypoxic stress (limited free radicals 
generation, enhanced drug detoxification, increased genomic instability, and HIF1) 
mediated transcriptional activation of survival signals and inhibits apoptosis124. On the 
other hand, stromal cells can induce chemoresistance via antiapoptotic signaling 
pathway.125  
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1.3.5.2.1.3 Cancer- cell-specific 
Tumor- cell-specific mechanisms have been the leading research emphasis on drug 
resistance as well as those that influence drug-target interactions and subsequent cell 
damage. The hypothesis has it that drug resistance develops due to progressively acquired 
somatic mutation or epigenetic changes inside the tumor cells as they develop gradually 
with time126. It is essential to consider the primary effectiveness of cytotoxic agent against 
rapid cell and tumor proliferation where a significant amount of cancer cells are in a 
quiescent state. These quiescence cells, however, show a degree of drug resistance127 (Fig 
1.10). 
1.3.5.2.2 Cellular mechanism of multidrug resistance 
The two main classifications of anticancer drug resistance are those that impair drug 
delivery to tumor cells and those that develop in the cancer cell itself as a result of genetic 
and epigenetic alterations that affect drug sensitivity. Poor absorption of orally 
administrated drugs can lead to impaired drug delivery since it can increase drug 
metabolism or excretion, results in lowering drug level in the blood and reduce diffusion 
of drugs from the blood into the tumor mass128’129. The important of the vasculature of the 
tumor and appropriate pressure gradient for effective drug delivery to cancer has 
extensively been studied 129. Cells that are sensitive to chemotherapy as monolayer cells in 
culture become resistance when transplanted into animal model125; this supports the fact 
that environmental factors such as extracellular matrix or tumor geometry may play a part 
in drug resistance. The growth of cancer cells in cell culture as three-dimensional 
spheroids, imitating their in vivo geometry is another evidence of resistance to cancer 
drugs125. Cancer cell in culture can become resistant to a single or multidrug with similar 
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mechanical action, by altering the cellular target of the drug or increasing the repair of 
drug-induced damage frequent to DNA. Cells that are resistant to a single drug can also 
show cross-resistance to another drug that is different structurally and mechanistically- a 
situation called multi-drug resistant130.  
Many anticancer drugs currently in the market have shown multi-drug resistance problems 
in most cancer patients, and there is an urgent need for new and potent anticancer therapies 
to address the multi-drug resistant problem.   
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Figure 1.10 Drug resistance mechanism130 
 
1.3.6 Molecular targets for the treatment of ovarian cancer 
There has been a various range of molecular targets that have been discovered in different 
arrays of malignancies. Many therapeutic agents have been developed to target multiple 
processes such as cell cycle regulation, angiogenesis, protein translation, apoptosis 
induction, metastasis and signal transduction84 (Fig 1.11). However, there has been no 
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identification of specific gene amplification or gene mutation responsible for progression 
or initiation of the disease. The nonexistence of single pathogenic mutation is a challenge 
for target therapy131 and the need for molecular targeted agents with cytotoxic regimens is 
likely to yield significant benefits towards the treatment of ovarian cancer. These agents 
include non-receptor tyrosine kinase, receptor tyrosine kinases inhibitors (RTK), 
transfereaces, serine-threonine kinases, selective inhibitors with either multiple or dual 
inhibitors, proteases and other pathways. The search for new and active molecular target 
anti-cancer agent for the treatment of ovarian cancer has become a significant area for 
research due to the urgent need to address the problem of drug toxicity and cellular 
resistance. Also, identification of the molecular target is vital for the discovery of potent 
treatment to overcome drug resistance and decreases the side effects. Several types of 
molecular targets for the treatment of ovarian cancer such as Erbb receptor pathway, VEGF 
family of receptors, PARP inhibitors and other pathways are elaborated in the next section.  
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Figure 1.11 Target therapies for ovarian cancer 
1.3.6.1.1 ErbB receptor pathway  
Diverse signaling pathways and biological events are contributed by homo and 
heterodimerization within the ErbB family of RTK which are regulated by this class of 
receptors, and results in the activation of intracellular signaling pathways such as the 
phosphatidylinositol 3- kinase (P13K)-AKT and MAPK (mitogen-activated protein kinase 
pathways that involved in proliferation and survival of cells132’133.  ErbB receptors and 
their ligands initiate tumorigenesis by inducing tumor survival, growth, invasion, 
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migration, vasculogenesis, angiogenesis and drug resistance. Several small molecular 
inhibitors and antibodies have been developed to inhibits various ErbB receptors132’133. 
High levels of several ErbB ligands such as EGF, HB-EGF, TGFα are expressed in ovarian 
cancer which can result in amplification and expression of EGFR and Her2, ErbB3 and 
ErbB4134.  Among the small molecule inhibitors of EGFR are gefitinib and erlotinib.  
Gefitinib as a single agent is well tolerated, but its activity decreased in unscreened patients 
with recurrent ovarian or primary potential carcinoma135. However, the activity of erlotinib 
(similar EGFR inhibitor) marginally increased when used as a monotherapy and was well 
tolerated in patients with refractory, recurrent, EGFR-positive epithelial ovarian tumors 
who exhibited resistant to platinum-based chemotherapy136.    
1.3.6.1.2 VEGF family of receptors 
Vascular endothelial growth factor receptor (VEGFR) and VGFR2 are members of the 
family of RTK activated by vascular endothelial growth factor (VEGFR), an angiogenic 
factor that involves a progression of malignancy and the formation of ascites in ovarian 
cancer. VEGF overexpression corresponds with microvessel density and has been linked 
to inferior survival137’138. Antibody against VEGF in pre-clinical murine models of bearing 
human xenografts was able to suppress and reverse the formation of ascites139. Also, a 
partial combination of VEGF-paclitaxel resulted in potential synergy and inhibited 
apoptosis140. Bevacizumab, a monoclonal antibody and small molecule inhibitors such as 
decoy receptors and sorafenib have been developed against VEGFR and VEGF. 
1.3.6.1.3 c-Kit and PDGFR 
Stem cell factor receptor, platelet-derived growth factor receptor (PDGFR)-α and PDGFR-
β are RTK that stimulate the growth of tumor cell. Various small molecule inhibitors have 
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been developing as novel Abelson (ABL) inhibitors for imatinib mesylate-resistance 
tumors141. Studies have found out that c-kit and PDGFR with their respective ligands are 
expressed in ovarian cancer137. Furthermore, the overall survival rate in patients with 
PDGFR-α positive ovarian cancer is shorter compared to patients with PDGFR-α negative 
tumors138.  
1.3.6.1.4 PARP inhibitors 
PARP is one of the inhibitors that target one of the genes in synthetic lethal pair while other 
is defective (e.g., BCRA mutation), selectively kills the tumor cells while sparing healthy 
cells and create a potential substantial therapeutic window142. Patients with BRCA1 or 
BRCA2 mutation are susceptible with the treatment of PARP inhibitors and has been 
supported by phase II trials of olaparib in patients with germ-line BRCA1 or BRCA2 
mutation ovarian cancer as well as patients with platinum-resistance disease143.  
1.3.6.1.5 Ras/Raf/MEK/ERK pathway 
Activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase-kinase (MEK) signaling pathway by RTK’s, cytokines receptor and integrins is 
reported to suppress tumorigenesis by stimulating tumor growth, matrix degradation 
metalloproteinases (MMP) production and drug resistance144. These pathways are activated 
or mutated via autocrine and paracrine loops in ovarian cancer as well as other cancers. 
Expression of Raf is reported in various ovarian carcinomas, high expression of b-Raf has 
been associated with improved survival while high expression of c-Raf is related to poor 
prognosis145.   
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1.3.6.1.6 PI3K/AKT/mTOR pathway 
The phosphatidylinositol-3-kinase (PI3K) signaling pathway is reported to regulate 
growth-related cellular functions such as transcription membrane trafficking protein 
degradation, translation, and reorganization of the actin cytoskeleton146. Amplification or 
mutation of PI3KCA or ATK occurs in 40% of ovarian cancer cases, which leads to 
phosphorylation of ovarian mTOR and results in tumor cell survival147. PI3K mediates 
angiogenesis as well as vascular permeability in ovarian tumor and is associated with 
regulation of cisplatin resistance in ovarian cancer 148’149. 
1.3.6.1.7 JAK/STAT pathway 
Janus-activated kinase (JAK) family of tyrosine kinases are members of RTK and cytokine 
receptors which subsequently triggers the activation of members of the signal transducer 
and activator of transcription (STAT) family. JAK and STAT pathways regulate cellular 
processes such as cell survival, cell proliferation, angiogenesis and antitumor immunity 
that imitate tumorigenesis150. Overexpression and phosphorylation of STAT3 downstream 
of JAK2 are daily observations in an advanced stage of ovarian cancers151.  Compared with 
early and normal ovarian cancer cells, STAT5 and STAT3 phosphorylation have also been 
reported in endothelial ovarian cancer as well as elevated tumor cell152.  
To understand the interaction between a small molecule and a protein at atomic level which 
allows us to characterize the behavior of compounds in the binding site of the target protein 
as well as predict the fundamental biochemical processes is essential. One of the techniques 
known to assist with the design and predict the interaction of compounds inside the 
molecular target is molecular modeling.    
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1.4 Molecular modeling 
1.4.1 Introduction 
Molecular docking is one of the critical components of structure-based drug design and has 
been used to design potential virtual drug candidates in silico by optimizing lead drug 
candidates targeted against the protein. The lead compound is identified using docking 
algorism that screen for optimal binding mode of the ligand within the active site of the 
macromolecule or a receptor. The purpose of docking in drug discovery is to identify a 
drug candidate that binds strongly to a given protein or receptor than the natural product 
and alter the biochemical process that catalyzes the molecular target153. A library of 
thousands of compounds is screened against a given receptor. This approach, although 
long, allows for cheaper and faster identification of drug candidate for immediate synthesis, 
toxicological studies, and clinical trials. Docking employs energy-based scoring function 
to identify the most stable ligand conformation as it binds to the receptor. The Lower the 
energy score, the better the protein-ligand binding affinity. Molecular docking can, 
therefore, be formulated as optimization of problem during identification of ligand-binding 
mode at the lowest energy. Docking remains one of the challenging issues as a high number 
of possible docking conformations prevents a systematic brute force154. The process starts 
with the applications of docking algorism that present small molecules to the active site 
and create a conformational degree of freedom. The degree of freedom must accurately be 
performed to identify an active and stable conformation for the receptor to achieve a 
docking run for thousands of compounds155. Algorithms are accompanied by scoring 
functions that are designed to predict the biological activity through the evaluation of 
interrelations between compounds and potential targets155  
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1.4.2 Molecular docking approaches 
In docking, the main goal is to predict the best binding mode that allows a compound to fit 
into the binding site of a receptor. Docking involves two independent approaches: (1) 
Simulation approach, where the ligands position, conformation, and configuration are 
separated by certain distance to predict ligand pose within the binding site of a receptor; 
(2) Shape complementary approach, where the ranking is typically an arbitral reflection of 
how well the ligand is expected to bind to the receptor155.  
1.4.3 Molecular representations for docking  
It is essential to consider the representation of protein and ligands before various docking 
is evaluated. There are three underlying receptor representations, and they include (1) 
Atomic, (2) surface and (3) grid156. Atomic representation, among these methods, is the 
only method that is used concurrently with potential energy function during the final 
ranking procedures. Surface-based docking programs, on the other hand, is not used in 
protein-protein docking. These methods align points on the surfaces by minimizing the 
angle between the surfaces of opposing molecules157. The grid methods, however, stores 
information about the energetic contribution of the receptor on the grid point which is read 
during ligand scoring.  
1.4.4 Scoring functions in docking 
 
One of the problems associated with molecular docking is to develop an energy scoring 
function that can accurately describe the protein-ligand interactions. The scoring function 
has three main applications in molecular docking: (1) Determination of site and binding 
mode ligand on protein, (2) Prediction of absolute binding affinity between protein and 
ligand, and (3) virtual library screening. Scoring functions that are commonly used are the 
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field of force, knowledge-based scoring function, consensus core, empirical scoring 
function and the like. However, all scoring functions suffer from a significant size 
dependent on the score, the larger the molecule, the higher the possibility that its score rank 
higher. Also, scoring function ignores entropic effects by assessing the interaction between 
a ligand and a rigid receptor without taking ensemble averages over many structures and 
also ignore the specific solvation and desolvation effects158.  
Molecular docking is one of the essential techniques in the computational methodology of 
drug discovery. It helps to find the appropriate conformational structure that binds to 
protein active site and score a higher binding affinity. Docking process provides a pattern 
or a set of compounds with specific pharmacophores as a result of how they interact with 
the target protein and may result in the discovery of potential drug candidates. Molecular 
docking process imitates by creating a database of molecules and a structure of target 
proteins to identify compounds with higher binding affinity. However, docking may take 
a long time to determine the hit compound which can be optimized to lead compound (LC), 
but it is cost effective technique that protects the research should help in case there is a 
failure to discover the lead compound; the study can go back to the database to find another 
hit molecule159. 
To this end, molecular modeling is one of the essential tool necessary to find the potential 
drug candidate for synthesis and structurally optimized. These candidates can be 
synthesized and biologically evaluated to provide the clinical form of the synthesized 
compounds. Virtual compounds that show higher calculated binding affinity to the 
molecular target can be synthesized and biologically evaluated for their activities.  
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1.5 Biological screening of active compounds  
 
Compounds with high binding affinity during docking must be synthesized and 
biologically screened to ascertain their potency on the targeted molecular receptor. 
Antiproliferation assay is important tools in drug discovery to initially evaluate the anti-
cancer activities of both natural product and synthesized derivatives. The biological assay 
can be performed on living animal (in vivo) or tissues (in vitro)160. Initial Screening of 
potential drug candidate by in vitro assay is less expensive compared to in vivo assay and 
has been used extensively in number primarily anti-cancer evaluations. 
In vitro cytotoxicity assay is one of the most commonly used bioassays that measure the 
50% growth inhibition concentration (IC50) of a specific biological response and the most 
common, convenient and reliable among these methods is MTT assay. In MTT assay, 3-
(4,5 dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide is enzymatically reduced by 
dehydrogenase inside the living cells to form a colored formazan dye161. 
Enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA) are other 
quantitative methods used in drug discovery processes. These methods show antigen-
antibody reactions through color change acquired using enzyme-linked conjugates and 
enzyme substrates that serve to identify the concentration and the presence of molecules 
such as protein, peptides,  hormones, antibody, and antigens in biological fluid162  
Applications of bioassays are essential to the protein and enzymes target as they measure 
the affinity of test compounds for a target receptor and has been used successfully by 
researchers and pharmaceutical for structural optimization, identification of hit and 
candidates molecules. 
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1.6 Project objectives  
 
In this communication, we use ormeloxifene and novel analogs that have inhibitory 
activities towards epidermal growth factor receptor (EGFR) to develop a potential drug 
candidate for the treatment of ovarian cancer. Recent studies have reported the ability of 
ormeloxifene to attenuate the EGFR pathway in ovarian cancer cell lines. However, an 
effort to synthesize ormeloxifene analogs and biologically evaluated in ovarian cancer cell 
lines has not been reported.   
The main objectives for this project are: 
1. Study of ormeloxifene as a potential candidate targeting epidermal growth factor 
(EGFR) pathway towards the treatment of ovarian cancer using in silico molecular 
studies and biological evaluation. 
2. Design a novel ormeloxifene analogs targeting epidermal growth factor receptor 
(EGFR) pathway using molecular docking studies. 
3. Synthesis of novel ormeloxifene analogs  
4. Examine the biological profile of synthesized novel ormeloxifene analogs targeting 
EGFR pathway towards the treatment of ovarian cancer. 
5. Study structural activity relationships of synthesizing novel ormeloxifene analogs.  
Docking studies were conducted to identify various binding modes with the receptors to 
facilitate the design of novel ormeloxifene analogs. The synthetic routes were outlined and 
put into effect using optimal structural design methods where different functionalities were 
installed on C-7, ring D and ring E of ormeloxifene scaffold. Different side chains were 
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installed employing mitsunobu reaction, hydroarylation, and condensation. The biological 
evaluation of the synthesized ormeloxifene analogs was executed to ascertain their 
inhibitory effects towards EGFR pathway.  
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Chapter 2 
Design of Ormeloxifene analogs, a potential drug candidate targeting epidermal 
growth factor Receptor (EGFR) pathway 
2 Introduction 
2.1 Ormeloxifene (Centchroman) 
 
Ormeloxifene is a reversible post-coital/weekly oral contraceptive (half-life 168 hours), 
designed and developed at Central Drug Research Institute (CDRI) Lucknow India. It is 
the only non-steroidal oral contraceptive in clinical use in the world today. Ormeloxifene 
was synthesized in 1967, and pre-clinical and clinical studies were completed in 1989. The 
drug was approved for marketing in 1991, social marketing in 1995 and non-pollinating 
fig wasps (NPFW) in April 20161. It acts by suppressing implantation of the blastocyst in 
endometrium2. Ormeloxifene is the only contraceptive that neither suppresses ovulation 
nor interferes with the hypothalamic-pituitary-ovarian axis. It has a high level of safety, 
and it is virtually free from side effects except for a delay in about 8% menstrual cycles 
which is not confined to any woman3. However, ormeloxifene is currently banned in the 
United States due to the concern of causing cardiovascular problems.  
Ormeloxifene is a white powder with a melting point of 163°C -166°C. It is very stable 
under room temperature. The pyrrolidine moiety in ormeloxifene is optimal and is 
responsible for its antagonistic activity. The receptor binding ability and estrogen agonistic 
activity of ormeloxifene are as a result of its benzopyran base. The strategy has led to the 
development of a pharmacophore model that attributes the differences in effects on the 
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uterus. Ormeloxifene competes with estradiol for binding the cytosol receptors. Unlike 
other SERM, the action of ormeloxifene last longer even after the drug has been 
withdrawn4. Studies have confirmed the effectiveness of ormeloxifene in advanced breast 
cancer cell lines, as well as other tumor cells and one of the advantages, is, it does not 
exhibit progestational, androgenic or antiandrogenic properties and does not affect the 
secretion of some hormones in the usual therapeutic dosage5.  
2.1.1  Ormeloxifene as selective estrogen receptor modulator (SERM) 
 
Estrogen receptors (ER) regulates mammalian hormonal and physiological processes by 
interacting with steroid hormone 17-β-estradiol (E2)6. The two central estrogen receptors 
are ERα and ERβ with each showing distinct expression. ERα is expressed in the bone, 
breast and the uterine while ERβ is distributed in the lungs, prostate, the cardiovascular 
system, and the central nervous system7. Studies have shown that ERs are responsible for 
several estrogen-related diseases such as breast cancer, ovarian cancer, prostate cancer, and 
other inflammatory diseases7b. ER modulators have been used in several hormonal 
replacement therapies (HRT) to treat postmenopausal disease caused by a lack of naturally 
occurring hormones. SERMs are a class of compounds that shows tissues specific 
estrogenic activities with the possibility of selectively exert agonistic or antagonistic 
estrogen-like actions in various tissues 8. One of such SERMs is ormeloxifene, a marked 
ER modulator with estrogenic effect on bone and anti-estrogenic on breast and uterus and 
its ability to suppress uterus and breast cancer has been reported (Fig.2.1 )8. Studies have 
also shown that ormeloxifene can suppress breast and ovarian cancer by targeting EGFR 
pathway9. 
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Figure 2.1  Structure of 17β-estradiol and some selected SERMs 
 
 
2.2 The epidermal growth factor receptor (EGFR).  
 
The family of epidermal growth factor receptor  (EGFR)  is made up of extracellular ligand 
binding domain, an intracellular region which contains kinase domain and single 
transmembrane spanning region (Fig)10’11’12. More than 30 ligands that bind to EGFR have 
been identified in humans, these include EGF and EGF-like ligands, transforming growth 
factor (TGF)-α, and heregulins13 (Fig 2.2). The EGFR become activated after binding with 
a ligand, this leads to a conformational change in the extracellular domain, which results 
in homo or heterodimerization with another EGFR family member. Binding of EGFR to a 
partner mostly depends on many properties such as members of EGRF family in the 
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membrane, type, and proportion ligand and cell lineage which relate in the expression of 
additional members of the signaling processes13’
14. The preferred binding partner of all the 
EGFR family is HER2, while HER3 acts as an obligatory partner which is inactive of its 
own or as a homodimer since it lacks intrinsic kinase activity as a result of mutation of 
critical amino acids in the kinase domain15.  Activation of the EGFR Family member can 
lead to transduction of EGFR signals such as mitogen-activated protein kinase (MAPKs) 
and activated protein kinase B (AKT) which can alter multiple cellular responses such as 
cell proliferation, differentiation, cell survival, and motility16. The EGFR family members 
can also be activated by other signaling proteins such as receptor tyrosine kinase (RTKs), 
tyrosine kinase B receptor (TRKB) and G-protein-coupled receptors (GPCRs)17,18,19.  
 
2.2.1 Targeting the EGFR pathway in ovarian cancer 
 
 In ovarian cancer cells, EGFR and its downstream effectors may be activated directly or 
indirectly by several other signaling molecules. Some functions of antibodies such as their 
action as modulators of the immune response, molecular carriers and pharmacological 
agents that interfere directly with activation of the receptors and its downstream pathways 
can contribute to their effectiveness as anticancer agents20.  Anti-EGFR mAbs used in the 
treatment of ovarian cancer normally binds to the extracellular domain of EGFR21. 
However there are potentially different mechanisms of inhibitions where the antibodies 
prevent ligand binding (wild type EGFR), promotes antibody-receptor complex 
internalization, alter transient decrease of EGFR expression22, inhibits EGFR 
heterodimerization and trigger ubiquitin-mediated degradation23.   The inhibition of EGFR 
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downstream dependent cancer cells can result in decreased TGF-α secretion, angiogenesis, 
cell migration, cell invasion, and apoptotic induction24’25. 
Small molecular inhibitors have been developed using structure-based drug design (such 
as Ormeloxifene) which appear to act intracellularly through ATP binding in the catalytic 
region of the kinase domain and evade an enzymatic activity of the kinase and its 
subsequent downstream signaling effects26. In this communication, we report the 
development of novel ormeloxifene analogs as small molecular inhibitors to suppress 
ovarian cancer cell line via the EGFR pathway (Fig 2.3).   
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Figure 2.2  EGFR pathway Adapted from (Wu et al. 2012 #526) 
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2.3 Mechanism of action of ormeloxifene as cytotoxic agents  
 
Several studies have been conducted on the cytotoxic activity of ormeloxifene on ovarian 
cancer cell lines. It has been reported that ormeloxifene can decrease Akt phosphorylation 
and modulate the expression and localization of CDK2 27. It is believed that the benzopyran 
base structure of ormeloxifene is responsible for its estrogen activity and receptor binding 
ability.  
Recent studies have revealed that ormeloxifene inhibits epithelial-mesenchymal transition 
(EMT) process by suppressing the β-catenin/TCF-4 transcriptional activity and influence 
the expression of Pgsk3β28.  
Currently, Ormeloxifene is being investigated to target the Akt/mTOR/PIK3 pathways, and 
the ability of ormeloxifene to inhibit Akt phosphorylation in Head and neck squamous cell 
carcinomas (HNSCC)29 has been reported.  Activation of mTOR induces phosphorylation 
of effector molecule P70S6K and S6 ribosomal proteins, which effectively results in 
mTOR dependent gene transcription that control cell proliferation, metabolism, and protein 
synthesis 30. The knowledge of varying inhibitory activity of ormeloxifene on multiple 
pathways is a possible lead towards the discovery of potential anticancer agent; we propose 
that ormeloxifene framework can be altered to generate possible drug candidates, which 
can affect multiple targets following multi-faceted drug strategies to combat ovarian 
cancer.  
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2.4 Molecular modeling 
 
Molecular modeling study calculations were achieved using HP Pavilion 27xi with window 
7, Intel ® Core ™ processor, 8.0 GB installed memory (RAM) and 64-bit operating system. 
Open Eye ® scientific software which is semi-flexible docking program was utilized in 
this study. MMF94 semi-empirical calculation was employed to conduct energy 
minimization, followed by processing using OMEGA, FRED, and VIDA applications.  
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Figure 2.3  Proposed ormeloxifene analogs 
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2.4.1 Creating a virtual library 
 
A virtual library of 900 ormeloxifene analogs including ormeloxifene as a standard and 
EGFR inhibitors were prepared and their energy using Chemoffice® 2012. MMF94 energy 
minimization of the compounds was calculated to develop structural conformation (3-D) 
of each compound. 
2.4.2 Using Omega to generate conformers 
 
The energy minimized compounds were converted to *pdb file maintaining all heavy 
atoms.  All the *pdb files were converted into one continuous *pdb file to be used as an 
impute parameters for Omega calculations. Omega produces different conformers of each 
molecule in the virtual library to generate ligand flexibility in a rigid model. Omega 
produces an optimal balance between speed and performance when used in a large library 
of compounds and reproduce the desired conformations31,32. 
2.4.3 Receptor preparation using FRED 
 
The PDB files of receptors such as EGFR (PDB ID # 1M17), GSK3β (PDB ID # 1Q3D), 
ERK (PDB ID # 2OJG), CDK2 (PDB ID # 3QLS), mTOR (PDB ID # 4JSV), Akt (PDP 
ID # 3MV5), PI3K (PDB ID # 3L54), STAT3 (PDB ID # 1BG1), Era (PDB ID # 1A52), 
Erb (PDB ID # 3OLS) were downloaded from the protein data bank (PDB)  (Fig 2.5) and 
were prepared using FRED receptor software. The FRED program uses a search algorithm 
that searches for translations and rotations of each conformer of the ligand within the active 
site at a specific resolution.  
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In the preparation of our receptor, the receptor of interest is loaded into FRED which makes 
receptor application and converts the *pdb file into three-dimensional view (3-D) of the 
receptor chain which includes the binding ligand as well as the co-factors. After locating 
the binding pocket and the co-crystallized ligand, the grid box is generated to a specific 
range, not more than 60,000 A°. In a situation where the grid box requires more than 60,000 
A°, it is divided into two boxes to avoid inaccurate or docking irregularities.  The mode 
selection window finally specified the pocket shape to allow the docking program to 
recognize both the inner and outer contours. The ligand input file and the receptor input 
files are moved into FRED application to initiate molecular docking process. Multiple 
scoring functions such as consensus score, oechemscore, shapeguass, shapegauss3, screen 
score, and PLP were used to achieve a consensus structure. Visual representation, in 3-D 
mode, of docking results, can be obtained using OprnEye® VIDA application. All 
information about OpenEye® FRED application can be found at 
www.eyesopen.com/prpducts.  
 
                        PDB ID: 1M17
Epidermal Growth Factor Receptor 
tyrosine kinase domain with 4-
anilinoquinazoline inhibitor erlotinib         
                   PDB ID:1Q3D
GSK-3 Beta complexed with Staurosporine  
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                PDB ID: 3QL8
CDK2 in complex with inhibitor JWS-6-260  
PDB ID: 4JSV
mTOR kinase structure, mechanism and regulation    
  Figure 2.4 3-D structure of proteins co-crystallized with standard inhibitors, 
(Downloaded from protein data bank) 
 
 
2.5 Results and discussion of molecular modeling 
 
The virtual library of compounds including ormeloxifene and known standard inhibitors 
were docked against 12 different proteins including EGFR and downstream EGFR 
pathways such as Akt, ERK, GSK3β, CDK2, STAT3, mTOR, and others. Ormeloxifene 
analogs were designed base on the benzopyran and the pyrrolidine moieties that are 
responsible for its pharmacological and biological interactions. While maintaining the 
benzopyran base, modifications of the main skeleton were made mainly at three positions. 
Incorporation of various side chains such as methytlhiophene, benzotrifluoride, anisole, 
hydroxylethylphenol, and pyrrolidine side chains at C-7 resulted in alteration of 
pharmacophore of the compound. Also, the para position of 3-phenyl-2H-chromen was 
substituted with halogens as well as stronger activating (electron donating group) OH, NH2, 
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and deactivating (electron withdrawal group) CF3.  Finally, the phenoxy position was 
installed with other functionalities to alter pharmacophore of ormeloxifene scaffold (Fig 
2.4). 
In average, a total of 80 analogs exhibited better receptor-ligand binding affinity (lower 
consensus scores) than the known inhibitors. 
The designed virtual library was grouped into three categories. (1) Installing various 
functionalities such as halogens, electron donating and electron withdrawing groups para 
to 3-phenyl-2H-chromen position while maintaining the rest of ormeloxifene framework 
(Fig 2.6 ).  (2)  Switching the pyrrolidine side chain to C-7 and install electron donating, 
withdrawing and other functional substituents at phenoxy position (Fig 2.7 ) and (3) 
Substituting the ormeloxifene side chain at C-7 and phenoxy position with aromatic 
functional groups as well as hydroxyl, methyl and trifluoromythylated moieties (Fig 2.8). 
Full docking results are discussed in the next sections.  
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Figure 2.5. First set of synthesized compounds containing halogens, electron donating or 
electron withdrawing group para to 3-phenyl-2H-chromen position while maintaining the 
rest of ormeloxifene framework. 
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Figure 2.6 Second synthesized analogs. Switching the pyrrolidine side chain to C-7 and 
install electron donating, withdrawing and other functional substituents at phenoxy 
position  
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Figure 2.7  Third synthesized analogs substituting the ormeloxifene side chain at C-7 and 
phenoxy position with aromatic functional groups as well as hydroxyl, methyl and 
trifluoromythylated moieties 
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2.5.1 Results of molecular modeling of ormeloxifene analogs on cyclin-dependent 
kinase inhibitor protein ( CDK2 ). 
Molecular docking results on CDK2 crystal structure revealed a significant increase in 
binding affinity of ormeloxifene analogs relative to known estrogen receptor modulator 
ormeloxifene (Table 2.1). Replacing the   (ethyl)pyrrolidine moiety at the phenoxy position 
with trifluoromethoxy group and substitution of methoxy group at C-7 with 
(ethyl)pyrrolidine moiety such as in JA_15, JA_16, JA_17, and JA_18 demonstrated 
significant binding mode with CDK2 pocket by forming hydrogen bond with HIS:84: A, 
the same amino acid in CDK2 pocket that ormeloxifene binds to induce its anticancer 
activity. It is fascinating to note that the substitution of halogen at the para position of the 
aromatic ring at C-3 altered the binding affinity of the entire compound in the CDK2 
pocket. As the size of the halogen atom at para position increases (from F to I), the binding 
affinity of the compound in CDK2 pocket decreases. Also, JA_15 which is an 
unsubstituted analog exhibited higher binding affinity relative to the halogenated analogs 
(JA_16, JA_17, JA_18) (Fig 2.9). 
Table 2.1  Sample of consensus score of FRED docking in CDK2 receptor 
VIDA Name VIDA ID PLP Chemgauss3 OEChemscore Screenscore 
Consensus 
Score 
JA_15_8 2 
-
62.1912 -98.9223 -50.9355 -161.426 4 
JA_23_65 3 
-
63.1604 -85.4124 -53.3115 -148.521 9 
JA_18_194 4 
-
55.5819 -94.061 -49.7552 -156.399 15 
JA_31_197 5 
-
58.7091 -78.7798 -50.6628 -138.252 31 
ORM_Me_70 6 
-
58.9203 -88.0918 -48.9543 -130.846 31 
JA_17_124 7 
-
60.2571 -82.0704 -46.9993 -151.993 33 
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JA_30_136 8 
-
54.9044 -82.1141 -49.7006 -133.778 34 
JA_20_91 9 
-
55.1979 -82.9193 -52.6244 -128.111 34 
JA_29_196 10 
-
56.4896 -74.7738 -51.4356 -136.43 37 
JA_22_18 11 
-
57.7173 -76.0436 -49.6441 -141.795 38 
JA_24_136 12 
-
54.9044 -82.1141 -49.7006 -133.778 38 
JA_16_118 13 
-
50.2681 -89.5709 -47.0727 -145.829 41 
JA_19_43 14 
-
51.9849 -86.1558 -49.8197 -128.74 41 
JA_33_173 15 
-
52.6577 -80.5097 -48.3041 -139.799 43 
JA_35_136 16 
-
49.7391 -81.7393 -46.085 -134.599 58 
JA_25_26 17 -52.629 -76.5679 -47.4447 -128.804 63 
JA_28_130 18 
-
52.1154 -73.6299 -49.4652 -122.123 65 
JA_26_58 19 
-
50.8557 -75.0371 -48.8462 -128.441 65 
JA_32_166 20 
-
49.3175 -79.5876 -48.1438 -121.453 68 
JA_34_4 21 
-
48.3862 -71.7791 -48.2779 -130.937 69 
ORM_188 22 
-
46.7276 -86.295 -45.0742 -110.072 69 
JA_27_4 23 
-
48.3862 -71.7791 -48.2779 -130.937 73 
ORM_F_106 24 -54.664 -70.7967 -42.5575 -119.368 79 
ORM_Cl_107 25 
-
46.5579 -78.3947 -41.5806 -103.429 86 
ORM_Br_166 26 
-
36.8834 -79.3884 -41.2741 -92.8488 87 
ORM_I_109 27 
-
30.6345 -79.4347 -40.6518 -85.7905 89 
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Figure 2.8. Ormeloxifene (Gray) and JA_15 (Blue). The two compounds overlaid and 
their nitrogen forming hydrogen bonding with His: 84: A in CDK2 binding pocket 
  
  
Figure 2.9  Ormeloxifene (Gray) and JA_18 (Purple) showing hydrogen bonding with 
His:84: A in CDK2 binding pocket  
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Figure 2.11 ORM-CH3 in fitting inside the hydrophobic pocket of CDK2 with no 
observed hydrogen bonding or non-covalent interaction.  
 
Figure 2.10 ORM (Gray) and ORM-CH3 (Blue) with nitrogen  forming hydrogen 
bonding with His: 84:A in CDK2 pocket 
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Analogs with 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-en-1-yl) phenol at 
C-7 and phenol at C-4 such as JA_24, JA_29, JA_30, and JA_31 showed hydrophobic 
interaction mode in CDK2 pocket. Presence of double bond at C-1’ Position played a 
significant role in binding to the crystal structure of CDK2 as demonstrated in JA_31 and 
JA_29. The binding affinity of JA_31 and JA_29 were significantly higher (lower 
consensus score) compared to the counterparts JA_24, and JA_30. Generally, the ORM-
series (ORM-Br, ORM-Cl, ORM-F, ORM-CH3, ORM-I) (Fig 2.6) of compounds 
displayed an exciting trend in CDK2 binding site. Incorporation of electron donation group 
(EDG) at the para position of aromatic C-3 resulted in higher binding affinity with 
hydrophobic interaction in CDK2 binding pocket as shown in ORM-CH3. However, the 
binding affinity of ORM-series forming hydrogen bond with HIS:84: An in the crystal 
structure of CDK2 binding site decreases when the para position of aromatic C-3 was either 
unsubstituted or substituted with electron withdrawing groups (EWG) such as F, Cl, Br, 
and I as indicated in ORM, ORM-F, ORM-Cl, ORM-Br, ORM-I.  
Analogs such as JA_32, JA_33, and ORM-I showed an outstanding hydrophobic 
interaction and hydrogen bonding with HIS:84: A in the CDK2 pocket and showed a 
drastic decreased in binding mode with the crystal structure of CDK2 when iodine moiety 
was incorporated at the para position of aromatic C-3. The decrease in binding affinity of 
these analogs may be attributed to the larger size of iodine which is sticking out of the 
hydrophobic pocket of CDK2. (Fig 2.13). Analogs with trifluoromethyl group at phenoxy 
position and (ethyl)pyrrolidine moiety at C-7 such as JA_15, JA_18, JA_17, and JA_16 
showed higher binding affinity by forming hydrophobic interaction as well as hydrogen 
bonding in the crystal structure of CDK2. 
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Figure 2.12 JA_23 in CDK2 Pocket with Iodine (purple) sticking out of the hydrophobic 
pocket 
 
Figure 2.13 Ormeloxifene (gray) and JA_31 (yellow) overlaying each other, however, 
JA_31showed no hydrogen bonding in CDK2 binding pocket 
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Figure 2.14. JA_31 forming hydrophobic interactions inside CDK2 binding  Pocket, 
however no hydrogen bonding or non-covalent interactions were observed. 
 
 
Figure 2.15 JA_29 displaying hydrophobic interaction in CDK2 Pocket. The double 
bond on C-1’ improved its receptor binding affinity.  
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In conclusion, analogs with trifluoromethyl group at phenoxy position and 
(ethyl)pyrrolidine moiety at C-7 such as JA_15, JA_16, JA_17, and JA_18 showed higher 
binding affinity by forming hydrophobic interaction as well as hydrogen bonding toward 
the crystal structure of CDK2. Analogs with 4-(3-hydroxypropyl) phenol at C-7 
demonstrated significant binding mode in the CDK2 binding pocket relative to 
ormeloxifene. However, halogenated ormeloxifene although with both hydrogen bonding 
and hydrophobic interactions showed lower in binding activities towards the CDK2 pocket 
compared to Ormeloxifene. Orm_CH3 (Fig 2.12) on the other hand performed better among 
the ORM- series in the CDK2 binding pocket. Finally, analogs with (E)-4-(3-hydroxyprop-
1-en-1-yl) phenol as C-7 such as JA_31 and JA_29 had an outstanding binding affinity 
with the crystal structure of CDK2 than similar analogs with no double bond (Fig 2.16, Fig 
2-17).  
2.5.2 Molecular modeling of ormeloxifene analogs on EGFR  
 
Docking on EGFR showed that, compounds with 4-(3-hydroxypropyl) phenol and (E)-4-
(3-hydroxyprop-1-en-1-yl) phenol at C-7 and phenol at C-4 such as JA_31, JA_29, JA_30, 
JA_33 and JA_24 formed hydrogen bond and hydrophobic interaction in EGFR pocket. 
JA_31 binds significantly with amino acids such as ASP:292: A and THR:291: A in the 
EGFR binding site (Fig 2.18). However, the introduction of bromine atom at C-4’ position 
such as JA_29  (Fig 2.21) led to the loss of hydrogen bonding and reduction in binding 
affinity in EGFR binding pocket and may have something to do with the size of bromine 
and its electron withdrawing effect.  
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The binding affinity of Orm-series such as ORM-CH3, ORM-Cl, ORM-F, and ORM-Br, 
significantly improved by forming a hydrogen bond with THR:291: A inside of EGFR 
pocket in comparison with Ormeloxifene which showed no hydrogen bonding with EGFR. 
 
Figure 2.16  JA_31  (blue) and ORM  forming two hydrogen bonding with THR:291: A 
and ASP;292: A in EGFR binding pocket 
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Figure 2.17  JA_29 (left) with no hydrogen bond and JA-31 (right) with two hydrogen 
bonds in EGFR pocket 
 
Introduction of (ethyl)pyrrolidine moiety at the C-7 position, and installing moieties such 
as anisole and aniline at C-4 as in JA_25 and JA_19 improved binding activities as it 
formed hydrophobic interaction with EGFR binding pocket. But binding affinity with 
EGFR decreases when  phenol and trifluoromethoxy benzene  moieties were installed at 
C-4 position as shown in JA_23,JA_20, JA_15,JA_16, JA_17, JA_18, JA_22 and JA_26 
(Fig 2.17, 2.18, 2.21) Although there was strong hydrogen bonding of JA_15 and JA_17 
with GLU: 234: A in the crystal structure of EGFR, this factor did not improve the binding 
affinities of these analogs in EGFR binding pocket. In the case of the crystal structure of 
EGFR, the trend of halogen atomic size as well as electron donating and electron 
withdrawing groups did not show any consistency. 
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2.5.3 Results of molecular modeling of ormeloxifene analogs on Glycogen synthase 
kinase three beta (GSK3B) 
Molecular docking results of ormeloxifene analogs with GSK3B protein demonstrated 
different binding modes. Analogs with (ethyl)pyrrolidine side chain at C-7 of 
Ormeloxifene scaffolds such as JA_20, JA_25 JA_15, JA_18, JA_19, and JA_17 showed 
both hydrophilic and hydrophobic interactions in GSK3B binding pocket. For instance, 
JA_20 and JA_25 with anisole and aniline respectively at C-4 of Ormeloxifene scaffolds 
showed the highest binding affinity and forms two hydrogen bonds with LYS:85: B and 
ASP:200: B in GSK3B binding pocket (Fig 2.22).  
 
Figure 2.18  JA-20 showing oxygen at position number 1forming two hydrogen bonding 
with GLY:68: B and PHE:201: B  in GSK3B pocket 
 
99 
 
 
 
Meanwhile, analogs with trifluoromethoxy benzene at C-4 of Ormeloxifene scaffold such 
as JA_22, JA_15, and JA_33, formed hydrogen bond with LYS: 85: B and ASP: 200: B 
in GSK3B binding pocket. However, the introduction of halogen at the para position of 
aromatic C-3 such as JA_18, JA_17 resulted in the loss of hydrogen bond with ASP: 200: 
B in GSK3B binding pocket (Fig 2.24). Ormeloxifene analogs with 4-(3-hydroxypropyl) 
phenol at C-7 as shown in JA_33, JA_35, JA_25, 28, JA_22 and JA_28 demonstrated a 
higher binding affinity by forming hydrogen bonds with LYS:85: B and LYS:183: B in 
the GSK3B binding pocket. JA_35, on the other hand, showed an outstanding binding 
affinity in the crystal structure of GSK3B when the C-4 position was substituted with 
aniline which leads to the formation of three hydrogen bonds with LYS: 85: B, LYS: 183: 
B and ASN: 186: B (Fig 2.23).  
 
Figure 2.19. The nitrogen on JA_35 showed hydrogen bonding ASN:186: B. Meanwhile, 
the oxygen at the para position of the aromatic ring formed  hydrogen bond with 
LYS:183: B in GSK3B pocket 
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Also, ORM-series of compounds also performed very well in the crystal structure of 
GSK3B by forming hydrophobic interaction as well as hydrogen bonding relative to 
ormeloxifene. Introduction of halogens at the para position of the aromatic ring at C-3 as 
in ORM-Cl, ORM-F and ORM-Br led to the formation of a hydrogen bond with ASP: 
200: B inside GSK3B binding pocket. Binding affinities of these analogs increase with 
increasing the size of the halogenated substituent in the GSK3B pocket (Fig.2.24). 
 
Figure 2.20. Orm-I forming hydrogen bond with ASP: 200: B in GSK3B pocket. However, 
the large size of iodine caused the loss in receptor binding affinity.  
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Figure 2.21. Oxygen at the para position of JA_24 Formed two hydrogen bonds with 
ASP:200: B and GLU:97; B in the crystal structure of GSK3B. 
  
It is interesting to note that the introduction of phenol at C-4 and substitution of 4-(3-
hydroxypropyl) phenol at the C-7 position of ormeloxifene scaffold resulted in higher 
binding mode with the crystal structure of GS3KB. The hydroxyl group of 4-(3-
hydroxypropyl) phenol JA-24 formed two hydrogen bonds with GLU: 97: B and PHE: 
201: B in the crystal structure of GSK3B (Fig 2.25). 
 
2.5.4 Results of molecular modeling of ormeloxifene analogs on the mammalian 
target of rapamycin (mTOR)   
Molecular modeling of analogs JA_22, JA_19, JA_15, JA_30, JA_29 and JA_23 towards 
mTOR showed various binding modes. The first set of ormeloxifene analogs with 
trifluoromethoxy benzene at C-4 and (ethyl)pyrrolidine side chain at C-7 of Ormeloxifene 
frameworks such as JA_19 and JA_15 performed better compared with Ormeloxifene. 
JA_15 formed three hydrogen bonds with SER:21655: B, LYS:2187: B and THR:2245: 
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B whiles JA_19 exhibited three hydrogen bonds with two amino acids, two bonds with 
THR:2245: B and another bond with LYS:2187: B in mTOR binding pocket (Fig 2.26) 
     
Figure 2.22. JA_19 (Blue) and JA_15 each forming two hydrogen bonding with 
THR:2245: B and  LYS: 2187: B in mTOR binding pocket 
 
The second set of analogs with 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-
en-1-yl) phenol at C-7 and phenol, aniline and anisol moieties at C-4 position such as 
JA_22, JA_29, JA_30, and JA_23 showed better binding affinities relative to 
ormeloxifene. These analogs formed both hydrogen bonds as well as hydrophobic 
interaction with the crystal structure of mTOR (Fig 2.27). 
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Figure 2.23. JA_22 forming hydrogen bonding with LYS:227: B in mTOR binding pocket 
 
The third series of ormeloxifene analogs such as ORM-CH3, ORM-Cl, ORM-F, and 
ORM-Br performed poorly with the crystal structure of mTOR compared to ormeloxifene. 
They showed hydrophobic interaction in the mTOR binding pocket with no hydrogen 
bonding.  
 
2.5.5 Results of molecular modeling of ormeloxifene analogs on ERK 
 
In the crystal structure of ERK, only the first set of ormeloxifene analogs that have anisole, 
phenol and trifluoromethoxy benzene at C-4 and (ethyl)pyrrolidine side chain at C-7 of 
Ormeloxifene scaffolds such as JA_19, JA_17, JA-20, and JA_15 performed better in 
ERK binding pocket as compared to the known inhibitor Ormeloxifene. JA_20 formed a 
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hydrogen bond with ASP: 109: B, meanwhile the remaining analogs formed hydrophobic 
interaction inside ERK pocket(Fig 2.29). 
The second and the third series of ormeloxifene analogs (ORM-series and JA-24 to JA-
31), although they showed both hydrogen bonding and hydrophobic interaction with the 
crystal structure of ERK did not perform better compare to ormeloxifene.  
 
Figure 2.24  JA_19 showing hydrogen bonding with ASP:109: A in ERK binding pocket 
 
 
  
2.5.6 Results of molecular modeling of ormeloxifene analogs on the β-catenin  
 
Molecular docking studies of ormeloxifene analogs on beta-catenin binding pocket 
revealed various binding modes. For instance, analogs with trifluoromethyl at the para 
position of the aromatic ring at C-3 such as JA-33, JA-27, and JA-34 showed higher 
binding affinity towards the beta-catenin binding pocket. However, these analogs only 
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exhibited hydrophobic interaction inside the binding pocket. The reasons for their higher 
binding activities may be attributed to the higher covalent bonding between the tree 
fluorine atom and the receptor binding pocket of beta-catenin (Fig 2.25).  
 
Figure 2.25. JA-33 forming hydrophobic interactions inside beta-catenin binding pocket. 
However, there was no evidence of hydrogen bonding. 
 
Analog ORM-Br (Fig 2.26), among ORM-series, performed relatively better in the beta-
catenin binding pocket with lower consensus score (higher binding affinity) compared to 
ormeloxifene. This analog showed only hydrophobic interactions in the beta-catenin 
binding site. It is interesting to note that analogs with halogens have a higher affinity 
towards beta-catenin. Other analogs without halogens such as ORM-CH3, JA-28, 
performed moderately well inside the beta-catenin binding site with better binding affinity 
than ormeloxifene.  
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Figure 2.26. Visual representation of ORM-Br inside beta-catenin binding pocket. The 
analog fit perfectly  inside the hydrophobic pocket resulting in stronger hydrophobic 
interactions 
 
 
2.6 Conclusion 
 
Molecular modeling is important to approach to identify and discover compounds 
exhibiting high specificity of recent potential drug candidates from the basis of the 
structure-based drug design approach. In our docking studies, the proposed analogs were 
docked against the molecular target that causes ovarian cancer. The in-silico study outlined 
the basis of designing analogs which will filter out and helps us focus on synthesizing with 
higher binding affinity to the molecular targets.  
Molecular docking studies revealed that replacing the methoxy group at C-7 with 
pyrrolidine side chain improved the binding affinity in almost all the receptors downstream 
107 
 
 
 
EGFR (CDK2, ERK, mTOR, GSK3B). Analogs  JA-15, JA_18 and JA_17 showed 
significant binding affinity in all the receptors relative to other analogs. The size of 
halogens, on the other hand, had a significant effect on most of the receptors. For instant 
presences of halogen with larger atomic size such as iodine reduces the binding affinity in 
CDK2 binding pockets while the larger size of halogen favors higher binding affinity in 
GSK3B. Presence of double bonds at C-1’ also played an important role in CDK2, GSK3B 
and EGFR, analogs with double bonds on (E)-4-(3-hydroxyprop-1-en-1-yl)phenol at C-7 
improved the binding affinity in these receptors compared to similar analogs without 
double bonds. Analogs with halogen at the para position of aromatic rings at C-3 and C-4’ 
such as JA-33, JA-34, JA-27, and ORM-Br increased binding affinity in the beta-catenin 
binding pocket.  
On the other hand, docking studies assisted in exploring different aromatic substituents at 
C-4, ortho and meta substituents led to a drastic reduction in binding activity in all the 
receptors. Meanwhile, binding activity in all receptors increases with para-substituted 
aromatic moieties. Also, para-substituted aromatic moieties and trifluoromethoxy benzene 
showed higher binding affinity in all receptors by forming hydrogen bonding and 
hydrophobic interactions. These results help us to assemble various aromatic and aliphatic 
groups at C-7 and C-4 of ormeloxifene scaffold.  
Finally, the result of molecular docking provided an opportunity to outline the synthetic 
schemes towards the installation of different functionalities and side chains on 
ormeloxifene framework. It also proved as a reliable tool for designing drug candidates for 
the inhibition of EGFR, ERK, GSK3B, CDK2, mTOR and all downstream proteins.  
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Chapter 3 
Design, synthesis and biological evaluation of ormeloxifene Analogs: Potential 
Protein kinase inhibitors 
3 Introduction 
 
Despite the recent advancement in diagnosis and improved strategies for the treatment of 
cancer, the disease is still the leading cause of death for much of the world population. The 
occurrence and death rate continues to increase for several cancer types, which is costing 
billions of dollars every year.  The estimated national expenditure for cancer care in the 
United States in 2010 alone was about 125 billion dollars, and it is expected to skyrocket 
to about 156 billion dollars in 20201. Several clinical studies and research on the fight 
against cancer have led to the discovery of many anticancer drugs and therapies. However, 
they are associated with severe side effects and high cost. Among these drugs is Tamoxifen, 
a molecular treatment targeting the estrogen receptor (ER) by a Selective Estrogen 
Receptor Modulator (SERM). The drug is effective in reducing risk of breast cancer but 
also found to increase the risk of adverse effects such as lower-limb lymphedema, increase 
risk of bone loss in premenopausal women, and has been linked to endometrial cancer in 
some women2. The need for a potent and cost-effective drug candidate to fight against the 
proliferation of ovarian cancer has become a significant concern to humanity.  
Ormeloxifene, one of the Selective Estrogen Receptor Modulator (SERM) that acts on the 
estrogen receptor, has been available as an oral contraceptive with trade names Saheli, 
novex-DS, sevista. Studies have shown its effectiveness for abnormal uterine bleeding 
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(AUB), fibroadenomas, and advanced breast cancer with excellent therapeutic index and 
safety for chronic administration3. Anti-tumorigenic effect of ormeloxifene in different 
cancers, such as breast, ovarian, head and neck, and chronic myeloid leukemia had been 
confirmed. To date, there is no proven evidence of an adverse effect, but there are concerns 
that ormeloxifene may cause a delay in menstruation, which has not yet proven4. These 
advantages of ormeloxifene over tamoxifen has made it an excellent candidate for the 
treatment of cancer.  
In previous studies, it was confirmed that ormeloxifene could decrease Akt 
phosphorylation and increase p53 phosphorylation5. Phosphorylation of Akt by PI3K 
activates the protein to signal for cell survival (by resisting apoptosis), proliferation, 
growth, motility, and angiogenesis.  Levels of p53 increase in response to hypoxia or 
physiologic signals that damage DNA, to prevent the progression of the cell cycle and in 
some cases, they promote apoptosis. Phosphorylation of p53 protects it from degradation 
from the Mdm2 protein, hence contributing to the increase of p53 levels in the cell6. Mdm2 
activity is influenced by Akt signaling activity. Akt is one of the many signal-transducing 
proteins among a web of kinases that signal for cell growth and proliferation downstream 
of the EGFR kinase. Cytotoxic activity of ormeloxifene on ovarian cancer cell lines has 
demonstrated its ability to significantly decrease Akt phosphorylation and modulate the 
expression and localization of CDK25. 
 
The standard treatment of ovarian cancer includes surgical approaches followed by 
platinum and alkylating–based chemotherapy7. Manipulation of combinations dosages of 
existing drugs have resulted in marginal gains, but the use of these agents in standard 
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therapy has not improved the overall survival of ovarian cancer patients. Several clinical 
controlled trials have predicted the platinum-paclitaxel combination regimen as the initial 
treatment for advanced ovarian cancer with the responds rate of more than 80% and 40-
60% complete responses8. However, a number of these patients suffer deterioration after a 
period of improvement. The established records of the safety of Ormeloxifene along with 
its favorable bioavailability and ability to inhibit rapid cell proliferation in the endometrium 
during embryonic implantation has made it one of the best drug candidate for controlling 
undesirable rapid cell growth such as endometriosis and cancerous tumor conditions9. 
Previous studies have confirmed the effectiveness of Ormeloxifene in preventing and 
suppressing ovarian cancer cell lines due to its potent estrogen agonist and antagonist’s 
functions of the reproductive tissues as well as non-reproductive tissues10. In this 
communication, a novel ormeloxifene analogs with inhibitory activities towards epidermal 
growth factor receptor (EGFR) is studied to develop a potential drug candidate for the 
treatment of ovarian cancer. Introduction of electron withdrawing groups such as halogens 
at the para position of the aromatic ring at C-3 of the benzopyran framework improved the 
inhibitory activity of the compound in different proteins relative to Ormeloxifene. The 
knowledge of varying inhibitory activity of ormeloxifene on multiple pathways provided a 
possible lead towards the discovery of a potential anticancer agent.  
 
Computational chemistry (Molecular modeling) is a valuable tool that provides an 
understanding of various interactions made by known ligand and to examine the potential 
new interactions of designed ligand11’12. The desire to understand and predict these 
interactions outlined a successful virtual screening, structure-based drug design, and 
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accurate ligand placement proved to be very important12. This tool is vital to determine the 
energy parameters for various molecules. A potential anticancer agent such as 
ormeloxifene was obtained from structural modification of benzopyran framework and 
allowed for the formation of the hypothesis that benzopyran framework containing receptor 
binding affinity and agnostic properties for selective estrogen receptors modulators 
(SERM’S) related to ormeloxifene could be applied to inhibit EGFR pathway (Fig 3.1).  
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Ormeloxifene  
Figure 3.1  Benzopyran, Ormeloxifene, and significant sites for activity 
 
Ormeloxifene has demonstrated a wide range of biological activities as illustrated from the 
antiproliferation activities via ER-dependent and ER-independent pathways on various 
cancer cell lines as well as their potency on different biological pathways10. The pyrrolidine 
moiety in ormeloxifene is favorable and is responsible for its antagonistic activity. The 
receptor binding ability and estrogen agonistic activity of ormeloxifene are due to its 
benzopyran base13. This design by  (Central Drug Research Institute) CDRI led to the 
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development of ormeloxifene which compete with estradiol for binding the cytosol 
receptors3. In our study modification of the structure of ormeloxifene was based on the 
concept of bioisosterism to systematically design and installed different functionalities on 
the ormeloxifene core as well as the benzopyran base to increase the potency and reduce 
any undesirable side effects.  
                                                         
OO
X
O
N
X = CH3 F, Cl, Br, I, OH, NH2  
Figure 3.2. Proposed ormeloxifene analogs  
 
3.1 Results and discussion 
 
3.1.1 Results of molecular docking of Halogenated ormeloxifene on EGFR  and its 
downstream 
                                               
Molecular docking results revealed that introduction of electron donating (particularly 
methyl, amine and hydroxyl) groups at C-4’ as in ORM-CH3, ORM-OH, ORM-NH2 
increased the binding affinity two folds towards EGFR (ORM-CH3, ORM-OH) in 
comparison to ormeloxifene (Fig 3.3), (Table 3.1).  ORM-CH3 (Fig 3.4) formed 
hydrophobic interaction with EGFR binding pocket, but there was no evidence of hydrogen 
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bonding inside EGFR binding pocket.  Installing halogen electron withdrawing groups (F, 
Cl, Br, and I) at C-4’ position as in ORM-F, ORM-Cl, ORM-Br, and ORM-I resulted in 
stronger hydrophobic interactions inside EGFR binding pocket. It is worth mentioning that, 
as the size of halogens on an aromatic ring on C-3 increases, the strength of hydrophobic 
interactions with the crystal structure of EGFR decreases and results in a decrease in 
binding affinity inside the EGFR binding pocket (Increasing binding affinity with 
decreasing size: trend: ORM-I < ORM-Br < ORM-Cl < Orm-F).  Among all the docked 
compounds, ORM-CH3, ORM-OH, ORM-NH2, and ORM-F were identified to have the 
highest calculated binding affinity towards EGFR. Ligand-protein interactions of para-
substituted analogs such as ORM-Br, ORM-F, ORM-OH, ORM-NH2, and ORM-CH3 
had higher binding affinity to EGFR compared to meta and ortho-substituted analogs. 
Molecular docking results revealed that ORM-Br and ORM-F forms hydrogen bond with 
Glu:234: A inside the hydrophobic pocket of Akt kinase via the nitrogen on the pyrrolidine 
group in comparison to ormeloxifene showed no hydrogen bond in the Akt kinase binding 
pocket.  ORM-F, ORM-Cl, ORM-Br, and ORM-I exhibited strong binding affinity as 
they fill the entire hydrophobic pocket of Akt.  Compounds ORM-Br and ORM-I were 
also predicted to have enhanced ligand-protein interactions with GSK3B binding pocket, 
which is also downstream of the EGFR pathway. ORM-Br and ORM-I form hydrogen 
bonding with ASP:200: B as well as strong hydrophobic interactions inside GSK3B 
binding pocket (Fig 3.7).   These results imply that para-substituted halogen analogs are 
more likely to inhibit EGFR pathway activity than ormeloxifene. Also, inside the binding 
pocket of beta-catenin, ORM-Br exhibited outstanding hydrophobic interaction compared 
to ormeloxifene although there was no evidence of hydrogen bonding between beta-catenin 
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and these analogs (Fig. 3.5). All compounds showing lower consensus scores (higher 
binding affinity) will be chemically synthesized to be evaluated biologically as an anti-
cancer candidate (Table 3.1).   
Table 3.1 Sample of consensus score of FRED docking in the EGFR receptor 
VIDA Name VIDA 
ID 
PLP Chemgauss
3 
OEChemsco
re 
Screenscor
e 
Consensu
s Score 
JA_31_1 2 -
45.247 
-68.4535 -38.6503 -104.501 3 
JA_30_39 3 -
44.971
9 
-60.5825 -40.8394 -90.4211 13 
JA_24_39 4 -
44.971
9 
-60.5825 -40.8394 -90.4211 15 
JA_35_39 5 -
44.689
5 
-62.8689 -38.1707 -92.5443 15 
ORM_Me_1
90 
6 -
41.698
6 
-53.6256 -36.454 -106.272 17 
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JA_25_38 7 -
44.758
5 
-57.4479 -34.8473 -101.471 17 
JA_19_38 8 -
42.004
3 
-58.1483 -33.9175 -99.8021 20 
ORM_F_51 9 -
38.690
6 
-45.5903 -35.0408 -96.5411 30 
ORM_Br_51 10 -
39.034
5 
-48.4712 -33.0672 -97.0094 31 
ORM_Cl_52 11 -
36.616
2 
-47.8941 -32.9173 -98.0451 34 
JA_29_122 12 -
33.842
3 
-36.6207 -35.0655 -83.5629 40 
ORM_69 13 -
33.810
4 
-42.1914 -33.7609 -92.4648 40 
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ORM_I_51 14 -
34.144
5 
-41.1615 -33.5722 -76.1835 44 
JA_20_65 15 -
31.000
4 
-54.6548 -30.0644 -68.121 47 
JA_15_175 16 -
17.843
4 
-36.0847 -28.6275 -60.5747 60 
JA_28_177 17 -
20.294
7 
-25.438 -30.9079 -65.3065 61 
JA_23_90 18 -
9.9837 
-34.0844 -31.1391 -31.8667 63 
JA_26_45 19 -
7.8375 
-28.432 -22.4842 -36.7958 68 
JA_17_10 20 -
5.1128 
-31.1933 -17.2967 -41.8368 69 
JA_22_165 21 -
2.1763 
-25.8179 -17.5796 -33.7014 73 
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JA_18_177 22 0.6849 -24.4723 -16.1185 -27.703 80 
JA_16_178 23 24.838
3 
-15.6823 -13.7416 -4.1119 84 
 
 
 
 
Figure 3.3 ORM (purple) and ORM-CH3 (green) overlaying inside hydrophobic pocket 
of EGFR and no hydrogen bonding were observed. 
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Figure 3.4  ORM-CH3 inside the hydrophobic pocket of EGFR with no observed hydrogen 
bonding and non-covalent interactions.  
 
Figure 3.5 ORM and ORM-Br bonding to different amino acids GSK3B binding pocket.  
  
125 
 
 
 
 
Figure 3.6 Orm-Br forming hydrogen bonding with ASP: 200: B in GSK3B binding pocket 
 
Figure 3.7  ORM-I (ash) and ORM-Br (blue) binding to ASP:200: B in GSK3B binding 
pocket. 
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Figure 3.8 ORM-F (left) and ORM-Br (right) in ATK Kinase showing hydrogen bonding 
with Glu: 234: A 
 
Figure 3.9  ORM-Br forming hydrophobic interaction in the β-catenin binding pocket, 
however no hydrogen bond with various amino acids were observed.    
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Figure 3.10  Ormeloxifene and ORM-Br overlaying inside beta-catenin binding pocket; 
however, no hydrogen bonding was observed.  
 
3.1.2 Synthesis of methyl, hydroxyl, amine, and halogenated ormeloxifene 
 
To synthesis of various analogs of ormeloxifene, several synthetic approaches were 
employed to arrive at successful and productive synthetic routes. The initial synthesis 
proceeded using the published synthetic route by suprabhat et al.,1975 (Scheme 3.1) 
where Ormeloxifene was synthesized by Friedel-Crafts like acylation of 4-hydroxybenzoic 
acid and 3-methoxyphenol to give (2-hydroxy-4-methoxyphenyl)(4-
hydroxyphenyl)methanone (a)14’15. Nucleophilic addition-elimination of (a) with 
phenylacetic acid in the presence of triethylamine to produce cis-3-phenyl-4-p-
acetoxyphenyl-7-methoxy-3,4-dihydrocoumarin (b). Grignard reaction of (b) using methyl 
magnesium iodide with THF as a solvent to provide 2-(3-hydroxy-1-(4-hydroxyphenyl)-3-
methyl-2-phenylbutyl)-5-methoxyphenol (c)16. This step gave varieties of side reactions 
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which resulted in low yield. Cyclization of compound (c) with polyphosphoric acid at a 
temperature of 75 - 80°C to produce (d). Condensation of 1-(2-chloroethyl) pyrrolidine 
with potassium carbonate (K2CO3) in acetone at 60 °C yields (e) and isomerization of (e) 
with n-butyl lithium DMSO afforded centchroman (f)17. This synthetic route, although 
successful was discontinued due to the use of unfriendly environmental reagents such as 
polyphosphoric acid, phosphorus trichloride acid, and n-butyl lithium. The reaction was 
also cost ineffective and time-consuming relative to the yield obtained. It was essential to 
find an alternative and improved synthetic procedure with excellent yield, atom economy 
and environmentally friendly.    
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Scheme 3.1 Total synthesis of ormeloxifene (Centchroman), proposed by suprabhat et 
al.,1975  
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Synthesis of Ormeloxifene analogs started again by employing the synthetic procedure 
proposed by XS Ji et al.,1998 ORM-X as outlined in Scheme 2 18’19. Commercially 
available 2, 4-hydroxybenzaldehyde and various derivatives of phenylacetic acid undergo 
nucleophilic addition-elimination in the presence of triethylamine and acetic anhydride to 
give compound (1). Hydrolysis of (1) with triethylamine using methanol as a solvent gave 
compound (2), followed by alkylation using methyl iodide in the presence of K2CO3 and 
acetone to produce (3). Grignard reaction of (3) with methylmagnesium bromide in THF 
produced (4), followed by intramolecular dehydration with TFA and NaHCO3 to give (5)20. 
Hydroarylation of phenol with (5) in benzene and cyclohexane afforded a 1:1 (w/w) 
racemic mixture of D- and L- enantiomers (6). Previous studies17 have shown that these 
racemic mixtures can be resolved into D- and L- enantiomers with L-isomer showing more 
receptor binding potency and about two-fold higher anti-implantation activity in rat than 
D- and DL- ormeloxifene17. The presence of halogens para to the aromatic ring at C-3 
changed the confirmation of ormeloxifene analogs and improved the binding affinity 
toward EGFR binding pocket.  Condensation of (6) with 1-(2-chloroethyl)-pyrrolidine.HCl 
(responsible for antagonistic activity) in the presence of NaH and DMF finally gave the 
titled compounds ORM-X in approximately 70% yield. Analogs such as ORM-Br, ORM-
F, ORM-OH, and ORM-CH3 were synthesized via synthetic route outlined in (Scheme 
3.2) which resulted in higher percentage yield.   On the other hand, Grignard reaction of 
tert-butyl 4-(7-methoxy-2-oxo-2H-chromen-3-yl) phenyl carbamate (3a) produced a lower 
yield (3%) (Scheme 3.3) which resulted in dropping out of this synthetic route (Scheme 
3.3).  
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Scheme 3.2  Reagents and conditions: An improved synthesis of ormeloxifene analogs 
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Scheme 3.3  Synthesis of compound 4a 
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Table 3.2 First series of ormeloxifene analogs showing various substituents at C-4’’ (X) 
position and their percentage yields 
Compound (X) = Halogen, CH3 
  
% Yield 
ORM-F F  85 
ORM-Cl Cl  87 
ORM-Br Br  70 
ORM-I I  68 
ORM-CH3 CH3  86 
ORM-OH                      OH  62 
 
3.1.3 Biological evaluation of ormeloxifene analogs. 
 
The biological assay was conducted to study the antiproliferation of ORM- analogs in 
comparison to standard (ormeloxifene). MTT cell viability assay was first undertaken to 
measure the cytotoxicity and anti-proliferation activity of synthesized analogs.  Among all 
the analogs, ORM-Br showed stronger cytotoxicity on ovarian cancer cell line (A2780) 
with an IC50 value of 11.2 µM relative to ormeloxifene which showed IC50 of 17.5 µM 
(Table 3.2). However, compounds such as ORM-F and ORM-CH3 moderate cytotoxicity 
on ovarian cancer cell lines with IC50 value 36.3 µM and 37.9 µM respectively as compared 
to ormeloxifene. However, compounds such as ORM-Cl, ORM-I, and ORM-OH showed 
no cytotoxicity on ovarian cancer cell lines. This result demonstrated that the presence of 
a bromine atom at the para position of aromatic at C-3 improves the overall cytotoxicity 
activity of the compound on the ovarian cancer cell line. The higher cytotoxicity of Br can 
be explained in two ways. First, the size of the Bromine atom is a perfect fit for receptor 
binding pocket which resulted in the formation of hydrogen bonding with ASP:200: A (Fig 
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3.6). Second, the electronegativity of the Bromine atom on ORM-Br might be a 
contributing factor for its cytotoxicity.  
 
   
Table 3.3  MTT Cell viability results for ORM-analogs tested against A2780  ovarian 
cancer Cell line 
Compound IC50 (𝝁𝑴) Compound IC50 (𝝁𝑴) 
Ormeloxifene 17.5 𝜇𝑀 ORM-CH3 37.9 𝜇𝑀 
ORM-Br 11.2 𝜇𝑀 ORM-I NA 
ORM-F 36.3 𝜇𝑀 ORM-OH NA 
ORM-Cl NA   
 
                         
 
To further understand the anti-proliferation mechanism of ORM-Br, further biological 
assay was conducted using cervical cancer cell lines CaSki and SiHa. Western blot analysis 
was conducted to investigate the effect of ormeloxifene analogs on protein levels of β-
catenin on the ovarian cancer cell line. Ovarian cancer cell (70 – 80% confluent) were 
treated with 10-20mmol/L of ormeloxifene analogs for 72 hours. The control was treated 
with 0.1% DMSO. Total lysates were prepared as reported by M Sikander et al., 2016.  
  
  Western blot analysis conducted to determine the effect of ORM-Br on β-catenin 
degradation, Using ORM-Br and translational inhibitor (cycloheximide) as control, the 
result showed a significant decrease in protein levels of β-catenin in CaSki and SiHa cells 
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relative to cycloheximide treatment (Fig 3.12a). On the other hand, to study the 
effectiveness of ORM-Br on survival and proliferation of cervical cancer cell, clonogenic 
assay was conducted. The results showed that ORM-Br suppresses the clonogenic potential 
of CaSki and SiHa cell lines (Fig 3.13).  Also, ORM-Br inhibits the migration of cervical 
cancer cells as indicated by agarose bead assay (Fig 3.15a). Boyden chamber and 
xCELLigence assay revealed that Br-ORM inhibits the invasion of cervical cancer (CaSki 
and SiHa) cells (Fig 3.17a). There was a decrease in expression of nuclear β-catenin in the 
cytoplasm (Ai and Bi) of cervical cancer cell lines when subjected to western blot analysis 
to detect the protein levels of β-catenin (Fig 3.17b). Also, cell lysates and western blot 
analysis conducted for EMT markers and MMPs analysis showed that ORM-Br inhibits 
the EMT associated markers in both CaSki and SiHa cell lines (Fig 3.18). 
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Figure 3.11. Effect of ORM-Br on β-catenin degradation analyzed by pulse-chase 
experiment. 
 SiHa cells were treated with cycloheximide (CHX: 50 mg) alone or in combination with 
ORM-Br (15 mmol/L) at indicated time points. Protein lysates were prepared and subjected 
to western blot analysis to ascertain the levels of protein of β-catenin in cycloheximide-
treated (top) and ORM-Br and cycloheximide-treated (bottom).   
 
 
 
 
 
A B 
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Figure 3.12. A and B represent the effect of Br-ORM on the clonogenic potential of 
cervical cancer cells. Representative colony images of control and Br-ORM treated CaSki 
(Ai) and SiHa (Bi) cells. The bar graphs represent the quantification of colony formation 
in CaSki (Aii) and SiHa (Bii) cells.  
 
 
 
 
 
 
 
138 
 
 
 
 
 
Figure 3.13  Br-ORM inhibits the growth of cervical cancer (CaSki and SiHa) cells 
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Figure 3.14  (A) Br-ORM inhibits the migration of cervical cancer (CaSki and SiHa) cell. 
 (B)  Effect of ORM-Br on motility potential of CaSki and SiHa cells as predicted by 
agarose bead assay. Images represent the migratory cells (MC) in control, and ORM-Br 
treated groups at 0 and 48 hours. AB means agarose beads. Images magnification were at 
4.   
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Figure 3.15  Effect of ORM-Br on the invasion of CaSki and SiHa cell lines in the Boyden 
chamber and xCELLigence assay. Images represent the invaded cells of control and ORM-
Br-treated CaSki and SiHa cells as determined by Boyden Chamber kit. Image 
magnification was set at 20.  
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Figure 3.16  Effect of ORM-Br on β-catenin distribution in the cytoplasm and nucleus of 
CaSki and SiHa cell lines. Cells were subjected to treatment with a 15µM concentration of 
ORM-Br for 24 hours, nuclear extracts were prepared, and western blot analysis was used 
to detect the protein levels of β-catenin. The results revealed a decrease in the expression 
of nuclear β-catenin and increased expression of β-catenin in the cytoplasm (Ai and Bi) of 
CaSki and SiHa cells. Western blots were reprobed with β-actin and Histone H3 antibodies 
as an internal control. Effect of ORM-Br on β-catenin localization in CaSki cells as 
illustrated by confocal microscopy (c).  
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Figure 3.17. Effect of ORM-Br on EMT markers. About 70% of confluent SiHa and CaSki 
were treated with ORM-Br (10-20 mmol/L) for 24 hours. Cell lysates were prepared, and 
western blot analysis was conducted for EMT markers and MMPs analysis. Effect of 
ORM-Br on protein levels of cell-cycle regulatory proteins (cyclin E1 and p27) in both 
CaSki and SiHa cell lines.  
 
 
3.2 Conclusion 
 
In summary, analogs of ormeloxifene ORM-F, ORM-Br, ORM-Cl, ORM-I, ORM-OH, and 
ORM-CH3 were designed using structural based drug design (SBDD). Docking studies 
revealed that the installation of halogens on the ormeloxifene scaffold improved both 
binding affinity in GSK3B, EGFR, and CDK2 binding pockets and, this prediction was 
also confirmed by biological evaluation. The IC50 of ORM-Br (11.2 µM) was superior to 
all other analogs including ormeloxifene in MTT analysis.  Further biological studies 
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confirmed that ORM-Br inhibits the localization and invasion of β-catenin in cervical 
cancer cell lines. We, therefore, conclude that it is essential to conduct further studies on 
the potency of ORM-Br on various cancer cell lines.  
 
3.3 Experimental section 
 
3.3.1 General  
 
Based on the current literature and related organic synthetic approach, various synthetic 
routes were optimized for the synthesis of halogenated ormeloxifene analogs. Standard 
spectroscopic, analytical and chromatographic procedures were employed to achieve better 
results. The melting points were determined using Meltemp apparatus was used and 
uncorrected. Analytical TLC was performed using silica gel with a fluorescent indicator 
coated on a 1x3 inch flexible plate with 0.2 mm thickness. Column chromatography 
separations were carried out on standard silica gel 60-120 mesh. IR spectra  were performed 
with a Perkin Elmer Spectrum one FT-IR Spectrometer and all solid samples recorded 
using a salt plate. The molecular weights of the compounds were determined on a high-
performance Varian 500-MS.  1H NMR and 13C NMR were conducted using Bruker 
Avance – 600, 400 MHz Spectrometer. The samples were dissolved in CDCL3 containing 
0.03% tetramethylsilane (TMS) as internal standard and chemical shift recorded in δ (ppm) 
relative to tetramethylsilane signal. Coupling constant (J) was measured in Hz and the 
multiplicities of the signals recorded as follows: singlet(s), doublet (d) doublet of doublet 
(dd), triplet (t), and multiple (m).  The chemicals obtained from Aldrich and Fisher 
Scientific were used without purification. 
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3.3.2 Synthesis of 3-(4-bromophenyl)-2-oxo-2H-chromen-7-yl acetate 
 
HO
O
+
OH
HO O
Br
Acetic anhydride
Et3N, 127 °C, 84% O
O
O
Br
O
1  
 
To a round bottom flask with a stir bar under nitrogen was added 2, 4-
dihydroxybenzaldehyde (5g, 36.20 mmol) followed by 4-bromophenylacetic acid (5.1g, 
23.72 mmol) and acetic anhydride (11.30ml). Triethylamine (6.6 ml, 65.22 mmol) was 
slowly added, and the mixture was refluxed at 127°C for 7 hours. The reaction was 
monitored by TLC till completion and quenched with distilled water (89 ml) to give a gray 
solid. The solid was crushed and recrystallized using methanol (100 ml) to afford (7.2g) 
84% of the desired product as white solid.  
 
 1H NMR (400Mz, CDCl3, δ ppm) 2.25 (s, 3H), 6.99 (s, 1H), 7.03 (d, J = 2.27, 1H), 7.07 
(d, J = 2.27), 7.19 (s, 1H), 7.46 (d, J = 8.56), 7.72 (s, 1H).  13C NMR (400Mz, CDCl3 δ 
ppm) 168, 160, 154.1, 153.3, 139.5, 133.4, 131.8, 130.3, 128.9, 126.5, 123.3, 118.7, 117.3, 
109.9, 20.9. 
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3.3.3 Synthesis of 3-(4-Bromo-phenyl)-7-hydroxy-chromen-2-one 
 
O
O
O
Br
O
1
MeOH, Et3N
80 °C, 93% HO O
Br
O
2  
 
To a stirred solution of methanol (39.3 ml) and triethylamine (3.93 ml, 38.83 mmol) in a 
round bottom flask under nitrogen atmosphere was added 3-(4-bromophenyl)-2-oxo-2H-
chromen-7-yl acetate (4.0g, 11.17 mmol). The reaction mixture was refluxed at 80ºC for 
24 hours. After the reaction was completed as shown by TLC, it was quenched by adding 
1M HCl until the pH became acidic. The mixture was extracted using ethyl acetate, water 
(25 mil) and recrystallized using methanol (70 ml) to give (3.28) 93% expected compound. 
 
1H NMR (400Mz, CDCl3) 5.15 (s, 1H) 6.78 (s, 1H), 6.79 (d, J = 2.52 Hz ,1H), 7.19 (s, 1H), 
7.36 (d, J = 8.31 Hz, 1H), 7.51 (d, J = 4.03 Hz, 1H), 7.70 (s, 1H).) 13C NMR (400Mz, 
CDCl3 δ ppm) 161.3, 159.8, 155.4, 139.6, 131.7, 129.4, 128.4, 127. 5, 123.5, 117. 1, 107.4, 
102.9 
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3.3.4 Synthesis of 3-(4-bromophenyl)-7-methoxy-2H-chromen-2-one 
 
HO O
Br
O
2
MeI, K2CO3
O O
Br
O
3
Acetone, 56OC, 80%
 
 
To a stirred solution of acetone (16.5 ml) was added 3-(4-bromophenyl)-7-hydroxy-2H-
chromen-2-one (1.18g, 4.933 mmol) under nitrogen atmosphere. K2CO3 (1.362g, 9.89 
mmol) was added while stirring followed by careful addition of MeI (0.614 ml, 9.86 mmol) 
and the mixture was refluxed overnight at 56ºC. Excess acetone was evaporated under 
reduced pressure after completion of the reaction, and the mixture dissolved in CH2Cl2, 
washed with water (15 ml x 3), dried over MgSO4 and evaporated under reduced pressure 
to give a yellow solid (1.164g) of 90% yield. 1H NMR (400Mz, CDCl3, δ ppm) 3.83 (s, 
3H), 6.78 (s, 1H), 6.79 (d, J = 2.52 Hz, 1H), 7.19 (s, 1H), 7.36 (d, J = 8.31 Hz, 1H), 7.51 
(d, J = 4.03 Hz, 1H), 7.70 (s, 1H).) 13C NMR (400Mz, CDCl3 δ ppm) 161.3, 159.8, 155.4, 
139.6, 131.7, 129.4, 128.4, 127. 5, 123.5, 117. 1, 107.4, 102.9, 56.8 
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3.3.5 Synthesis of 2-((Z)-2-(4-bromophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol 
 
 
 
 
To a stirred solution of 3-(4-bromophenyl)-7-methoxy-2H-chromen-2-one (0.51g, 1.5 
mmol) in THF (10 ml) under nitrogen atmosphere at -20°C was added MeMgBr (in 3M 
diethyl ether, 1 ml, 0.60 mmol) and stirred for 45 min. The reaction mixture was warmed 
to -10°C and monitored by TLC for 7 hours. After completion, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution (40 ml) and extracted with ethyl acetate 
(60 ml). The organic layer was separated, and the aqueous layer was again extracted with 
ethyl acetate (25 ml). The combined organic layer was dried over anhydrous MgSO4 
concentrated under reduced pressure and purified by column chromatography (20% ethyl 
acetate: 80% hexane) to give a semi-solid (0.37g) with 66% yield. 
 
 1H NMR (400Mz, CDCl3) 1.45 (s, 3H), 1.96 (s, 1H), 3.68 (s, 3H), 5.01 (s, 1H), 6.23 (s, 
1H), 6.42 (s, 1H), 6.46 (d, J = 8.45, 1H), 6.89 (d, J = 8.31 Hz, 1H), 7.08 (d, J = 8.03 Hz, 
1H), 7.38 (d, J = 8.06 Hz, 1H). 13C NMR (400Mz, CDCl3 δ ppm) 161, 156.4, 138.8, 131.6, 
129.9, 127.4, 122.5, 115. 8, 107.4, 102.9, 73.6, 55.2, 26.8 
 
O O
Br
O
3
MeMgBr
THF, 00C, 66% O OH
Br
HO
4
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3.3.6 3-(4-bromophenyl)-7-methoxy-2,2-dimethyl-2H-chromene 
 
O OH
Br
HO
4
TFA
Toluene, rt, 
85%
O O
Br
5
 
 
To a solution of 2-((Z)-2-(4-bromophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol (0.1199g, 0.11 millimole) , toluene (5.25 ml) were added TFA (0.021 ml, 
0.26 mmol) and refluxed for 30 minutes mixture was diluted with ethyl acetate (13.20 ml) 
followed by 5% aqueous NaHCO3 (18.4 ml) and stirred continuously  until the reaction 
was completed (TLC). The organic layer was separated, and the aqueous layer was 
extracted with ethyl acetate (15 ml), and the combined organic layer was dried with 
anhydrous Na2SO4 and evaporated under reduced pressure. The mixture was purified by 
column chromatography (70% hexane: 30% ethyl acetate) to give a semi-solid (0.971g) 
with 85% yield. 
 
 1H NMR (400Mz, CDCl3 δ ppm) 1.47 (s, 3H), 3.66 (s, 3H), 6.23 (s, 1H), 6.42 (s, 1H), 6.46 
(d, J = 8.45, 1H), 6.89 (d, J = 8.31 Hz, 1H), 7.08 (d, J = 8.03 Hz, 1H), 7.38 (d, J = 8.06 Hz, 
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1H). 13C NMR (400Mz, CDCl3 δ ppm) 161, 154.3, 138.8, 131.6, 129.9, 127.4, 122.5, 115. 
8, 107.4, 102.9, 78.7, 55.2, 22.3. 
 
 
 
3.3.7 Synthesis of 4-(3-(4-bromophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenol 
 
O O
Br
5
AlCl3, Phenol
Benzene, 
cyclohexane 
00C, 73%
O O
Br
OH
6  
 
To a stirred solution of 3-(4-bromophenyl)-7-methoxy-2, 2-dimethyl-2H-chromene (0.4g, 
1.12 mmol) and phenol (0.24 g, 2.25 mmol) in benzene-cyclohexane mixture (1:1 ratio, 15 
ml) at 0°C was added anhydrous aluminum chloride (0.24 g, 1.8 mmol) in portions. A 
solution of phenol (0.117 g, 1.25 mmol) in benzene- cyclohexane mixture (1:1 Ratio, 15 
ml) was added after 30 min, and the mixture further stirred for 8 hrs. The reaction mixture 
was quenched by adding a mixture of ice and cone. Hydrochloric acid (0.4 ml) and the 
organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (5 ml). The combined extract was washed with NaHCO3 (10 %, 5 ml), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-
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solid obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) 
to obtain the title compound (0.38g) with 73% yield.  
 
1H NMR (400Mz, CDCl3, δ ppm) 1.17 (s, 3H) 1.29 (s, 3H), 3.84 (s, 3H), 4.27 (d, J = 12.34 
Hz, 1H), 4.81 (s, 1H), 6.24 (dd, J = 8.06, 2.52 Hz, 1H), 6.31 (d, J = 2.5 Hz, 1H), 6.47 (d, J 
= 8.3 Hz, 2H), 6.59 (dd, J = 7.30, 1.05 Hz, 1H), 6.78 ( d, J = 8.56 Hz, 2H), 7.24 ( d, J = 
8.31 Hz, 2H). 13C NMR (400Mz, CDCl3 δ ppm) 158.9, 155.2, 153.7, 138.3, 135.6, 131.1, 
131.1, 129.7, 128.3, 120.9, 120.2, 115.6, 102.1, 78.4, 60.7, 55.5, 32.4, 23.4. 
 
 
3.3.8 1-(2-(4-(3-(4-bromophenyl)-1,2,3,4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenoxy)ethyl)pyrrolidine 
O O
Br
OH
6
DMF,500C,70%
NaH, Cl N
O O
Br
O
N
7
 
To a stirred solution of 4-(3-(4-bromophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenol (1.84 g, 3.44 mmol) and DMF (49 ml) was added NaH 
(0.74 g, 30.72 mmol) under nitrogen atmosphere. The reaction mixture was vented with a 
needle for 20 min to allow the evolution of H2 gas and then quenched with methanol (2 
ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride was 
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added sequentially, and the reaction mixture was heated at 50°C overnight. After 
completion as indicated by TLC, the reaction mixture was quenched at 0°C by dropwise 
addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate (3x 15 ml) and 
the organic layer washed with water (3 x 25 ml). The organic layer was washed with brine, 
dried over MgSO4, evaporated and purified by column chromatography (30% ethyl acetate:  
70% hexane) to afford a semi-solid (1.751g) with 70% yield.  HR-FT-MS calcd for 
C30H34BrNO3 536.49 found 536.41 
 
 
1H NMR (400 MHz, Chloroform-d) δ 0.87 (q, J = 8.4, 7.2 Hz, 6H), 0.95 (td, J = 8.4, 7.3, 
5.0 Hz, 2H), 1.08 (s, 1H), 1.15 (s, 2H), 1.22 (d, J = 10.2 Hz, 4H), 1.29 (d, J = 22.1 Hz, 
15H), 1.65 – 1.71 (m, 1H), 1.71 – 1.86 (m, 11H), 2.55 – 2.70 (m, 10H), 2.77 – 2.95 (m, 
8H), 3.12 (dd, J = 12.2, 3.1 Hz, 1H), 3.63 – 3.78 (m, 3H), 3.96 (t, J = 5.9 Hz, 1H), 4.08 (t, 
J = 5.9 Hz, 4H), 4.20 (dd, J = 16.1, 12.1 Hz, 1H), 6.34 (d, J = 8.5, 2.6 Hz, 1H), 6.38 – 6.47 
(m, 1H), 6.49 – 6.68 (m, 2H), 6.70 – 7.05 (m, 12H), 7.06 – 7.17 (m, 2H), 7.17 – 7.23 (m, 
3H), 7.23 – 7.35 (m, 3H). 13C NMR (400Mz, CDCl3 δ ppm) 159.3, 156.9, 153.9, 138.5, 
135.6, 130.9, 129.9, 129.4, 120.5, 118.1, 114.7, 107.8, 101.3, 77.9, 71.2, 66.5, 56.9, 54.6, 
44.4, 28.7, 23.4, 20.2. 
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3.3.9  Synthesis of 3-(4-fluoro-phenyl)-2-oxo-2H-chromen-7-yl acetate 
 
 
 
To a round bottom flask with a stir bar under nitrogen was added 2, 4-
dihydroxybenzaldehyde (3g, 19.5 mmol) followed by 4-fluorophenyacetic acid (3.0g, 19.5 
mmol) and acetic anhydride 7.0 ml). Triethylamine (3.5 ml, 34.60 mmol) was slowly 
added, and the mixture was refluxed at 127°C for 7 hours. The reaction was monitored by 
TLC till completion and quenched with distilled water (50 ml) to give a yellow solid. The 
solid was crushed and recrystallized using methanol (80 ml) to afford (4.12g) 80% of the 
desired product as a cream solid.    
 
1H NMR (400Mz, CDCl3, δ ppm) 2.05 (s, 3H), 6.90 (s, 1H), 6.94 (d, J = 2.27, 1H), 7.07 (d, 
J = 2.27), 7.19 (s, 1H), 7.62 (d, J = 8.56), 7.97 (s, 1H).  13C NMR (400Mz, CDCl3 δ ppm) 
168.1, 162.2, 161.3, 153.4, 151.6, 135.5, 131.4, 130.3, 128.9, 127.2, 123.9, 118.7, 115.0, 
114.1, 17.6. 
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3.3.10 Synthesis of 3-(4-Fluoro-phenyl)-7-hydroxy-chromen-2-one 
 
 
 
 
To a stirred solution of methanol (49.3 ml) and triethylamine (4.8 ml, 47.40 mmol) in a 
round bottom flask under nitrogen atmosphere was added 3-(4-fluoro-phenyl)-2-oxo-2H-
chromen-7-yl acetate (4.9g, 16.43 mmol). The reaction mixture was refluxed at 80ºC for 
24 hours. After the reaction was completed as shown by TLC, it was quenched by adding 
1M HCl until the pH became acidic. The mixture was extracted using ethyl acetate (20 x 3 
ml) and water (35 mil) and recrystallized with methanol (70 ml) to give (2.98) 71% 
expected compound. 
 
 1H NMR (400Mz, CDCl3) 5.15 (s, 1H) 6.65 (s, 1H), 6.68 (d, J = 2.52 Hz, 1H), 7.19 (s, 
1H), 7.38 (d, J = 8.31 Hz, 1H), 7.47 (d, J = 4.03 Hz, 1H), 7.98 (s, 1H).) 13C NMR (400Mz, 
CDCl3 δ ppm) 161.8, 161.5, 159.7, 155.6, 134.3, 130.7, 129.4, 128.4, 127. 3, 120.5, 115. 
2, 102.3, 107.9.  
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3.3.11 Synthesis of 3-(4-Fluoro-phenyl)-7-methoxy-chromen-2-one 
 
 
To a stirred solution of acetone (16.5 ml) was added 3-(4-fluorophenyl)-7-hydroxy-2H-
chromen-2-one (2.50g, 9.25 mmol) under nitrogen atmosphere. K2CO3 (2.9g, 20.9 mmol) 
was added while stirring followed by careful addition of MeI (1.30 ml, 9.16 mmol) and the 
mixture was refluxed overnight at 56ºC. Excess acetone was evaporated under vacuum 
after completion of the reaction, and the mixture dissolved in CH2Cl2, washed with water 
(15 ml x 3), dried over MgSO4 and evaporated under reduced pressure to give a yellow 
solid (1.80 g) of 75% yield. 
 
1H NMR (400Mz, CDCl3, δ ppm) 3.83 (s, 3H), 6.72 (s, 1H), 6.93 (d, J = 2.52 Hz, 1H), 6.98 
(s, 1H), 7.30 (d, J = 8.31 Hz, 1H), 7.51 (d, J = 4.03 Hz, 1H), 7.94 (s, 1H). 13C NMR (400Mz, 
CDCl3 δ ppm)161.9 161.3, 159.7, 151.4, 139.6, 133.8, 129.4, 128.4, 127. 9, 120.5, 115. 4, 
110.3, 106.5, 55.2 
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3.3.12 Synthesis of 2-((Z)-2-(4-flourophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol 
 
 
 
 
To a stirred solution of 3-(4-fluorophenyl)-7-methoxy-2H-chromen-2-one (1g, 3.30 mmol) 
in THF (20 ml) under nitrogen atmosphere at -20°C was added MeMgBr (in 3M diethyl 
ether, 2.38 ml, 19.9 mmol) and stirred for 45 min. The reaction mixture was warmed to -
10°C and monitored by TLC for 7 hours. After completion, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution (50 ml) and extracted with ethyl acetate 
(65 ml). The organic layer was separated, and the aqueous layer was again extracted with 
ethyl acetate (25 ml). The combined organic layer was dried over anhydrous MgSO4 
concentrated under reduced pressure and purified by column chromatography (20% ethyl 
acetate: 80% hexane) to give a semi-solid (0.60g) with 60% yield.  
 
1H NMR (400Mz, CDCl3) 1.35 (s, 3H), 1.96 (s, 1H), 3.64 (s, 3H), 5.01 (s, 1H), 6.23 (s, 
1H), 6.26 (d, J = 8.45, 1H), 7.13 (d, J = 8.31 Hz, 1H), 7.24 (d, J = 8.03 Hz, 1H), 7.39 (d, J 
= 8.06 Hz, 1H). 13C NMR (400Mz, CDCl3 δ ppm) 161.9, 161.8, 156.4, 143.8, 130.6, 128.6, 
127.8, 127.3, 115. 8, 104.4, 102.9, 73.6, 5582, 26.9. 
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3.3.13 Synthesis of 3-(4-fluorophenyl)-7-methoxy-2,2-dimethyl-2H-chromene 
 
 
 
To a solution of 2-((Z)-2-(4-fluorophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol (1.25g, 4.13 mmol) in toluene (15.8 ml) was added TFA (0.22 ml, 1.92 
mmol) stirred for 30 min. The reaction mixture was diluted with ethyl acetate (20.0 ml) 
followed by 5% aqueous NaHCO3 (23.1 ml) and stirred vigorously until the reaction was 
completed (TLC). The organic layer was separated, and the aqueous layer was extracted 
with ethyl acetate (32 ml), and the combined organic layer was dried with anhydrous 
Na2SO4 and evaporated under reduced pressure. The mixture was purified by column 
chromatography (70% hexane: 30% ethyl acetate) to give a semi-solid (0.98g) with 84% 
yield. 
 
1H NMR (400Mz, CDCl3 δ ppm) 1.57 (s, 3H), 3.56 (s, 3H), 6.23 (s, 1H), 6.38 (s, 1H), 6.91 
(d, J = 8.45, 1H), 6.95 (d, J = 8.31 Hz, 1H), 7.22 (d, J = 8.03 Hz, 1H), 7.39 (d, J = 8.06 Hz, 
1H). 13C NMR (400Mz, CDCl3 δ ppm) 161.5, 161.2 157.2, 131.8, 129.9, 227.9, 127.4, 
121.5, 115. 4, 107.4, 102.9, 79.7, 56.2, 23.3. 
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3.3.14 Synthesis of 4-(3-(4-fluorophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl) phenol 
 
 
 
To a stirred solution of 3-(4-fluorophenyl)-7-methoxy-2, 2-dimethyl-2H-chromene (0.4g, 
1.05 mmol) and phenol (0.24 g, 2.25 mmol) in benzene-cyclohexane mixture (1:1 ratio, 15 
ml) at 0°C was added anhydrous aluminum chloride (0.24 g, 1.8 mmol) in portions. A 
solution of phenol (0.117 g, 1.25 mmol) in benzene- cyclohexane mixture (1:1 Ratio, 15 
ml) was added after 30 min, and the mixture further stirred for 8 hrs. The reaction mixture 
was quenched by adding a mixture of ice and cone. Hydrochloric acid (0.4 ml) and the 
organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (5 ml). The combined extract was washed with NaHCO3 (10 %, 5 ml), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-
solid obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) 
to obtain the title compound (0.32g) with 62% yield. 
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 1H NMR (400Mz, CDCl3, δ ppm) 1.26 (s, 3H) 1.29 (s, 3H), 3.84 (s, 3H), 4.29 (d, J = 12.34 
Hz, 1H), 4.71 (s, 1H), 6.27 (dd, J = 8.06, 2.52 Hz, 1H), 6.67 (d, J = 2.5 Hz, 1H), 6.87 (d, J 
= 8.3 Hz, 2H), 6.90 (dd, J = 7.30, 1.05 Hz, 1H), 6.98 (d, J = 8.56 Hz, 2H), 7.10 ( d, J = 8.31 
Hz, 2H). 13C NMR (400Mz, CDCl3 δ ppm) 159.9, 159.3, 158.8, 155.2, 153.7, 138.3, 136.6, 
135.1, 130.1, 129.7, 128.3, 121.0, 116.2 114.6, 102.1, 78.4, 60.7, 55.5, 33.1, 22.9 
 
 
3.3.15 1-(2-(4-(3-(4-fluorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenoxy)ethyl)pyrrolidine 
 
 
 
 
To a stirred solution of 4-(3-(4-fluorophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenol (0.1 g, 0.21 mmol) and DMF (2.7 ml) was added NaH 
(0.04 g, 16.67 mmol) under nitrogen atmosphere. The reaction mixture was vented with a 
needle for 20 min to allow the evolution of H2 gas and then quenched with methanol (0.3 
ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.102 
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g) was added sequentially, and the reaction mixture was heated at 50°C overnight. After 
completion as indicated by TLC, the reaction mixture was quenched at 0°C by dropwise 
addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate (3x 5 ml) and 
the organic layer washed with water (3 x 3 ml). The organic layer was washed with brine, 
dried over MgSO4, evaporated and purified by column chromatography (30% ethyl acetate:  
70% hexane) to afford a semi-solid (0.084g) with 85% yield.  
 
1H NMR (400 MHz, Chloroform-d) δ 0.77 – 0.99 (m, 7H), 1.04 – 1.08 (m, 1H), 1.09 (s, 
1H), 1.17 – 1.44 (m, 17H), 1.59 (t, J = 6.5 Hz, 1H), 1.68 – 1.73 (m, 1H), 1.74 – 1.87 (m, J 
= 4.0, 3.2 Hz, 12H), 2.57 – 2.75 (m, 12H), 2.80 – 2.99 (m, 6H), 3.63 – 3.76 (m, 3H), 3.76 
– 3.85 (m, 1H), 3.97 (t, J = 5.7 Hz, 1H), 4.09 (t, J = 5.9 Hz, 5H), 6.36 (ddt, J = 9.0, 4.9, 2.3 
Hz, 1H), 6.40 – 6.54 (m, 2H), 6.56 – 6.64 (m, 1H), 6.70 – 6.96 (m, 14H), 6.97 – 7.05 (m, 
2H), 7.06 – 7.30 (m, 9H). 13C NMR (400Mz, CDCl3 δ ppm) 160.3, 159.9, 158.156.1, 136.4, 
134.6, 130.9, 129.9, 129.4, 120.5, 118.1, 114.7, 114.6, 107.8, 101.3, 78.1, 71.9, 61.2, 56.9, 
54.6, 44.4, 28.7, 23.6, 21.4. HR-FT-MS calcd for C30H34FNO3 475.25 found 475.28 
 
 
3.3.16 Synthesis of 3-(4-Iodo-phenyl)-2-oxo-2H-chromen-7-yl acetate 
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To a round bottom flask with a stir bar under nitrogen was added 2, 4-
dihydroxybenzaldehyde (1g, 6.4 mmol) followed by 4-Iodo-phenylacetic acid (1.02g, 3.90 
mmol) and acetic anhydride 2.26 ml). Triethylamine (1.32 ml, 13.06 mmol) was slowly 
added, and the mixture was refluxed at 127°C for 7 hours. The reaction was monitored by 
TLC till completion and quenched with distilled water (30 ml) to give a yellow solid. The 
solid was crushed and recrystallized using methanol (60 ml) to afford (1.27g) 77% of the 
desired product as brown solid. 
 
1H NMR (400Mz, CDCl3, δ ppm) 2.19 (s, 3H), 6.99 (s, 1H), 7.03 (d, J = 2.27, 1H), 7.07 (d, 
J = 2.27), 7.19 (s, 1H), 7.63 (d, J = 8.56), 8.01 (s, 1H).  13C NMR (400Mz, CDCl3 δ ppm) 
168.2, 161.9, 153.1, 151.3, 137.5, 133.4, 130.3, 127.9, 127.3, 126.5, 124.3, 118.7, 117.3, 
96.0, 17.1. 
 
 
3.3.17 Synthesis of 3-(4-Iodo-phenyl)-7-hydroxy-chromen-2-one 
 
 
 
To a stirred solution of methanol (9.7 ml) and triethylamine (0.98g. 9.68mmol) in a round 
bottom flask under nitrogen atmosphere was added 3-(4-Iodo-phenyl)-2-oxo-2H-chromen-
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7-yl acetate (1.27g, 3.0 mmol). The reaction mixture was refluxed at 80ºC for 24 hours. 
After the reaction was completed as shown by TLC, it was quenched by adding 1M HCl 
until the pH became acidic. The mixture was extracted using ethyl acetate (15 x 3 ml) and 
water (11 ml) and recrystallized with methanol (50 ml) to give (0.95g) 83% expected 
compound. 
 
1H NMR (400Mz, CDCl3) 5.10 (s, 1H) 6.78 (s, 1H), 6.79 (d, J = 2.52 Hz, 1H), 7.10 (s, 1H), 
7.36 (d, J = 8.31 Hz, 1H), 7.62 (d, J = 4.03 Hz, 1H), 7.89 (s, 1H).) 13C NMR (400Mz, 
CDCl3 δ ppm) 161.9, 157.8, 152.1, 137.6, 133.2, 129.4, 128.4, 125. 1, 121.5, 117. 1, 107.4, 
96.2 
 
3.3.18 Synthesis of 3-(4-Iodo-phenyl)-7-methoxy-chromen-2-one 
 
 
 
To a stirred solution of acetone (13.3 ml) was added 3-(4-Iodo-phenyl)-7-hydroxy-2H-
chromen-2-one (0.95g, 2.60 mmol) under nitrogen atmosphere. K2CO3 (1.10g, 8.0 mmol) 
was added while stirring followed by careful addition of MeI (0.49 ml, 3.50 mmol) and the 
mixture was refluxed overnight at 56ºC. Excess acetone was evaporated under vacuum 
after completion of the reaction and the mixture dissolved in CH2Cl2, washed with water 
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(8.0 ml x 3), dried over MgSO4 and evaporated under reduced pressure to give a yellow 
solid (0.76) of 77% yield. 
1H NMR (400Mz, CDCl3, δ ppm) 3.70 (s, 3H), 6.68 (s, 1H), 6.71 (d, J = 2.52 Hz ,1H), 7.19 
(s, 1H), 7.49 (d, J = 8.31 Hz, 1H), 7.61 (d, J = 4.03 Hz, 1H), 7.98 (s, 1H).) 13C NMR 
(400Mz, CDCl3 δ ppm) 161.9, 160.0, 152.4, 137.6, 132.7, 129.4, 128.4, 127. 5, 123.5, 117. 
1, 107.4, 96.1, 55.8 
 
 
3.3.19 Synthesis of 2-((Z)-2-(4-Iodophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol 
 
 
 
To a stirred solution of 3-(4-Iodo-phenyl)-7-methoxy-2H-chromen-2-one (0.3g, 0.79 
mmol) in THF (11.0 ml) under nitrogen atmosphere at -20°C was added MeMgBr (in 3M 
diethyl ether, 1.5 ml, 12.5 mmol) and stirred for 45 min. The reaction mixture was warmed 
to -10°C and monitored by TLC for 7 hours. After completion, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution (40 ml) and extracted with ethyl acetate 
(60 ml). The organic layer was separated, and the aqueous layer was again extracted with 
ethyl acetate (20 ml). The combined organic layer was dried over anhydrous MgSO4 
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concentrated under reduced pressure and purified by column chromatography (20% ethyl 
acetate: 80% hexane) to give a semi-solid (0.24g) with 75% yield. 
1H NMR (400Mz, CDCl3) 1.35 (s, 3H), 1.98 (s, 1H), 3.68 (s, 3H), 5.00 (s, 1H), 6.27 (s, 
1H), 6.38 (s, 1H), 6.86 (d, J = 8.45, 1H), 6.99 (d, J = 8.31 Hz, 1H), 7.19 (d, J = 8.03 Hz, 
1H), 7.61 (d, J = 8.06 Hz, 1H). 13C NMR (400Mz, CDCl3 δ ppm) 158.0, 156.5,141.2 137.2, 
133.6, 129.9, 127.4, 122.5, 115. 8, 107.4, 95.9, 73.1, 55.8, 27.2. 
 
 
 
3.3.20 Synthesis of 3-(4-Iodo-phenyl)-7-methoxy-2,2-dimethyl-2H-chromene 
 
 
 
To a solution of 2-((Z)-2-(4-Iodo-phenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol (.383g, 0.93 mmol) in CHCl3 (13.6 ml) was added para-toluene sulfonic 
acid (0.077 ml, 0.45 mmol) stirred overnight at 0°C. The reaction mixture was diluted with 
ethyl acetate (20.0 ml) followed by saturated aqueous NaHCO3 (10.0 ml) and stirred 
vigorously until the reaction was completed (TLC). The organic layer was separated, and 
the aqueous layer was extracted with CH2Cl2 (25 ml) and the combined organic layer was 
dried with anhydrous Na2SO4 and evaporated under reduced pressure. The mixture was 
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purified by column chromatography (70% hexane: 30% ethyl acetate) to give a semi-solid 
(0.35g) with 96% yield. 
1H NMR (400Mz, CDCl3 δ ppm) 1.49 (s, 3H), 3.69 (s, 3H), 6.27 (s, 1H), 6.38 (s, 1H), 6.92 
(d, J = 8.45, 1H), 7.01 (d, J = 8.31 Hz, 1H), 7.09 (d, J = 8.03 Hz, 1H), 7.61 (d, J = 8.06 Hz, 
1H). 13C NMR (400Mz, CDCl3 δ ppm) 161, 154.3, 137.8, 131.6, 129.9, 127.4, 122.5, 115. 
8, 107.4, 96.9, 78.3, 55.2, 23.8. 
 
 
 
3.3.21 Synthesis of 4-(3-(4-Iodo-phenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl) phenol 
 
 
 
To a stirred solution of 3-(4-fluorophenyl)-7-methoxy-2, 2-dimethyl-2H-chromene (0.35g, 
0.89 mmol) and phenol (0.24 g, 2.25 mmol) in benzene-cyclohexane mixture (1:1 ratio, 15 
ml) at 0°C was added anhydrous aluminum chloride (0.22 g, 1.8 mmol) in portions. A 
solution of phenol (0.2 g, 2.13 mmol) in benzene- cyclohexane mixture (1:1 Ratio, 20 ml) 
was added after 30 min, and the mixture further stirred for 8 hrs. The reaction mixture was 
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quenched by adding a mixture of ice and cone. Hydrochloric acid (0.5 ml) and the organic 
layer was separated. The aqueous layer was re-extracted three times with dichloromethane 
(15 ml). The combined extract was washed with NaHCO3 (10 %, 8ml), dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-solid 
obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) to 
obtain the title compound (0.31g) with 72% yield. 
 
1H NMR (400Mz, CDCl3, δ ppm) 1.27 (s, 3H) 1.39 (s, 3H), 3.80 (s, 3H), 4.41 (d, J = 12.34 
Hz, 1H), 4.91 (s, 1H), 6.22 (dd, J = 8.06, 2.52 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H), 6.67 (d, J 
= 8.3 Hz, 2H), 6.88 (dd, J = 7.30, 1.05 Hz, 1H), 6.96 ( d, J = 8.56 Hz, 2H), 7.48 ( d, J = 
8.31 Hz, 2H). 13C NMR (400Mz, CDCl3 δ ppm) 160.9, 158.2, 154.6, 140.3, 136.6, 131.1, 
131.1, 129.7, 128.3, 121.8, 120.2, 115.6, 94.5, 78.4, 60.7, 55.5, 33.6, 23.9. 
 
 
3.3.22 1-(2-(4-(3-(4-Iodo-phenyl)-1,2,3,4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenoxy)ethyl)pyrrolidine 
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To a stirred solution of 4-(3-(4-fluorophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenol (0.48 g, 0.99 mmol) and DMF (13.0 ml) was added NaH 
(0.19 g, 8.0 mmol) under nitrogen atmosphere. The reaction mixture was vented with a 
needle for 20 min to allow the evolution of H2 gas and then quenched with methanol (0.6 
ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.49 g, 
2.66 mmo1) was added sequentially, and the reaction mixture was heated at 50°C 
overnight. After completion as indicated by TLC, the reaction mixture was quenched at 
0°C by dropwise addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate 
(3x 10 ml) and the organic layer washed with water (3 x 5 ml). The organic layer was 
washed with brine, dried over MgSO4, evaporated and purified by column chromatography 
(30% ethyl acetate:  70% hexane) to afford a semi-solid (0.039g) with 68% yield.  
 
1H NMR (400 MHz, Chloroform-d) δ 0.73 – 0.84 (m, 4H), 0.84 – 0.98 (m, 11H), 1.08 (d, 
J = 6.6 Hz, 3H), 1.18 – 1.34 (m, 26H), 1.38 (s, 2H), 1.68 (d, J = 5.7 Hz, 2H), 1.74 – 1.80 
(m, 3H), 1.82 (dt, J = 7.2, 3.4 Hz, 5H), 2.74 (q, J = 6.7 Hz, 5H), 2.88 (dd, J = 17.8, 9.4 Hz, 
1H), 2.96 (t, J = 5.7 Hz, 2H), 3.59 – 3.83 (m, 4H), 4.10 (t, J = 5.9 Hz, 2H), 6.33 – 6.47 (m, 
2H), 6.57 (dt, J = 15.7, 8.2 Hz, 2H), 6.80 (d, J = 7.7 Hz, 9H), 6.82 – 6.93 (m, 4H), 6.97 (dt, 
J = 12.2, 6.7 Hz, 1H), 7.14 (t, J = 7.8 Hz, 4H), 7.21 (t, J = 7.9 Hz, 2H), 7.43 – 7.56 (m, 
1H), 7.96 – 8.02 (m, 1H).13C NMR (400Mz, CDCl3 δ ppm) 160.3, 158.6, 155.7, 140.5, 
136.6, 130.9, 129.9, 129.4, 120.5, 118.1, 114.7, 107.8, 95.3, 77.9, 71.2, 66.5, 60.9, 55.6, 
51.4, 28.7, 24.4, 23.1. HR-FT-MS calcd for C30H34INO3 583.50 found 583.51 
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3.3.23 Synthesis of 3-(4-Chloro-phenyl)-2-oxo-2H-chromen-7-yl acetate 
 
 
 
To a round bottom flask with a stir bar under nitrogen was added 2, 4-
dihydroxybenzaldehyde (1.06g, 7.84 mmol) followed by 4-Chloro-phenylacetic acid 
(1.24g, 7.27 mmol) and acetic anhydride (2.80 ml). Triethylamine (1.40 ml, 13.85 mmol) 
was slowly added, and the mixture was refluxed at 127°C for 7 hours. The reaction was 
monitored by TLC till completion and quenched with distilled water (30 ml) to give a white 
solid. The solid was crushed and recrystallized using methanol (70 ml) to afford (1.85g) 80 
% of the desired product as white solid. 
 
1H NMR (400Mz, CDCl3, δ ppm) 2.19 (s, 3H), 6.99 (s, 1H), 7.02 (d, J = 2.27, 1H), 7.05 (d, 
J = 2.27), 7.19 (s, 1H), 7.56 (d, J = 8.56), 7.85 (s, 1H).  13C NMR (400Mz, CDCl3 δ ppm) 
168, 160, 154.1, 153.3, 139.5, 133.4, 131.8, 132.9, 128.9, 126.3, 123.3, 118.5, 117.3, 109.9, 
18.9. 
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3.3.24 Synthesis of 3-(4-Chloro-phenyl)-7-hydroxy-chromen-2-one 
 
 
To a stirred solution of methanol (15.0 ml) and triethylamine (1.43g. 14.1mmol) in a round 
bottom flask under nitrogen atmosphere was added 3-(4-Chloro-phenyl)-2-oxo-2H-
chromen-7-yl acetate (1.85g, 5.90 mmol). The reaction mixture was refluxed at 80ºC for 
24 hours. After the reaction was completed as shown by TLC it was quenched by adding 
1M HCl until the pH became acidic. The mixture was extracted using ethyl acetate (20 x 3 
ml) and water (15 ml) and recrystallized with methanol (60 ml) to give (1.13 g) 71 % 
expected compound. 
1H NMR (400Mz, CDCl3) 5.10 (s, 1H) 6.68 (s, 1H), 6.71 (d, J = 2.52 Hz, 1H), 7.19 (s, 1H), 
7.24 (d, J = 8.31 Hz, 1H), 7.35 (d, J = 4.03 Hz, 1H), 7.90 (s, 1H).) 13C NMR (400Mz, 
CDCl3 δ ppm) 161.3, 159.8, 155.4, 139.6, 133.2, 129.4, 128.4, 127. 3, 123.1, 117. 4, 107.4, 
107.5 
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3.3.25 Synthesis of 3-(4-Cloro-phenyl)-7-methoxy-chromen-2-one 
 
 
 
To a stirred solution of acetone (6.74 ml) was added 3-(4-Cloro-phenyl)-7-hydroxy-2H-
chromen-2-one (0.49g, 2.60 mmol) under nitrogen atmosphere. K2CO3 (0.57 g, 4.13 mmol) 
was added while stirring followed by careful addition of MeI (0.25 ml, 1.82 mmol) and the 
mixture was refluxed overnight at 56ºC. Excess acetone was evaporated under vacuum 
after completion of the reaction and the mixture dissolved in CH2Cl2, washed with water 
(5.0 ml x 3), dried over MgSO4 and evaporated under reduced pressure to give a white 
solid (0.54) of 73% yield. 
1H NMR (400Mz, CDCl3, δ ppm) 3.71 (s, 3H), 6.71 (s, 1H), 6.77 (d, J = 2.52 Hz, 1H), 7.20 
(s, 1H), 7.36 (d, J = 8.31 Hz, 1H), 7.53 (d, J = 4.03 Hz, 1H), 7.96 (s, 1H).) 13C NMR 
(400Mz, CDCl3 δ ppm) 161.9, 159.8, 155.4, 139.6, 132.7, 129.4, 128.4, 127. 5, 123.5, 117. 
1, 107.8, 102.9, 56.1. 
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3.3.26 Synthesis of 2-((Z)-2-(4-Clorophenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol 
 
 
 
To a stirred solution of 3-(4-Cloro-phenyl)-7-methoxy-2H-chromen-2-one (0.32 g, 1.00 
mmol) in THF (6.40 ml) under nitrogen atmosphere at -20°C was added MeMgBr (in 3M 
diethyl ether, 0.55 ml, 4.83 mmol) and stirred for 45 min. The reaction mixture was warmed 
to -10°C and monitored by TLC for 7 hours. After completion, the reaction mixture was 
quenched with saturated aqueous NH4Cl solution (30 ml) and extracted with ethyl acetate 
(55 ml). The organic layer was separated, and the aqueous layer was again extracted with 
ethyl acetate (20 ml). The combined organic layer was dried over anhydrous MgSO4 
concentrated under reduced pressure and purified by column chromatography (20% ethyl 
acetate: 80% hexane) to give a semi-solid (0.27g) with 85% yield. 
 
1H NMR (400Mz, CDCl3) 1.35 (s, 3H), 1.98 (s, 1H), 3.71 (s, 3H), 5.00 (s, 1H), 6.23 (s, 
1H), 6.42 (s, 1H), 6.56 (d, J = 8.45, 1H), 6.97 (d, J = 8.31 Hz, 1H), 7.21 (d, J = 8.03 Hz, 
1H), 7.38 (d, J = 8.06 Hz, 1H). 13C NMR (400Mz, CDCl3 δ ppm) 161.9, 156.4, 138.5, 
131.6, 129.9, 127.4, 122.5, 114. 6, 107.4, 102.9, 73.6, 55.2, 27.3 
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3.3.27 Synthesis of 3-(4-Cloro-phenyl)-7-methoxy-2,2-dimethyl-2H-chromene 
 
 
 
To a solution of 2-((Z)-2-(4-Cloro-phenyl)-3-hydroxy-3-methylbut-1-enyl)-5-
methoxyphenol (0.36g, 1.13 mmol) in CHCl3 (12.00 ml) was added para-toluene sulfonic 
acid (0.077 ml, 0.32 mmol) stirred overnight at 0°C. The reaction mixture was diluted with 
ethyl acetate (20.0 ml) followed by saturated aqueous NaHCO3 (10.0 ml) and stirred 
vigorously until the reaction was completed (TLC). The organic layer was separated, and 
the aqueous layer was extracted with CH2Cl2 (23 ml), and the combined organic layer was 
dried with anhydrous Na2SO4 and evaporated under reduced pressure. The mixture was 
purified by column chromatography (70% hexane: 30% ethyl acetate) to give a semi-solid 
(0.29 g) with 86% yield. 
 
1H NMR (400Mz, CDCl3 δ ppm) 1.57 (s, 3H), 3.69 (s, 3H), 6.30 (s, 1H), 6.32 (s, 1H), 6.99 
(d, J = 8.45, 1H), 7.23 (d, J = 8.31 Hz, 1H), 7.28 (d, J = 8.03 Hz, 1H), 7.35 (d, J = 8.06 Hz, 
1H). 13C NMR (400Mz, CDCl3 δ ppm) 161.6, 156.3, 142.8, 131.6, 129.9, 127.4, 122.0, 
115. 8, 107.4, 99.9, 78.7, 56.2, 23.3. 
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3.3.28 Synthesis of 4-(3-(4-Cloro-phenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl) phenol 
 
 
 
To a stirred solution of 3-(4-Chloro-phenyl)-7-methoxy-2, 2-dimethyl-2H-chromene (0.29 
g, 0.96 mmol) and phenol (0.17 g, 1.6 mmol) in benzene-cyclohexane mixture (1:1 ratio, 
15 ml) at 0°C was added anhydrous aluminum chloride (0.22 g, 1.8 mmol) in portions. A 
solution of phenol (0.18 g, 1.92 mmol) in benzene- cyclohexane mixture (1:1 Ratio, 15ml) 
was added after 30 min, and the mixture further stirred for 8 hrs. The reaction mixture was 
quenched by adding a mixture of ice and cone. Hydrochloric acid (0.4 ml) and the organic 
layer was separated. The aqueous layer was re-extracted three times with dichloromethane 
(15 ml). The combined extract was washed with NaHCO3 (10 %, 8ml), dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-solid 
obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) to 
obtain the title compound (0.33g) with 87 % yield. 
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1H NMR (400Mz, CDCl3, δ ppm) 1.32 (s, 3H) 1.29 (s, 3H), 3.84 (s, 3H), 4.27 (d, J = 12.34 
Hz, 1H), 4.81 (s, 1H), 6.24 (dd, J = 8.06, 2.52 Hz, 1H), 6.72 (d, J = 2.5 Hz, 1H), 6.92 (d, J 
= 8.3 Hz, 2H), 6.98 (dd, J = 7.30, 1.05 Hz, 1H), 7.01 ( d, J = 8.56 Hz, 2H), 7.22 ( d, J = 
8.31 Hz, 2H). 13C NMR (400Mz, CDCl3 δ ppm) 158.9, 155.2, 153.7, 139.3, 135.6, 131.1, 
131.1, 129.7, 128.3, 120.9, 120.2, 115.6, 103.2, 78.4, 60.7, 55.5, 33.0, 23.1  
 
 
 
 
 
3.3.29 1-(2-(4-(3-(4-Cloro-phenyl)-1,2,3,4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenoxy)ethyl)pyrrolidine 
 
 
 
To a stirred solution of 4-(3-(4-Chlorophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy-2,2-
dimethylnaphthalen-4-yl)phenol (0.33 g, 0.84 mmol) and DMF (8.90 ml) was added NaH 
174 
 
 
 
(0.13 g, 5.47 mmol) under nitrogen atmosphere. The reaction mixture was vented with a 
needle for 20 min to allow the evolution of H2 gas and then quenched with methanol (0.5 
ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.34 g, 
1.83 mmo1) was added sequentially, and the reaction mixture was heated at 50°C 
overnight. After completion as indicated by TLC, the reaction mixture was quenched at 
0°C by dropwise addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate 
(3x 10 ml) and the organic layer washed with water (3 x 5 ml). The organic layer was 
washed with brine, dried over MgSO4, evaporated and purified by column chromatography 
(30% ethyl acetate:  70% hexane) to afford a semi-solid (0.36g) with 87% yield.  
 
1H NMR (400Mz, CDCl3, δ ppm) 1.17 (s, 3H) 1.29 (s, 3H), 1.70 (s, 4H,), 2.57 (s, 4H), 2.77 
(t, J = 6.0Hz, 2H), 3.08 (d, J = 12.09Hz, 1H), 3.61 (s, 3H), 3.91 (t, J = 5.62Hz, 2H), 4.22 
(d, J = 12.09 Hz, 1H), 6.28 (dd, J = 2.52, 2.52 Hz 1H), 6.72 (d, J = 2.52 Hz, 1H), 6.80 ( d, 
J = 6.55 Hz, 1H),  6.98 ( d, J =6.80 Hz, 2H), 7.03 (d, J =8.56 Hz, 2H), 7.21 (d, J = 7.30 Hz, 
2H);  13C NMR (400Mz, CDCl3 δ ppm) 159.3, 156.9, 153.9, 139.2, 136.5, 130.9, 129.9, 
129.4, 120.5, 119.2, 114.7, 107.8, 101.3, 77.9, 71.2, 66.5, 56.9, 54.6, 44.4, 28.7, 24.6, 22.8. 
HR-FT-MS calcd for C30H34ClNO3 492.04 found 492.09 
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3.3.30 Synthesis of 2-oxo-3-p-tolyl-2H-chromen-7-yl acetate 
 
 
 
To a round bottom flask with a stir bar under nitrogen was added 2, 4-
dihydroxybenzaldehyde (2g, 14.40 mmol) followed by P-toluic acid (2.24g, 14.92 mmol) 
and acetic anhydride (4.52ml). Triethylamine (2.64 ml, 32.42 mmol) was slowly added, 
and the mixture was refluxed at 127°C for 7 hours. The reaction was monitored by TLC 
till completion and quenched with distilled water (65 ml) to give a gray solid. The solid 
was crushed and recrystallized using methanol (100 ml) to afford (2.475g) 58% of the 
desired product as white solid. 
 
1H NMR (400 MHz, Chloroform-d) δ 7.80 (s, 2H), 7.60 (s, 1H), 7.57 (s, 5H), 7.55 (d, J = 
8.2 Hz, 3H), 7.15 (d, J = 2.2 Hz, 2H), 7.08 (dd, J = 8.5, 2.2 Hz, 2H), 2.39 (d, J = 7.9 Hz, 
1H), 2.35 (s, 5H). 13C NMR (400 MHz, CDCl3) δ 168.73, 159.94, 154.07, 153.06, 139.35, 
133.37, 131.70, 130.09, 128.72, 126.56, 123.28, 118.69, 117.30, 110.08, 23.24, 21.18. 
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3.3.31 Synthesis of 7-hydroxy-3-p-tolyl-2H-chromen-2-one 
 
 
To a stirred solution of methanol (25.0 ml) and triethylamine (2.34 ml, 16.82 mmol) in a 
round bottom flask under nitrogen atmosphere was added 2-oxo-3-p-tolyl-2H-chromen-7-
yl acetate (2.475, 8.41 mmol). The reaction mixture was refluxed at 80ºC for 24 hours. 
After the reaction was completed as shown by TLC, it was quenched by adding 1M HCl 
until the pH became acidic. The mixture was extracted using ethyl acetate (20 x 3 ml) and 
water (18 ml) and recrystallized using methanol (60 ml) to give (1.91) 86% expected 
compound. 
 
1H NMR (400 MHz, DMSO-d6) δ 10.67 (s, 1H), 8.15 (s, 2H), 7.69 – 7.54 (m, 10H), 6.83 
(dd, J = 8.5, 2.3 Hz, 2H), 6.75 (d, J = 2.3 Hz, 2H), 3.20 (s, 1H), 2.28 (s, 3H). 13C NMR 
(400 MHz, DMSO) δ 161.44, 159.79, 154.95, 141.27, 134.23, 131.02, 130.20, 130.03, 
121.24, 120.77, 113.44, 111.83, 101.70, 21.32. 
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3.3.32 Synthesis of 7-methoxy-3-p-tolyl-2H-chromen-2-one 
 
 
To a stirred solution of acetone (16.5 ml) was added 7-hydroxy-3-p-tolyl-2H-chromen-2-
one (1.905g, 7.55 mmol) under nitrogen atmosphere. K2CO3 (2.10g, 15.10 mmol) was 
added while stirring followed by careful addition of MeI (2.14 ml, 15.1 mmol) and the 
mixture was refluxed overnight at 56°C. Excess acetone was evaporated under vacuum 
after completion of the reaction and the mixture dissolved in CH2Cl2, washed with water 
(15 ml x 3), dried over MgSO4 and evaporated under reduced pressure to give a pale gray 
solid (1.85g) of 93% yield. 
 1H NMR (400 MHz, Chloroform-d) δ 7.67 (s, 1H), 7.53 – 7.43 (m, 4H), 7.35 (dd, J = 8.9, 
2.5 Hz, 1H), 6.84 – 6.72 (m, 2H), 3.80 (d, J = 1.8 Hz, 4H) 2.28 (s, 3H). 13C NMR (400 
MHz, CDCl3) δ 162.88, 160.60, 155.38, 140.14, 133.89, 131.58, 129.98, 129.00, 123.51, 
122.66, 113.15, 112.99, 100.44, 55.86, 21.28. 
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3.3.33 Synthesis of 2-((Z)-3-hydroxy-3-methyl-2-p-tolylbut-1-enyl)-5-
methoxyphenol 
 
 
 
 
To a stirred solution of Synthesis of 7-methoxy-3-p-tolyl-2H-chromen-2-one (5.27g, 19.80 
mmol) in THF (198 ml) under nitrogen atmosphere at 0°C was added MeMgBr (in 3M 
diethyl ether, 14 ml, 118.80 mmol) and stirred for 45 min. The reaction mixture was 
warmed to 22°C and monitored by TLC for 6 hours. After completion, the reaction mixture 
was quenched with saturated aqueous NH4Cl solution (80 ml) and extracted with ethyl 
acetate (75 ml). The organic layer was separated, and the aqueous layer was again extracted 
with ethyl acetate (3 x 50 ml). The combined organic layer was dried over anhydrous 
MgSO4 concentrated under reduced pressure and purified by column chromatography 
(10% ethyl acetate: 90% hexane) to give a semi-solid (4.58g) with 78% yield.  
1H NMR (400 MHz, Chloroform-d) δ 7.70 (s, 3H), 7.54 – 7.47 (m, 12H), 7.41 (s, 1H), 7.40 
– 7.36 (m, 4H), 7.19 (s, 4H), 7.13 (d, J = 8.5 Hz, 2H), 6.95 (dt, J = 7.7, 1.1 Hz, 1H), 6.82 
(d, J = 2.4 Hz, 2H), 6.80 (q, J = 2.4 Hz, 4H), 6.45 (s, 1H), 6.15 (d, J = 1.0 Hz, 1H), 3.83 (s, 
10H), 3.72 (s, 5H), 2.28 (s, 3H), 1.98 (s, 1H), 1.44 (s, 2H), 1.27 (s, 6H). (400Mz, CDCl3 δ 
ppm) 161, 156.4, 138.8, 131.6, 129.9, 127.4, 122.5, 115. 8, 107.4, 102.9, 73.6, 55.2, 26.8, 
21.32 
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3.3.34 Synthesis of 7-methoxy-2,2-dimethyl-3-p-tolyl-2H-chromene 
 
 
 
To a solution of 2-((Z)-3-hydroxy-3-methyl-2-p-tolylbut-1-enyl)-5-methoxyphenol (5.27g, 
17.67 mmol) in CH2Cl2 (176.0 ml) was added p-TSOH (0.91 ml, 5.30 mmol) and stirred 
for 12 hours. The reaction mixture was diluted with ethyl acetate (25. ml) followed by 5% 
aqueous NaHCO3 (45 ml) and stirred vigorously until the reaction was completed (TLC). 
The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 
x 50 ml) and the combined organic layer was dried with anhydrous Na2SO4 and evaporated 
under reduced pressure. The mixture was purified by column chromatography (70% 
hexane: 30% ethyl acetate) to give a semi-solid (2.81g) with 57% yield.  
1H NMR (600 MHz, Chloroform-d) δ 7.42 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.3 Hz, 2H), 
7.14 (d, J = 8.3 Hz, 1H), 6.73 (d, J = 2.9 Hz, 1H), 6.67 (dd, J = 8.3, 2.6 Hz, 1H), 6.49 (s, 
1H), 3.92 (s, 4H), 2.55 (d, J = 2.2 Hz, 4H), 1.78 (s, 7H). 13C NMR (600 MHz, CDCl3) δ 
160.92, 154.03, 139.30, 137.02, 129.10, 128.29, 127.38, 121.91, 116.56, 107.24, 102.31, 
79.09, 77.71, 77.50, 77.29, 55.27, 27.34, 21.35. 
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3.3.35 Synthesis of 4-(3, 4-dihydro-7-methoxy-2, 2-dimethyl-3-p-tolyl-2H-chromen-
4-yl) phenol 
 
 
 
To a stirred solution of 7-methoxy-2,2-dimethyl-3-p-tolyl-2H-chromene (1.03, 3.67 mmol) 
and phenol (0.52 g, 5.50 mmol) in benzene-cyclohexane mixture (1:1 ratio, 37 ml) at 0°C 
was added anhydrous aluminum chloride (0.59g, 4.40 mmol) in portions. A solution of 
phenol (0.21 g, 2.20 mmol) in benzene- cyclohexane mixture (1:1 Ratio, 24 ml) was added 
after 30 min, and the mixture further stirred for 8 hrs. The reaction mixture was quenched 
by adding a mixture of ice and conc. Hydrochloric acid (1:1, 2.0 ml) and stirred for 30 
minutes, the organic layer was separated, and the aqueous layer was re-extracted three 
times with dichloromethane (25 ml). The combined extract was washed with NaHCO3 (10 
%, 15 ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. 
The solid obtained was purified by column chromatography (20 hexane: 80 % ethyl 
acetate) to obtain the titled compound (0.58 g) with 43 % yield.  
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1H NMR (600 MHz, DMSO-d6) δ 9.24 (d, J = 150.4 Hz, 2H), 7.17 (t, J = 7.8 Hz, 3H), 
7.01 (d, J = 7.7 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 6.78 (d, J = 7.8 Hz, 3H), 6.52 (d, J = 8.0 
Hz, 2H), 6.48 (d, J = 8.7 Hz, 1H), 6.38 (s, 1H), 6.34 (d, J = 9.0 Hz, 1H), 4.39 (d, J = 12.4 
Hz, 1H), 4.16 (d, J = 6.4 Hz, 2H), 3.68 (d, J = 6.9 Hz, 3H), 3.45 (s, 4H), 3.20 (d, J = 4.3 
Hz, 8H), 2.51 (s, 2H), 2.21 (s, 4H), 1.26 (s, 3H), 1.17 (s, 3H). 13C NMR (600 MHz, 
DMSO) δ 158.57, 157.30, 155.31, 153.44, 136.27, 135.36, 133.88, 130.51, 129.87, 129.33, 
128.37, 118.94, 118.76, 115.19, 114.86, 106.80, 101.05, 77.91, 54.98, 54.90, 48.58, 42.13, 
39.84, 39.70, 39.56, 39.43, 39.29, 39.15, 39.01, 28.55, 20.50, 19.84.  
 
3.3.36 Synthesis of 1-(2-(4-(3,4-dihydro-7-methoxy-2,2-dimethyl-3-p-tolyl-2H-
chromen-4-yl)phenoxy)ethyl)pyrrolidine 
 
 
 
To a stirred solution4-(3, 4-dihydro-7-methoxy-2, 2-dimethyl-3-p-tolyl-2H-chromen-4-yl) 
phenol (0.18 g, 0.49 mmol) and DMF (4.88 ml) was added NaH (0.04 g, 1.46 mmol) under 
nitrogen atmosphere. The reaction mixture was vented with a needle for 20 min to allow 
evolution of H2 gas and then quenched with methanol (1.5 ml). After evolution of all H2 
182 
 
 
 
gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.13 g, 0.98 mmol) was added 
sequentially and stirred for 15 minutes. The reaction mixture was heated at 50°C overnight. 
After completion as indicated by TLC, the reaction mixture was quenched at 0°C by drop 
wise addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate (3x 10 ml) 
and the organic layer washed with water (3 x 25 ml) , dried over MgSO4, evaporated and 
purified by column chromatography (30% ethyl acetate:  70% hexane) to afford a semi-
solid (0.19 g) with 86% yield.  1H NMR (600 MHz, Chloroform-d) δ 7.10 – 7.07 (m, 1H), 
7.03 (d, J = 7.5 Hz, 2H), 6.98 – 6.96 (m, 2H), 6.93 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 8.7 Hz, 
2H), 6.66 (dd, J = 8.6, 0.9 Hz, 1H), 6.49 (d, J = 2.7 Hz, 1H), 6.41 (dd, J = 8.6, 2.6 Hz, 1H), 
4.49 – 3.65 (m, 10H), 3.20 (d, J = 12.2 Hz, 1H), 2.94 (t, J = 6.0 Hz, 1H), 2.86 (t, J = 6.1 
Hz, 2H), 2.67 (td, J = 6.8, 5.4, 2.8 Hz, 3H), 2.61 (td, J = 4.8, 4.3, 2.0 Hz, 3H), 2.28 (s, 3H), 
1.41 (s, 3H), 1.34 (d, J = 15.1 Hz, 4H), 1.29 (s, 3H). 13C NMR (600 MHz, CDCl3) δ 
159.22, 158.90, 157.13, 154.23, 136.33, 136.19, 136.07, 130.98, 130.04, 129.44, 128.72, 
120.73, 118.72, 114.61, 114.10, 107.45, 101.43, 78.27, 66.99, 66.82, 57.05, 55.20, 55.17, 
55.15, 54.77, 54.76, 43.96, 32.01, 29.79, 28.91, 23.57, 23.54, 22.78, 21.05, 20.21. HR-FT-
MS calcd for C31H37NO3 471.63 found 471.28 
 
3.4 Molecular Docking Studies 
 
To screen for analogs of ormeloxifene with specific inhibition activity on EGFR pathway, 
binding affinities of several designed analogs to essential protein kinases were predicted 
using molecular docking study. Molecular modeling was conducted with OpenEye® 
Scientific Software: Fast Rigid exhaustive docking (FRED), Omega2, and VIDA.   
Molecular docking calculations were performed by FRED (OpenEye Scientific Software 
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®) to obtain a consensus score of calculated binding affinity of the virtual analogs toward 
target proteins11. Detailed information on OpenEye® Scientific Software can be found at 
Software, Santa Fe, NM (USA). http://www.eyesopen.com. The results were visualized 
by VIDA (OpenEye Scientific Software ®) 
A virtual library of 800 analogs including ormeloxifene and a standard drug were designed 
using ChemDraw. Energy minimization, employing MMFF94 in ChemOffice, calculated 
the most stable conformation for each analog. Each analog was saved in .pdb format and 
compiled into a library of ligands. The compiled .pdb files were processed and used as 
input for Omega2, an OpenEye Scientific Software ® program that generates multi-
conformer structures for each ligand in the library to enhance ligand flexibility in an 
otherwise ridged model. The processed files were compiled into a .oeb.gz file. 
Protein kinase targets (EGFR, GSK3B, CDK2, mTOR, Akt, β-catenin, etc.) were 
downloaded from Protein Data Bank website in.pdb.gz format and were processed using 
Make Receptor, and the resulting protein receptor file was saved in.oeb.gz format. Docking 
was conducted using Open Eye Scientific Software ® including fast exhaustive docking 
(FRED), Omega and VIDA. 
3.5 MTT Assay 
 
Cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay21. Briefly, 5 X 106 cells of (A2780) were plated in 96 well plates and 
incubated for 24 hours at 37°C containing 5% of CO2. Cells were treated with various 
analogs of ormeloxifene for 24 hours. 20µL of 50 mg/mL MTT was added in each well 
containing 100 mL of cell media. The cells were incubated for a further 6 hours, and the 
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media was replaced with 150 mL of DMSO. Plates vigorously shaken for 15 minutes and 
absorbance was taken at 570 nm on a microplate reader. 
3.6 Western blot analysis 
 
Western blot analysis was conducted to investigate the effect of ORM-Br on protein levels 
on cervical cancer cell lines. (CaSki and SiHa) Cells were treated with ORM-Br (5-20µM) 
concentration for 24 hours using DMSO (0.1%) as control. Cytoplasmic and nuclear lysates 
were prepared using a nuclear extract kit (Active Motif). 40µg of protein lysates were 
subjected to western blot analysis using 4-20% SDS-PAGE gels, blotted onto PVDF 
membrane and blocked with 10% bovine serum albumin (BSA) 1hr at room temperature22. 
The membrane was later incubated with the indicated primary antibodies followed by 
horseradish peroxidase secondary antibody and developed using enhanced 
chemiluminescence reagent (Roche) using a gel documentation system. 
3.7 Cell Cycle analysis 
 
Cells were plated in a 100mm dish and allowed to attach overnight. Cells were later 
exposed to ORM-Br (9.0 and 17.2µM) for 48 hrs. Cells were collected after ORM-Br 
treatment, fixed with 70% Telford Reagent containing ethanol, stained with propidium 
iodide, incubated overnight at 4 °C, and analyzed with an Accuri C6 flow cytometer. Cells 
with hypodiploid DNA were deemed apoptotic (G0/G1)23.  
3.8 Clonogenic assay 
 
In the clonogenic assay, cells were seeded at 500 cells per 100 mm culture dish and allowed 
to attach overnight. The cells were treated with ORM-Br and maintained under standard 
cell culture conditions at 37 °C and 50% CO2 in a humid environment. 10 days later, the 
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dishes were washed twice in PBS, fixed with methanol, stained with hematoxylin, washed 
with water and air dried. Visible colonies (approx. 50 cells) were counted, and % colonies 
were calculated using the number of colonies formed in treatment divided by several 
colonies established in the vehicle control (ethanol) as describe previously24. 
3.9 Confocal Microscopy 
 
Cells were plated in four chamber slides at 5 x 104 cells per chamber and were allowed to 
attach at 60% confluence for 24 hours before being treated with 10µM ORM-Br for 18 
hours. Cells were later processed for confocal microscopy24. Treated cells were rinsed with 
1x HEPES/Hank buffer, fixed and permeabilized with cold methanol, washed with 1 x PBS 
and blocked with 10% normal goat serum in PBS. Cells were incubated with primary 
antibody followed by a species-specific Alexa Fluor® 488 secondary antibodies 
(Invitrogen). After washing, cells were stained with DAPI and coverslip were mounted in 
FluoroCare Anti-Fade mounting medium (Biocare Medical). Confocal microscopy was 
performed with Olympus Fluoview FV 1000 confocal microscope (Olympus 
cooperation)25. 
3.10 Cell Migration 
 
Cell migration assay was performed using Boyden’s Chambers assay, as per 
manufacturer’s protocol (BD Biosciences). After 48 hr incubation, the migratory cells were 
fixed with methanol and stained with crystal violet and photographed under a light 
microscope. Migratory cells in ORM-Br treated group was compared with control21. 
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3.11 Cell proliferation by xCELLigence assay 
 
Cervical cancer cells (10,000 cells) were seeded in E-plate (Roche) following the 
xCELLigence. Real-Time Cell Analyzer (RTCA) DP instrument manual as provided by 
the manufacturer (Roche)26. ORM-Br (5-15µM) or vehicle control (0.1% DMSO) were 
added after 24 hrs, and the experiment was allowed to run for 100 hrs. Average baseline 
index for ORM-Br treated cells compared to control cells was calculated for at least two 
measurements for replicated experiments27. 
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Chapter four 
Design, Synthesis and Biological Evaluation of Ormeloxifene Analogs with 
pyrrolidine Moiety at C-7 targeting Epidermal Growth Factor towards the 
Treatment of Ovarian Cancer 
4 Introduction  
4.1 Ovarian cancer 
 
In 2017, the incident of ovarian cancer rose to about 22,440 and caused over  14,080 death 
worldwide1. The occurrence of ovarian cancer rate is higher in Europe and North America, 
and it is known to be the 5th highest leading cause of deaths worldwide.2 The five-year 
survival rate of ovarian cancer is between 30 – 92% depending on the stage at which the 
disease was diagnosed.3 The risk factor includes null parity, age, late menopause and 
hereditary factors such as BRCA1 and BRCA2 mutation.4 Advanced chemotherapy and 
the improved understanding of genetic risk factors as well as molecular pathogenesis have 
paved the way for new treatment options (Fig 4.1).   
Different types of ovarian cancer have been identified according to the nature of cells from 
which they start. These include ovarian epithelial carcinoma, germ cell carcinoma tumor, 
stromal carcinoma, and small cell carcinoma5. 
Epithelial ovarian carcinogenesis makes up about 90% of all ovarian cancer cases and is 
rampant generally in postmenopausal women.  According to Bryan T et al., during 
postovulatory re-epithelial lisation, ovarian surface epithelial cells (OSE) (blue) divide and 
migrate to cover the ovulatory lesion (black arrow). Hyperplasia and transformation of 
OSE to adenocarcinoma can occur as a result of many factors including surges of pituitary 
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gonadotropins (red arrow, top left). The preovulatory surge of luteinizing hormone 
induces increased expression of cytokines and invasion of macrophages and monocytes 
(orange cells), leading to differentiation of follicle cells into luteal cells. Ovulation also 
stimulates the formation of invaginations and inclusion cysts. Cysts cells can differentiate 
between taking on Mullerian characteristics and proliferate under the effect of hormonal 
and cytokine stimulation and become ciliated (yellow cells) or secretory (tan cells). 
Eventually, these cells accumulate genetic aberrations. Rete ovarii tubules at the hilus of 
the ovary, close to the mesothelium to OSE (M-E) transition, also contain ciliated and 
secretory cells and can dilate to form a cyst.   Whether cells in both cysts types can become 
cancerous is unknown. The role of any proposed ovarian stem or progenitor cells (purple 
cells) in epithelial ovarian carcinogenesis remains to be elucidated (Fig 4.1)4. 
Ormeloxifene has demonstrated excellent anti-cancer activity in different cancer cell lines 
including ovarian cancer. Currently, Ormeloxifene is being investigated to target the 
EGFR, and it is downstream, and studies have shown the ability of ormeloxifene to inhibit 
Akt phosphorylation in Head and neck squamous cell carcinomas (HNSCC)6.  
Ormeloxifene has shown to activates mTOR induces phosphorylation of effector molecule 
P70S6K and S6 ribosomal proteins, which effectively results in mTOR dependent gene 
transcription that control cell proliferation, metabolism, and protein synthesis 7. The 
knowledge of varying inhibitory activity of ormeloxifene on multiple pathways is a 
possible lead towards the discovery of potential anticancer agent; we propose that 
ormeloxifene framework can be altered to generate possible drug candidates, which can 
help in the treatment of ovarian cancer. 
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Figure 4.1 Epithelial ovarian carcinogenesis. Reproduced from Bryan T Hennessy, Robert 
l Coleman, Maurie Markman, Ovarian cancer The Lancet 2009, 374 (9698), 1371-1382. 
Main source8. 
 
 
4.1.1 Diagnosis and treatment of ovarian cancer 
 
The use of magnetic resonance imaging or computed tomography has been used in the 
diagnosis of different types of cancers including ovarian cancer9. However, these two 
procedures tend to underestimate the peritoneal and mesenteric tumors which are common 
in advanced ovarian carcinoma. There is a higher probability of survival rate when the 
disease is diagnosed at the early stages10. In advanced ovarian cancer, cisplatin and 
paclitaxel combinations are the most commonly used combination therapy, with 
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approximately 80 percent responds rate11. However, most patients suffer deterioration after 
about eight months of improvement. A significant disadvantage of the current treatment of 
ovarian carcinoma is the ability of the current therapies to fail at the diagnosis stage and 
resistance to combination therapy. Recently, cytotoxic drugs such as trabectedin and 
canfosfamide are used as a single efficient therapy to overcome drug resistance in ovarian 
cancer12 compared to combination therapy.   
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Figure 4.2. Trabectedin and canfosfamide, a drug resistance therapy 
 
Currently, several therapeutic agents have been developed to target various stages of cell 
developments such as cell cycle regulation, protein translation angiogenesis, metastasis, 
apoptosis induction, and signal transduction13. However, no specific gene amplification or 
gene mutation responsible for progression or initiation of the disease has yet been 
identified. The nonexistence of a single pathogenic mutation is a challenge for target 
therapy14. Therefore the need for novel molecular targeted agents with potent and specific 
cytotoxic regiments would be a significant benefit towards the treatment of ovarian cancer. 
Ormeloxifene, a selective estrogen receptor modulator, has demonstrated excellent anti-
cancer activity in different cancer cell lines including ovarian carcinoma15, breast cancer16, 
Trabectedin  Canfosfamide 
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and head and neck squamous carcinoma6. Recent investigation has revealed the potential 
therapeutic index of ormeloxifene in pancreatic carcinoma via inhibiting sonic hedgehog 
(SHH) signaling pathway as well as modulating tumor microenvironment17. Bilal Bin 
Hafeez et al., 2017 recently reported the ability of ormeloxifene to effectively inhibit 
molecular signatures of epithelial-mesenchymal transducers (EMT), β-catenin/TCF-4 
transcriptional activity, induces phosphorylation of GSK3B and β-catenin degradation 
resulting in suppression of prostate tumor growth in xenograft mouse model18. 
The safe human use and excellent therapeutic index of ormeloxifene have as discussed in 
the previous chapter19 have made it a potential drug candidate towards the treatment of 
ovarian cancer.  In this study, we report the structural design, synthesis of novel 
ormeloxifene analogs with pyrrolidine moiety installed at the C-7 position of benzopyran 
skeleton to enhance its antiproliferation activities as well as the pharmacokinetic 
properties.  
4.2 Results and discussion  
4.2.1 Molecular docking 
  
 Molecular docking was conducted to know whether ormeloxifene and its analogs bind to 
various receptor proteins such as EGFR, GSK3B, and CDK2. Virtual library of 600 
structurally modified C-4, C-7, and C-3 ormeloxifene analogs containing pyrrolidine, 
trifluoromethoxy benzene side chain, standard ormeloxifene and known EGFR inhibitors 
were prepared, and their energies minimized using Chem Office, with PM3 minimization 
along with standard drug of choice for the treatment of ovarian cancer. These files were 
converted into *pdb files maintaining all heavy atoms and concentrated into single 
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continuous *pdb file to be used as an input for Omega. Omega uses the MMF94 force field 
to generate multiple conformers for each input ligand to induce ligand flexibility in a rigid 
model. Modifications were applied to the default settings of OMEGA20. Receptor files 
(PDB files) were downloaded from protein data bank (PDB) website (GSK3B, EGFR, 
CDK2, mTOR) were prepared using OpenEye,s Fred Receptor program21. This program 
defines the space in which the search algorithm performs and define the shape potential for 
calculation (shape fitting step)22. Multiple scoring functions such as shapegsuss, 
chemguass3, Oechemscore, Screen score, and PLP were employed to obtain a consensus 
structure and scores in the final output.  
 
                                                  
Figure 4.3  Proposed structure of ormeloxifene analogs with arrows showing various 
positions for structural modification 
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4.2.2 Results of molecular Docking  
 
Molecular modeling studies of ormeloxifene analogs showed quite several analogs with a 
significant calculated binding affinity towards EGFR and it downstream (Table 4.1). 
Analogs with (ethyl)pyrrolidine at C-7 and anisole at C-4 such as JA_20 showed higher 
binding mode in EGFR binding site by forming two hydrogen bonds with ASP:200: A  and 
GLY:65: B the same amino acid that bond to ormeloxifene in EGFR binding site (Fig.4.5). 
However, a stronger hydrogen bonding of JA_15 and JA_17 with GLU: 234: A in the 
crystal structure of EGFR, did not improve the binding affinities of these analogs in EGFR 
binding pocket. 
In GSK3B binding pocket, analogs with (ethyl)pyrrolidine side chain at C-7 of 
Ormeloxifene scaffolds such as JA_20, JA_25 JA_15, JA_18, JA_19, and JA_17 showed 
both hydrophilic and hydrophobic interactions. Most analogs with anisole and aniline at C-
4 of ormeloxifene skeleton revealed higher binding affinity by forming two hydrogen 
bonds with  LYS:85: B and ASP:200: B in GSK3B binding pocket (Fig 4.4). 
Ormeloxifene analogs with trifluoromethyl benzene at C-4 of ormeloxifene skeleton such 
as JA_22,  and JA_15 formed hydrogen bond with LYS: 85: B and ASP: 200: B in GSK3B 
binding pocket.  
Molecular docking also showed a significant number of analogs bind to CDK2 binding 
pocket also showed a significant binding mode with ormeloxifene analogs compared to 
known estrogen receptor modulators. Substitution the (ethyl)pyrrolidine group at the 
phenoxy position with trifluoromethoxy moiety and replacing the methoxy group at C-7 
with (ethyl)pyrrolidine moiety such as JA_15, JA_16, JA_17, and JA_18 resulted in 
hydrogen bond with HIS:84:A, the same amino acid in CDK2 pocket that ormeloxifene 
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binds to induce its anticancer activity (Fig 4.6, 4.7). JA_15, an analog with hydrogen at C-
4’ demonstrated outstanding binding affinity towards CDK2 binding site relative to similar 
analogs such as JA_16, JA_17, JA_18 with halogens substituted at C-4’(Table 4.1). All 
the designed analogs showing lower higher binding affinity will be chemically synthesized 
to be evaluated biologically as an anti-cancer candidate. 
Table 4.1 Sample of consensus score of FRED docking in CDK2 receptor 
VIDA Name VIDA 
ID 
PLP Chemgauss3 OEChemscore Screenscore Consensus 
Score 
JA_15_8 2 -
62.1912 
-98.9223 -50.9355 -161.426 4 
JA_23_65 3 -
63.1604 
-85.4124 -53.3115 -148.521 9 
JA_18_194 4 -
55.5819 
-94.061 -49.7552 -156.399 15 
JA_31_197 5 -
58.7091 
-78.7798 -50.6628 -138.252 31 
ORM_Me_70 6 -
58.9203 
-88.0918 -48.9543 -130.846 31 
JA_17_124 7 -
60.2571 
-82.0704 -46.9993 -151.993 33 
JA_30_136 8 -
54.9044 
-82.1141 -49.7006 -133.778 34 
JA_20_91 9 -
55.1979 
-82.9193 -52.6244 -128.111 34 
JA_29_196 10 -
56.4896 
-74.7738 -51.4356 -136.43 37 
JA_22_18 11 -
57.7173 
-76.0436 -49.6441 -141.795 38 
JA_24_136 12 -
54.9044 
-82.1141 -49.7006 -133.778 38 
JA_16_118 13 -
50.2681 
-89.5709 -47.0727 -145.829 41 
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JA_19_43 14 -
51.9849 
-86.1558 -49.8197 -128.74 41 
JA_33_173 15 -
52.6577 
-80.5097 -48.3041 -139.799 43 
JA_35_136 16 -
49.7391 
-81.7393 -46.085 -134.599 58 
JA_25_26 17 -52.629 -76.5679 -47.4447 -128.804 63 
JA_28_130 18 -
52.1154 
-73.6299 -49.4652 -122.123 65 
JA_26_58 19 -
50.8557 
-75.0371 -48.8462 -128.441 65 
JA_32_166 20 -
49.3175 
-79.5876 -48.1438 -121.453 68 
JA_34_4 21 -
48.3862 
-71.7791 -48.2779 -130.937 69 
ORM_188 22 -
46.7276 
-86.295 -45.0742 -110.072 69 
JA_27_4 23 -
48.3862 
-71.7791 -48.2779 -130.937 73 
ORM_F_106 24 -54.664 -70.7967 -42.5575 -119.368 79 
ORM_Cl_107 25 -
46.5579 
-78.3947 -41.5806 -103.429 86 
ORM_Br_166 26 -
36.8834 
-79.3884 -41.2741 -92.8488 87 
ORM_I_109 27 -
30.6345 
-79.4347 -40.6518 -85.7905 89 
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Figure 4.4. JA_15 is forming two hydrogen bonds in GSK3B binding pocket. 
 
 
Figure 4.5 JA-20 in EGFR pocket showing hydrogen bonding with ASP:200B and 
GLY:65: B 
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Figure 4.6  JA_17 forming hydrogen bonds with His:84: A in CDK2 binding pocket 
 
 
 
Figure 4.7 JA-18 form a hydrogen bond with HIS:84: A in the crystal structure of CDK2 
 
202 
 
 
 
 
 
4.2.3 Synthesis of ormeloxifene analogs  
 
Synthetic schemes of the top analogs that showed higher binding affinities toward 
molecular targets such as EGFR, CDK2, Akt, and GSK3B were outlines. Several synthetic 
trials were conducted to optimize the synthetic routes. Successful synthetic routes were 
employed to install (ethyl) pyrrolidine, side chain at C-7 or halogens at C-4’, and aniline, 
anisole, and trifluoromethyl benzene at C-4 of ormeloxifene skeleton (Fig 4.3). It was 
painstaking to install various functionalities on ormeloxifene skeleton, especially the 
installation of (ethyl) pyrrolidine side at C-7 of ormeloxifene skeleton. Due to the higher 
polarity of (ethyl) pyrrolidine, several chemical reactions were initiated, and the concept 
of trial and error were employed to optimize the complete reaction schemes. The synthesis 
started by protecting the alcohol on intermediate compound 2 using TBSCl/Imidazole in 
the presence of DMF to give compound23 8. Grignard reaction of 8 with methyl magnesium 
bromide (MeMgBr) in tetrahydrofuran (THF) produced compound 9. Intramolecular 
dehydration of 9 with TFA in the presence of toluene gave compound 10. Hydroarylation 
of 10 with phenol in benzene and cyclohexane afforded compound24 11. Deprotection of 
compound 11 using tetrabuthyl ammonium fluoride (TBAF) in THF produced compound25 
12. Condensation of compound 12 with 1-(2-chloroethyl) pyrrolidine in the presence of 
potassium carbonate (K2CO3) in acetone at 60 °C produced JA-15. Other analogs JA-16 
to JA-26 were synthesized using the same synthetic routes described in the scheme below 
(Scheme 4.1). The synthesized analogs are listed in Table 4.1 below. The stereochemistry 
of the analogs was achieved by using aprotic solvent such as THF was used.   
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So far, a total of 8 compounds with pyrrolidine moiety at C-7 have been synthesized, and 
their antiproliferation studies will be conducted to identify their effects on ovarian cancer 
cells.  
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Scheme 4.1 Synthesis of ormeloxifene analogs with a pyrrolidine side chain at C-7 
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Table 4.2 Synthesized ormeloxifene analogs 
OO
N
R
X
 
Compound R X 
JA_15 OCF3 H 
JA_16 OCF3 Br 
JA_17 OCF3 Cl 
JA_18 OCF3 F 
JA_19 OH H 
JA_20 OCH3 H 
JA_25 NH2 H 
JA_26 CH3 Br 
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4.2.4 Biological Evaluation of synthesized analogs  
 
 Treatment of ormeloxifene analogs such as JA_15, JA_17, JA_16, JA_20, JA_18, 
JA_19, JA_25 and JA_26 inhibits viability of A2780 cells in a (10-40 mm) dose-
dependent manner. The IC50 analogs including JA_15, JA_17, JA_16, JA_20, JA_18, 
JA_19, and JA_26 were 9.0µM, 20.4µM, 37.6µM, 74.8µM, 74.9µM, 36.2µ, and 67.3µM 
respectively, after 48 hours treatment (Table 4.3), but JA_25, completely lost its inhibitory 
activity in (A2780) ovarian cancer cell lines. Compounds with (ethyl) pyrrolidine side 
chain at C-7 of Ormeloxifene scaffold such as JA_15  showed higher inhibitory activity 
with IC50 of 9.0µM compared with ormeloxifene (IC50 = 17.5µM).  However, the 
introduction of halogen at C-4’ such as JA_17, JA-16, and JA_18 (IC50 20.4µM, 37.6µM, 
79.7µM respectively) decreases the inhibitory activity relative to Ormeloxifene. The same 
compound but with phenol at C-4 such as JA_19 (IC50 = 36.2µM) showed moderate 
inhibitory activity compared to ormeloxifene, but inhibitory activity reduced drastically 
when the phenol at C-4 was replaced with anisole as in JA_20 (IC50 = 74.8). This an 
evidence that presence of anisole, at C-4 and halogens at C-4’ reduces inhibitory activity 
in A2780 cells.    
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Table 4.3  MTT Cell viability results of ormeloxifene analogs on the A2780 Cell line 
 
Compound IC50  
(µM) 
Compound IC50  
(µM) 
Ormeloxifene 17.5 JA_16 37.6  
JA_15 9.0 JA_20 74.8 
JA_17 20.4 JA_26 N/A  
JA_18 79.7 JA_25 85.6  
 
 
 
 
Figure 4.8  Ability of Ormeloxifene analogs to inhibit the growth of A2780 cell lines 
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4.2.5 Cell cycle via modulation of cell-cycle regulatory proteins 
 
The effect of ormeloxifene analogs on ovarian cancer cell cycle distribution was 
determined using A2780 cells. The cells were synchronized and treated with the most 
active analogs JA-15 for 24 hours, with vehicle-control as DMSO.  The cell cycle analysis 
performed by flow cytometry revealed that JA-15 arrest A2780 cells in the G0 – G1 phase 
(Fig 4.10), (Table. 4.6). JA-15 showed an increase in the fraction of cells in the G0-G1 
phase with 61.98% compared to the control with 53.42% (Table. 4.6). This result indicates 
that JA-15 has the potential to chemotherapeutic effects because it arrests (A2780) ovarian 
cell cycle in G0-G1 phase
26’27. The promising antiproliferation activity data of JA_15 
demonstrated the importance of transposition of pyrrolidine moiety to C-7 of ormeloxifene 
skeleton. Docking results showed that JA-15 has a higher binding affinity than 
ormeloxifene. This observation coupled with biological effects can be attributed to several 
factors such as stereochemistry of the aromatic at C-4, type of pharmacophores at 
pyrrolidine side chain and the electron withdrawing functional groups at C-4’’. 
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 Control                                                                    ORM (17.2 µM) 
 
 
 
 
 
 
 
 
 
 
                       JA-15 (9.0 µM)                                                       
 
 
 
 
 
 
 
 
 
 
Table 4.4. Cell distribution in (A2780) ovarian cancer cells 
Groups  G0 – G1 S G2 - M 
Control 53.42 43.06 3.52 
Orm (17.2 µM/L) 60.69 27.93 11.38 
JA-15 (9.0 µM/L) 61.98 28.07 9.94 
 
Figure 4.9. Effects of Ormeloxifene and JA-15 on cell cycle phase distribution of ovarian cancer cells  
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4.3 Conclusion 
 
Ormeloxifene analogs were designed using structural based molecular modeling to installed 
biological important pharmacophores such as ethyl pyrrolidine at -7 and various aromatic and 
heterocyclic substituents at C-4 and C-7. All analogs were explored biologically to ascertain their 
potency towards ovarian cancer cell lines.  JA_15 performed better in cytotoxicity assays with IC50 
of 9 µM higher than a known EGFR inhibitor Ormeloxifene.  Installation of trifluromethoxybenze 
at the C-4 position of Ormeloxifene skeleton improved the cytotoxicity activities compared with 
similar compounds with anisole, aniline and phenol groups at C-4.  JA-15 caused cell cycle arrest 
in G0-G1 phase which indicates that JA-15 has the potential to chemotherapeutic effects. 
  
 
4.4 Experimental section 
4.4.1 General 
 
All chemicals and solvents were purchased from Fisher Scientific, Across Chemical or 
Sigma Aldrich and used without further purification. All glassware used was washed, 
cleaned and oven dried overnight before conducting any chemical reaction. Any reaction 
that requires anhydrous condition were performed under argon or nitrogen environment. 
Pre-coated silica gel plates were used to analyze the progress and completion reaction. UV 
light at 254 or 365 or CAM stain was used to visualize the chemical reaction spot. All 
synthetic intermediates and final compounds were purified by column chromatography 
with 230 x 400 silica gel. Proton (1H) and Carbon (13C) NMR spectra were analyzed by 
Bruker Avance-400 MHz and 600 MHz NMR using D-acetone or CDCl3. NMR chemical 
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shifts were presented in σ(PPM) using residual solvent peaks as standard ( CDCl3, 7.26 (H), 
77.16 (C)). High-resolution mass spectrometer (HRMS) was gained using Thermo 
Finnigan MAT 95XL mass spectrometer at the University of Buffalo mass spectroscopy 
facility. All synthetic intermediate and final compounds were purified using column 
chromatography with 230ˣ400 mesh silica gel.  1H and 13C NMR spectra were using Bruker 
AVANCE-400 MHZ and 600 MHZ NMR spectrometer, in CDCl3 and D-acetone. NMR 
chemical shifts were presented in 𝜎(PPM) using residual solvent peaks as standards 
(CDCl3, 7.26 (H), 77.16 (C)). 
 
4.4.2 3-(4-bromophenyl)-3,4-dihydro-2,2-dimethyl-4-(4-(trifluoromethoxy)phenyl)-
2H-chromen-7-ol 
 
 
OHO
10d
AlCl3,
Benzene, 
cyclohexane 
00C, 75%
OHO
O
CF3
12
Br
O CF3
Br
 
 
To a stirred solution of 10d (3.30 g, 9.96 mmol) and trifluoromethyl benzene (2.80 
g, 20.92 mmol) in benzene-cyclohexane mixture (1:1 ratio, 100 ml) at 0°C was 
added anhydrous aluminum chloride (1.6g, 11.95 mmol) in portions and stirred for 
30 min. The mixture further stirred at room temperature for 8 hrs. The reaction 
mixture was quenched by adding a mixture of ice and conc. Hydrochloric acid (1:1 
5.0 ml) and the organic layer was separated. The aqueous layer was re-extracted 
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three times with dichloromethane (35.0 ml). The combined extract was washed with 
NaHCO3 (10 %, 20.0ml), dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The semi-solid obtained was purified by column 
chromatography (70% hexane: 30% ethyl acetate) to obtain (3.69g, 75%) 12. 
1H NMR (600 MHz, Chloroform-d) δ 8.31 – 8.25 (m, 4H), 7.87 (dd, J = 8.3, 1.4 
Hz, 1H), 7.73 – 7.67 (m, 6H), 7.59 – 7.52 (m, 11H), 7.49 – 7.44 (m, 9H), 7.34 (ddd, 
J = 9.9, 5.7, 1.9 Hz, 10H), 7.30 – 7.24 (m, 10H), 7.20 (d, J = 8.5 Hz, 4H), 6.97 – 
6.92 (m, 1H), 6.89 – 6.84 (m, 2H), 6.60 (s, 1H), 6.23 (s, 1H), 4.35 – 4.28 (m, 1H), 
3.97 (s, 1H), 3.04 (s, 1H), 2.42 (d, J = 10.8 Hz, 1H), 1.61 (s, 7H). 13C NMR (151 
MHz, CDCl3) δ 160.18, 156.03, 151.04, 151.00, 139.11, 138.25, 137.92, 133.72, 
132.61, 131.93, 131.65, 131.55, 131.44, 131.38, 130.42, 130.25, 130.19, 129.88, 
129.66, 129.61, 129.59, 129.57, 129.00, 128.88, 128.86, 128.67, 128.53, 128.44, 
128.38, 126.40, 126.01, 121.83, 121.79, 121.66, 120.99, 120.39, 115.42, 114.83, 
113.71, 104.91, 80.41, 78.87, 68.33, 47.13, 30.44, 29.79, 29.46, 27.62, 22.79. 
 
4.4.3 1-{2-[3-(4-Bromo-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-
chroman-7-yloxy]-ethyl}-pyrrolidine 
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To a stirred solution of3-(4-bromophenyl)-2,2-dimethyl-4-(4-
(trifluoromethoxy)phenyl)chroman-7-ol (0.20 g, 0.41 mmol) and DMF (5.0 ml) was added 
NaH (0.034 g, 1.43 mmol) under nitrogen atmosphere. The reaction mixture was vented 
with a needle for 20 min to allow the evolution of H2 gas and then quenched with methanol 
(1.3 ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride 
(0.15g, 0.82 mmol) was added sequentially and stirred for 15 minutes. The reaction mixture 
was heated at 50°C overnight. After completion as indicated by TLC, the reaction mixture 
was quenched at 0°C by dropwise addition of NaHCO3 over 20 min. It was then extracted 
with ethyl acetate (3x 10 ml) and the organic layer washed with water (3 x 25 ml), dried 
over MgSO4, evaporated and purified by column chromatography (30% ethyl acetate:  70% 
hexane) to afford a semi-solid (0.20 g) with 83% yield. 
 
1H NMR (600 MHz, Chloroform-d) δ 8.08 – 8.04 (m, 1H), 7.80 – 7.75 (m, 3H), 
7.54 – 7.45 (m, 5H), 7.44 – 7.38 (m, 5H), 7.24 (s, 1H), 7.20 – 7.16 (m, 3H), 6.49 (s, 1H), 
6.29 (s, 1H), 4.48 (t, J = 6.0 Hz, 1H), 4.01 (t, J = 5.8 Hz, 4H), 3.36 (s, 1H), 2.89 (t, J = 6.0 
Hz, 2H), 2.64 (dq, J = 7.1, 3.7 Hz, 4H), 2.49 (t, J = 5.9 Hz, 3H), 2.32 (d, J = 6.1 Hz, 7H), 
1.66 (t, J = 3.5 Hz, 10H), 1.56 (s, 7H). 13C NMR (600 MHz, CDCl3) δ 158.79, 156.60, 
139.25, 138.64, 138.10, 132.89, 132.23, 131.68, 131.46, 131.37, 130.42, 129.87, 129.63, 
129.48, 128.91, 128.33, 128.25, 127.99, 122.09, 121.81, 121.67, 115.53, 100.85, 79.62, 
68.26, 64.24, 54.73, 54.56, 54.27, 54.18, 31.96, 29.74, 29.69, 29.40, 23.59, 23.44, 22.72, 
14.17. HR-FT-MS calcd for C31H31BrF3NO3 590.47 found 590.15 
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4.4.4 3,4-dihydro-2,2-dimethyl-3-phenyl-4-(4-(trifluoromethoxy)phenyl)-2H-
chromen-7-ol 
 
OHO OHO
O
CF3
12a10a
AlCl3,
Benzene, 
cyclohexane 
00C, 79 %
O CF3
 
 
To a stirred solution of 2,2-dimethyl-3-phenyl-2H-chromen-7-ol (0.40g, 1.6mmol) and 1-
(trifluoromethoxy) benzene (0.46ml, 3.40 mmol) in benzene-cyclohexane mixture (1:1 
ratio, 16.0 ml) at 0°C was added anhydrous aluminum chloride (0.26g, 1.92 mmol) in 
portions and the mixture further stirred for 8 hrs. The reaction mixture was quenched by 
adding a mixture of ice and conc. Hydrochloric acid (1:1 4.0 ml) and the organic layer was 
separated. The aqueous layer was re-extracted three times with dichloromethane (15.0 ml). 
The combined extract was washed with NaHCO3 (10 %, 5.0ml), dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. The semi-solid obtained was 
purified by column chromatography (70% hexane: 30% ethyl acetate) to obtain (0.52g, 
79%) 12a.  
1H NMR (400 MHz, Chloroform-d) δ 8.28 (dd, J = 8.3, 1.4 Hz, 1H), 7.73 – 7.67 (m, 3H), 
7.62 – 7.51 (m, 5H), 7.51 – 7.44 (m, 2H), 7.36 (dd, J = 13.0, 2.4 Hz, 11H), 6.61 (s, 1H), 
6.22 (s, 1H), 1.64 (s, 7H). 13C NMR (400 MHz, CDCl3) δ 160.23, 151.07, 140.38, 139.06, 
138.39, 133.59, 131.66, 131.49, 130.22, 130.11, 129.50, 128.89, 128.60, 128.34, 128.31, 
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128.24, 128.20, 127.67, 125.89, 121.79, 121.17, 115.03, 113.60, 104.84, 80.64, 32.05, 
29.84, 29.80, 29.50, 27.67, 22.82. 
 
 
4.4.5 1-{2-[2,2-Dimethyl-3-phenyl-4-(4-trifluoromethoxy-phenyl)-chroman-7-
yloxy]-ethyl}-pyrrolidine 
 
 
 
To a stirred solution of 2,2-dimethyl-3-phenyl-4-(4-(trifluoromethoxy)phenyl)chroman-7-
ol (0.23 g, 0.55 mmol) and DMF (5.51 ml) was added NaH (0.046 g, 1.93 mmol) under 
nitrogen atmosphere. The reaction mixture was vented with a needle for 20 min to allow 
evolution of H2 gas and then quenched with methanol (1.7 ml). After evolution of all H2 
gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.147 g, 1.10 mmol) was added 
sequentially and stirred for 15 minutes. The reaction mixture was heated at 50°C overnight. 
After completion as indicated by TLC, the reaction mixture was quenched at 0°C by drop 
wise addition of NaHCO3 over 20 min. It was then extracted with ethyl acetate (3x 15 ml) 
and the organic layer washed with water (3 x 35 ml) , dried over MgSO4, evaporated and 
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purified by column chromatography (30% ethyl acetate:  70% hexane) to afford a semi-
solid (0.21 g) with 75% yield. 
1H NMR (600 MHz, Chloroform-d) δ 7.83 – 7.78 (m, 2H), 7.70 – 7.65 (m, 2H), 
7.60 – 7.48 (m, 6H), 7.44 (t, J = 7.8 Hz, 3H), 7.39 – 7.33 (m, 10H), 7.32 – 7.28 (m, 6H), 
7.26 (s, 2H), 6.95 (dt, J = 8.8, 1.5 Hz, 2H), 6.56 – 6.50 (m, 2H), 6.33 (s, 1H), 6.21 (s, 1H), 
4.14 (t, J = 6.0 Hz, 2H), 4.03 (t, J = 5.9 Hz, 3H), 2.94 (t, J = 6.0 Hz, 2H), 2.66 (ddd, J = 
6.8, 4.8, 2.7 Hz, 4H), 2.52 (t, J = 5.9 Hz, 3H), 2.37 – 2.33 (m, 5H), 2.19 (s, 1H), 1.86 – 
1.81 (m, 5H), 1.69 (p, J = 3.2 Hz, 6H), 1.60 (d, J = 5.8 Hz, 15H), 1.30 (s, 9H). 13C NMR 
(600 MHz, CDCl3) δ 166.18, 160.19, 158.87, 158.67, 156.65, 140.38, 140.01, 139.34, 
139.25, 139.01, 138.33, 132.22, 131.65, 131.49, 130.09, 129.51, 129.43, 128.83, 128.71, 
128.34, 128.30, 128.25, 128.21, 128.17, 128.00, 127.78, 127.64, 127.55, 121.98, 121.31, 
121.12, 120.71, 115.84, 115.02, 114.60, 113.58, 104.77, 100.86, 80.66, 79.98, 68.28, 
66.95, 55.13, 54.74, 54.61, 54.23, 29.74, 27.65, 27.34, 23.52, 23.46. HR-FT-MS calcd for 
C30H32F3NO3 511.57 found 511.27 
 
4.4.6 3-(4-Fluoro-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-chroman-7-
ol 
 
 
OHO
F
OHO
O
CF3
12b
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Benzene, 
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To a stirred solution of 3-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-2H-chromen-7-ol 
(0.54g, 2.0 mmol) and 1-(trifluoromethoxy) benzene (0.68 g, 0.37 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 20.0 ml) at 0°C was added anhydrous aluminum chloride 
(0.32 g, 2.41 mmol) in portions and the mixture further stirred for 8 hrs. The reaction 
mixture was quenched by adding a mixture of ice and conc. Hydrochloric acid (1:1 3.0 ml) 
and the organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (8.0 ml). The combined extract was washed with NaHCO3 (10 %, 5.0ml), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-
solid obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) 
to obtain (0.87g, 69%) 12b.  
1H NMR (600 MHz, Chloroform-d) δ 7.49 (dd, J = 26.9, 8.1 Hz, 1H), 7.34 – 7.19 (m, 4H), 
7.09 – 6.98 (m, 1H), 6.97 – 6.87 (m, 2H), 4.18 (q, J = 7.2 Hz, 2H), 1.93 (d, J = 1.2 Hz, 2H), 
1.59 (s, 1H), 1.40 – 1.18 (m, 6H). 13C NMR (600 MHz, CDCl3) δ 162.44, 160.81, 160.24, 
156.43, 156.36, 139.34, 138.20, 135.26, 133.12, 131.08, 131.03, 130.21, 129.93, 129.55, 
128.85, 128.65, 128.50, 128.40, 128.32, 128.24, 126.85, 125.81, 121.75, 121.44, 120.06, 
115.48, 115.27, 115.20, 115.13, 115.10, 111.82, 111.63, 104.80, 102.96, 80.58, 60.74, 
34.52, 27.53, 26.96, 26.21. 
 
 
 
 
 
 
217 
 
 
 
4.4.7 1-{2-[3-(4-Fluoro-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-
chroman-7-yloxy]-ethyl}-pyrrolidine 
 
 
To a stirred solution of 3-(4-fluorophenyl)-2,2-dimethyl-4-(4-
(trifluoromethoxy)phenyl)chroman-7-ol (0.61g, 1.41 mmol) and DMF (14.11 ml) was 
added NaH (0.12 g, 4.93 mmol) under nitrogen atmosphere. The reaction mixture was 
vented with a needle for 20 min to allow the evolution of H2 gas and then quenched with 
methanol (1.1 ml). After the evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine 
hydrochloride (0.38 g, 2.82 mmol) were added sequentially and stirred for 15 minutes. The 
reaction mixture was heated at 50°C overnight. After completion as indicated by TLC, the 
reaction mixture was quenched at 0°C by dropwise addition of NaHCO3 over 20 min. It 
was then extracted with ethyl acetate (3x 20 ml) and the organic layer washed with water 
(3 x 40 ml), dried over MgSO4, evaporated and purified by column chromatography (30% 
ethyl acetate:  70% hexane) to afford a semi-solid (0.59 g) with 79% yield. 
 
1H NMR (600 MHz, Chloroform-d) δ 7.75 – 7.70 (m, 2H), 7.70 – 7.67 (m, 2H), 
7.67 – 7.61 (m, 2H), 7.50 – 7.40 (m, 3H), 7.38 (t, J = 7.7 Hz, 2H), 7.36 – 7.26 (m, 5H), 
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7.21 – 7.15 (m, 4H), 7.07 (d, J = 8.1 Hz, 2H), 7.03 – 6.92 (m, 6H), 6.92 – 6.85 (m, 4H), 
6.85 – 6.79 (m, 3H), 6.52 – 6.44 (m, 1H), 6.39 (s, 1H), 6.18 (s, 1H), 4.13 – 3.98 (m, 6H), 
3.92 (t, J = 5.8 Hz, 2H), 3.27 (d, J = 3.3 Hz, 2H), 2.89 – 2.77 (m, 5H), 2.60 – 2.52 (m, 9H), 
2.47 – 2.39 (m, 2H), 2.24 (d, J = 6.0 Hz, 3H), 1.96 (s, 2H), 1.86 – 1.78 (m, 2H), 1.73 (qd, 
J = 6.6, 2.7 Hz, 10H), 1.57 (p, J = 3.2 Hz, 4H), 1.46 (s, 4H), 1.22 – 1.12 (m, 9H), 0.78 (dq, 
J = 12.1, 6.5 Hz, 3H). 13C NMR (600 MHz, CDCl3) δ 162.53, 160.90, 155.92, 155.81, 
151.34, 149.98, 148.15, 145.30, 135.21, 131.10, 131.05, 130.07, 129.67, 128.90, 128.51, 
128.45, 128.37, 126.90, 125.86, 125.44, 120.53, 115.68, 115.49, 115.35, 115.21, 111.92, 
111.57, 103.05, 80.66, 61.02, 46.69, 44.71, 39.50, 39.20, 37.24, 34.58, 32.07, 29.86, 29.81, 
29.51, 27.03, 26.28, 22.83, 21.10. HR-FT-MS calcd for C30H31F4NO3 529.56 found 
529.20 
 
4.4.8 3-(4-chlorophenyl)-3,4-dihydro-2,2-dimethyl-4-(4-(trifluoromethoxy)phenyl)-
2H-chromen-7-ol 
 
 
 
To a stirred solution of 3-(4-chlorophenyl)-3,4-dihydro-2,2-dimethyl-2H-chromen-7-ol 
(0.41g, 2.4 mmol) and 1-(trifluoromethoxy) benzene (0.39 g, 2.97 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 15.0 ml) at 0°C was added anhydrous aluminum chloride 
OHO
Cl
OHO
O
CF3
12d
Cl
10d
AlCl3,
Benzene, 
cyclohexane 
00C, 68 %
O CF3
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(0.23 g, 1.69 mmol) in portions and the mixture further stirred for 8 hrs. The reaction 
mixture was quenched by adding a mixture of ice and conc. Hydrochloric acid (1:1 4.0 ml) 
and the organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (15.0 ml). The combined extract was washed with NaHCO3 (10 %, 
5.0ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. 
The semi-solid obtained was purified by column chromatography (70% hexane: 30% ethyl 
acetate) to obtain (0.75g, 68%) 12d. 
1H NMR (600 MHz, Chloroform-d) δ 7.81 – 7.76 (m, 1H), 7.68 (dt, J = 7.0, 1.4 Hz, 1H), 
7.51 (d, J = 7.8 Hz, 2H), 7.47 (d, J = 8.3 Hz, 3H), 7.35 – 7.28 (m, 5H), 7.23 (ddd, J = 10.7, 
8.3, 4.9 Hz, 11H), 7.08 – 7.03 (m, 2H), 6.96 – 6.89 (m, 8H), 6.79 (d, J = 8.4 Hz, 1H), 6.66 
(d, J = 2.5 Hz, 1H), 6.60 – 6.57 (m, 1H), 4.76 (s, 1H), 4.18 (q, J = 7.2 Hz, 9H), 2.09 (s, 
14H). 13C NMR (151 MHz, CDCl3) δ 160.81, 160.24, 156.43, 156.36, 151.25, 150.07, 
148.09, 145.28, 138.20, 135.26, 133.12, 131.08, 131.03, 130.21, 129.93, 129.55, 128.85, 
128.65, 128.50, 128.40, 128.32, 128.24, 126.85, 125.81, 125.36, 121.75, 121.44, 120.06, 
115.48, 115.27, 115.20, 115.13, 115.10, 111.82, 111.63, 104.80, 102.96, 80.58, 60.74, 
46.62, 44.64, 34.52, 27.53, 26.96, 26.21, 21.03. 
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4.4.9 1-{2-[3-(4-Chloro-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-
chroman-7-yloxy]-ethyl}-pyrrolidine  
 
 
To a stirred solution of 3-(4-chlorophenyl)-2,2-dimethyl-4-(4-
(trifluoromethoxy)phenyl)chroman-7-ol (0.16g, 0.35 mmol) and DMF (3.46ml) was added 
NaH (0.03 g, 1.21 mmol) under nitrogen atmosphere. The reaction mixture was vented 
with a needle for 20 min to allow evolution of H2 gas and then quenched with methanol 
(1.00 ml). After evolution of all H2 gas, 1-(2-chloroethyl) pyrrolidine hydrochloride (0.09 
g, 0.69 mmol) was added sequentially and stirred for 15 minutes. The reaction mixture was 
heated at 50°C overnight. After completion as indicated by TLC, the reaction mixture was 
quenched at 0°C by drop wise addition of NaHCO3 over 20 min. It was then extracted with 
ethyl acetate (3x 10 ml) and the organic layer washed with water (3 x 15 ml) , dried over 
MgSO4, evaporated and purified by column chromatography (30% ethyl acetate:  70% 
hexane) to afford a semi-solid (0.13 g) with 71% yield. 
1H NMR (600 MHz, Chloroform-d) δ 7.78 (dq, J = 6.9, 1.8 Hz, 2H), 7.56 – 7.50 
(m, 1H), 7.45 – 7.39 (m, 3H), 7.36 – 7.31 (m, 3H), 7.27 – 7.22 (m, 3H), 6.49 (s, 1H), 6.30 
(s, 1H), 4.02 (t, J = 5.9 Hz, 3H), 2.52 (t, J = 5.9 Hz, 3H), 2.42 – 2.28 (m, J = 3.9, 2.7 Hz, 
5H), 1.68 (p, J = 3.2 Hz, 5H), 1.57 (s, 7H). 13C NMR (600 MHz, CDCl3) δ 158.77, 156.59, 
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139.24, 138.67, 137.65, 133.52, 132.27, 129.57, 129.49, 128.90, 128.42, 128.01, 122.05, 
121.81, 115.55, 100.85, 79.72, 68.21, 54.55, 54.17, 27.25, 23.43.  HR-FT-MS calcd for 
C30H31ClF3NO3 546.02 found 546.23 
 
4.4.10 1-[2-(2,2-Dimethyl-3-phenyl-2H-chromen-7-yloxy)-ethyl]-pyrrolidine 
 
 
  
To a stirred solution of 2,2-dimethyl-3-phenyl-2H-chromen-7-ol (0.13 g, 0.35 mmol) and 
DMF (5.0 ml) was added NaH (0.04 g, 1.73 mmol) under nitrogen atmosphere. The 
reaction mixture was vented with a needle for 20 min to allow the evolution of H2 gas and 
then quenched with methanol (0.50 ml). After the evolution of all H2 gas, 1-(2-chloroethyl) 
pyrrolidine hydrochloride (0.13 g, 0.99 mmol)were added sequentially and stirred for 15 
minutes. The reaction mixture was heated at 50°C overnight. After completion as indicated 
by TLC, the reaction mixture was quenched at 0°C by dropwise addition of NaHCO3 over 
20 min. The mixture was extracted with ethyl acetate (3x 15 ml) and the organic layer 
washed with water (3 x 10 ml), dried over MgSO4, evaporated and purified by column 
chromatography (30% ethyl acetate:  70% hexane) to afford a semi-solid (0.17 g) with 50% 
yield. 
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1H NMR (600 MHz, Chloroform-d) δ 7.26 – 7.17 (m, 5H), 6.87 – 6.82 (m, 1H), 6.38 (d, J 
= 7.7 Hz, 2H), 6.18 (s, 1H), 4.00 (t, J = 6.0 Hz, 2H), 2.80 (t, J = 6.0 Hz, 2H), 2.55 – 2.50 
(m, 4H), 1.74 – 1.69 (m, 5H), 1.43 (s, 6H). 13C NMR (600 MHz, CDCl3) δ 159.96, 153.68, 
139.71, 139.19, 128.21, 128.11, 127.25, 127.11, 122.01, 116.27, 107.78, 102.69, 78.91, 
67.18, 55.05, 54.72, 54.20, 53.91, 29.75, 29.71, 29.41, 27.07, 23.52, 23.50, 22.74.  
 
4.4.11 1-{2-[4-(4-Methoxy-phenyl)-2,2-dimethyl-3-phenyl-chroman-7-yloxy]-ethyl}-
pyrrolidine 
 
 
To a stirred solution of1-(2-((2,2-dimethyl-3-phenyl-2H-chromen-7-
yl)oxy)ethyl)pyrrolidine (0.23 g, 0.69 mmol) and anisole (0.14 g, 1.25 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 4 ml) at 0°C was added anhydrous aluminum chloride (0.33 
g, 2.46 mmol) in portions. A solution of anisole (0.34 g, 3.14 mmol) in benzene- 
cyclohexane mixture (1:1 Ratio, 6.00 ml) was added after 30 min, and the mixture further 
stirred for 8 hrs. The reaction mixture was quenched by adding a mixture of ice and conc. 
Hydrochloric acid (1:1 2.0 ml) and the organic layer was separated. The aqueous layer was 
re-extracted three times with dichloromethane (10 ml). The combined extract was washed 
with NaHCO3 (10 %, 8ml), dried over anhydrous Na2SO4, filtered and concentrated under 
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reduced pressure. The semi-solid obtained was purified by column chromatography (70% 
hexane: 30% ethyl acetate) to obtain the titled compound. 
 
1H NMR (400 MHz, Chloroform-d) δ 7.27 – 7.23 (m, 2H), 7.22 – 7.12 (m, 9H), 
7.12 – 7.03 (m, 11H), 7.03 – 6.99 (m, 4H), 6.82 – 6.71 (m, 6H), 6.70 (d, J = 2.5 Hz, 2H), 
6.57 – 6.47 (m, 3H), 6.30 (qd, J = 8.7, 4.3 Hz, 3H), 4.00 (q, J = 7.1 Hz, 4H), 3.65 (t, J = 1.8 
Hz, 1H), 3.65 – 3.58 (m, 3H), 3.58 – 3.47 (m, 3H), 2.46 – 2.39 (m, 1H), 1.91 (s, 5H), 1.37 
– 1.22 (m, 11H). 13C NMR (400 MHz, CDCl3) δ 163.06, 158.06, 153.75, 139.27, 137.39, 
137.21, 130.10, 127.48, 122.69, 115.46, 108.62, 103.87, 92.73, 78.57, 36.83, 31.97, 31.79, 
29.74, 29.70, 29.41, 27.00,23.68, 23.67, 22.73. HR-FT-MS calcd for C30H35NO3 457.60 
found 457.25 
 
4.4.12  4-[2,2-Dimethyl-3-phenyl-7-(2-pyrrolidin-1-yl-ethoxy)-chroman-4-yl]-phenol 
  
OO
OH
N
JA_19
OO
N
11a
AlCl3, Phenol
Benzene, 
cyclohexane 
00C, 85%
 
To a stirred solution of1-(2-((2,2-dimethyl-3-phenyl-2H-chromen-7-
yl)oxy)ethyl)pyrrolidine (0.09 g, 0.25 mmol) and phenol (0.034 g, 0.37 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 3.0 ml) at 0°C was added anhydrous aluminum chloride 
(0.040 g, 0.29 mmol) in portions. A solution of phenol (0.004 g, 0.015 mmol) in benzene- 
cyclohexane mixture (1:1 Ratio, 2.0 ml) was added after 30 min and the mixture further 
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stirred for 8 hrs. The reaction mixture was quenched by adding a mixture of ice and conc. 
Hydrochloric acid (1:1 1.0 ml) and the organic layer was separated. The aqueous layer was 
re-extracted three times with dichloromethane (8.0 ml). The combined extract was washed 
with NaHCO3 (10 %, 3.0ml), dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The semi-solid obtained was purified by column chromatography 
(70% hexane: 30% ethyl acetate) to obtain (0.092g, 85%) the titled compound.  
1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H), 7.35 – 7.25 (m, 2H), 7.20 (t, J = 
7.5 Hz, 2H), 7.13 (dd, J = 7.3, 1.4 Hz, 1H), 6.91 – 6.81 (m, 2H), 6.54 – 6.43 (m, 3H), 6.41 
– 6.30 (m, 2H), 4.42 (d, J = 12.4 Hz, 1H), 3.69 (s, 3H), 3.37 (s, 4H), 2.51 (p, J = 1.9 Hz, 
4H), 1.26 (s, 3H), 1.16 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 158.56, 155.31, 153.41, 
139.39, 131.28133.78, 129.86, 122.58, 127.70, 118.86, 114.83, 101.06, 77.84, 55.42, 
54.93, 28.54, 19.90. HR-FT-MS calcd for C29H33NO3 443.57 found 443.35 
 
 
4.5 Molecular docking  
 
A virtual library of 800 analogs including ormeloxifene and a standard drug were designed 
using ChemDraw. Energy minimization, employing MMFF94 in ChemOffice, calculated 
the most stable conformation for each analog. Each analog was saved in .pdb format and 
compiled into a library of ligands. The compiled .pdb files were processed and used as 
input for Omega2, an OpenEye Scientific Software ® program that generates multi-
conformer structures for each ligand in the library to enhance ligand flexibility in an 
otherwise ridged model. The processed files were compiled into a .oeb.gz file. Protein 
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kinase targets (EGFR, GSK3B, CDK2, mTOR, Akt, β-catenin, etc.) were downloaded from 
Protein Data Bank website in.pdb.gz format and were processed using Make Receptor, and 
the resulting protein receptor file was saved in.oeb.gz format. Docking was conducted 
using Open Eye Scientific Software ® including fast exhaustive docking (FRED), Omega 
and VIDA. 
 
4.6 MTT Assay 
 
Cell proliferation was determined by MTT assay. Briefly, 5 X 106 cells of (A2780) were 
plated in 96 well plates and incubated for 24 hours at 37°C containing 5% of CO2. Cells 
were treated with various analogs of ormeloxifene for 24 hours. 20µL of 50 mg/mL MTT 
was added in each well containing 100 mL of cell media. The cells were incubated for a 
further 6 hours, and the media was replaced with 150 mL of DMSO. Plates vigorously 
shaken for 15 minutes and absorbance was taken at 570 nm on a microplate reader. 
 
4.7 Cell Cycle analysis 
 
Cell distribution of ormeloxifene analogs on A2780 cell lines were determined by cell cycle 
analysis. The cells were seeded as 2.5x105 cells/mL in a 6-well plate (2 mL/well) and 
allowed to adhere overnight at 37 °C and 5% CO2. The cells were incubated with JA-15 
(9.0 μM) and DMSO (0.001%) as a control for 24 h. The cells were washed twice with ice-
cold 1X PBS (Hyclone™ Laboratories, Inc) and collected after trypsinization28. The cell 
pellet was washed two times with ice-cold 1X PBS and fixed with ice-cold 70% ethanol 
overnight at -20 °C. After that, the cells were washed once with ice-cold PBS and the 
second wash with ice-cold PBS-2% FBS. The cell pellet was re-suspended in 500μL 
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propidium iodide (PI)/RNase staining solution (BD Biosciences) and 0.1% Triton x-100 
for 30 min. at room temperature in the dark and analyzed within one h by flow cytometer 
(BD Accuri C6, Becton-Dickinson, Mountain View, CA). Data were analyzed by MFLT32 
software, and 10,000 events with slow flow rate were recorded for each sample29’30 
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Chapter 5 
 
Design, synthesis and biological evaluations of selective estrogen receptor 
modulators analogs with 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-
en-1-yl) phenol at C-7  targeting EGFR pathway towards the treatment of ovarian 
cancer.  
 
5 Introduction 
 
5.1 Estrogen 
 
 Estrogens are class of naturally occurring sex hormones that are synthesized from 
cholesterol and are secreted by the ovaries. One of the most predominant intracellular 
estrogens is known to be 17β-estradiol (Fig 5.1).  They are critical to the function of the 
female reproductive system as well as healthy breast epithelium1. Estrogen has other 
essential effects on the heart2 and bones3. There is evidence that estrogen influence the part 
of the brain that regulates body temperature and enables the vaginal linings to stay thick 
and lubricated4. Loss of estrogen especially at the onset of menopause in women results in 
hot flashes and night sweats, a rise in low-density lipoprotein (LDL) cholesterol and other 
cardiovascular changes which usually leads to progressively increased in coronary diseases 
and heart attacks as well as an increase in bone loss. At this stage, most women compensate 
for the loss of estrogen by taking hormone replacement therapy (HRT), which effectively 
reduces the osteoporotic fractures and suppresses severe menopausal symptoms5. 
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Figure 5.1 Chemical structure of 17β-estradiol and the SERM’S 
 
 
The two major isoforms of the estrogen receptor (ER) (Fig 5-2) are ERα and ERβ. They 
are involved in a wide range of physiological processes such as the development of the 
female reproductive system, protection of cardiovascular tissue and the central nervous 
system6. Deregulation of ER signaling within breast, ovarian and the uterine tissue has been 
associated with the onset of cancerous tumors in these organs and has led to the 
investigation and development of antiestrogenic therapies7. ERα and ERβ are encoded by 
two essential genes that are located on distinct chromosomes, and each is responsible for 
the regulation of specific tissue effects8. The ER isoforms consist of different domains such 
as activated function (AF) domains, AF-1 (A/B domain) and AF-2 (E/F domain), which 
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facilitates transcriptional activation of the receptor. It has a DNA binding domain (C 
domain) that influence ER binding to DNA and a hinge region (D domain) which contains 
the nuclear delocalization signal (Fig 5.3). The role of ERα in breast cancer initiation and 
progression has been well established. However, little is known about its role in ovarian 
and endometrial cancers9. The role of ERβ on all cancers, on the other hand, remain 
unclear, but studies have shown that they are associated with elevated cell proliferation 
markers, Ki67, and cyclin A, in human breast cancer 10’11. 
 
 
 
Begam, A. J.; Jubie, S.; Nanjan, M., Estrogen receptor agonists/antagonists in breast cancer therapy: 
A critical review. Bioorganic chemistry 2017, 71, 257-274. 
Figure 5.2 Structure of estrogen receptor (ER) showing various structural domains at both 
N and C terminals.  
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 Lewis, J. S.; Jordan, V. C., Selective estrogen receptor modulators (SERMs): 
mechanisms of anticarcinogenesis and drug resistance. Mutation Research/Fundamental and 
Molecular Mechanisms of Mutagenesis 2005, 591 (1-2), 247-263. 
Figure 5.3 Functional domains and mechanism of action of ERα and ERβ in target cells 
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Selective estrogen receptor modulators are a class of agents available for the treatment of 
breast cancer and other diseases such as bone loss12. These class of compounds (e.g., 
Tamoxifen, ormeloxifene, raloxifene) (Fig.5.1) displays unusual tissue-selective 
pharmacology; they sometimes act as estrogen agonistic in tissues such as bone, liver and 
cardiovascular system and acts as estrogen antagonistic in other tissues such as brain and 
breast, and both in the uterus. Their therapeutic effects and lesser side effects have made 
them the best hormonal treatment for various carcinomas13.  
 
Though the antiestrogenic and estrogenic action of SERM is not well understood, it is 
believed that most of its unique pharmacology can be explained in three mechanisms: (1) 
Differential ER conformation upon ligand binding; (2) differential expression and binding 
to the ER of coregulator protein: and (3) differential ER expression and gene activation via 
none ERE interaction (tethered pathway) (Fig 5.4)14. 
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J.S. Lewis, V.C. Jordan / Mutation Research 591 (2005) 247–263 
Figure 5.4  A model for the action of SERMs via estrogen response element (ERE)-
dependent and none-ERE-dependent (AP1-tethered) pathway in target tissues. 
 
The biological evaluation and structural activity relationships (SAR) of SERMs have 
revealed that analogs with ring closure through proximal phenyl ring have a better affinity 
with estrogen receptors (ER) and more selectivity for ERα15 (e.g., Lasofoxifene in Fig. 
5.1). Also, the 2,2-dimethylbenzopyran scaffold is an important pharmacophore that needs 
to be incorporated in the designing of ER ligands as evident by many non-steroidal estrogen 
receptor modulators including ormeloxifene16’17’18’19’20. We envisage that incorporation 
of these moieties in these ligands will enhance the overall efficacy and reduce the issue of 
drug resistance. 
  The emergence of drug resistance as a major issue in the treatment of ovarian cancer, 
coupled with the problem of low tumor selectivity and toxicity, has made it an urgent need 
for discovery of less toxic and potent Selective estrogen receptor modulators with 
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protective effect as well as anti-cancer effect for the treatment of ovarian cancer. In this 
communication, we report the structural design, synthesis of novel selective estrogen 
receptor modulators using 2, 2-dimethylbenzopyran base and their biological efficacy for 
ER-mediated anti-ovarian cancer activity.  
To find the hit analogs and to identify the lead compounds (LDs) targeting EGFR, 
bioisosterism process was employed to design the ormeloxifene analogs (Fig 5.5). Several 
structural modifications were made at a various position such as C-7, C-4, C-4’ and C-4’’ 
of ormeloxifene skeleton to change the pharmacokinetics of the analogs as well as improve 
their biological activities (Fig 5.5).  Molecular docking was conducted to investigate 
whether ormeloxifene and its analogs bind to various receptor proteins such as EGFR, 
GSK3B, mTOR, STAT3, and CDK2. In our previous studies (Chapter 3 and 4), analogs 
showed higher binding affinity towards these receptors (EGFR, GSK3B, mTOR, STAT3, 
and CDK2). Therefore there is a need to investigate the effects of other structural 
modifications (analogs) on these proteins.  Preliminary docking results revealed that most 
analogs with 4-(3-hydroxypropyl) phenol at C-7 has better binding affinity to various 
receptor proteins compared to other analogs with functionalities such as ethyl alcohol, 
ethylamine, methylbenzene, etc. These studies and results proved that analogs with 4-(3-
hydroxypropyl) phenol at C-7 would enhance the anticancer activities as well as 
pharmacokinetic properties of ormeloxifene analogs.  Based on this modified structure (Fig 
5.5), a virtual library of analogs was prepared, and molecular docking was conducted using 
OpenEye®  scientific software utilizing fast executive docking (FRED), ONEGA and 
VIDA.   
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Figure 5.5  Proposed structure of ormeloxifene analogs with arrows showing various 
positions for structural modification 
 
5.2 Results and discussion 
5.2.1 Results of molecular Docking  
 
Molecular docking studies of ormeloxifene analogs with 4-(3-hydroxypropyl) phenol and 
(E)-4-(3-hydroxyprop-1-en-1-yl) phenol at C-7 revealed significant binding affinity toward 
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the crystal structure of EGFR. Analogs with 4-(3-hydroxypropyl) phenol and (E)-4-(3-
hydroxyprop-1-en-1-yl) phenol at C-7 and phenol at C-4 such as JA_31, JA_29, JA_30, 
JA_33, and JA_24 showed higher binding mode in EGFR binding site by forming 
hydrogen bond with HIS:84:A the same amino acid that  bond to ormeloxifene in EGFR 
binding site (Fig 5.6).  
In GSK3B binding pocket, analogs with 4-(3-hydroxypropyl) phenol at C-7phenol side 
chain at C-4 of Ormeloxifene scaffolds such as JA_31, JA_28, JA_29, and JA_24 showed 
hydrogen bond as well as hydrophilic and hydrophobic interactions. Most analogs with 
anisole and aniline at C-4 of ormeloxifene skeleton revealed higher binding affinity by 
forming two hydrogen bonds with  LYS:85: B and ASP:200: B in GSK3B binding pocket 
(Fig 5.7). Ormeloxifene analogs with trifluoromethyl benzene at C-4 of ormeloxifene 
skeleton such as JA_22, and JA_33 formed hydrogen bond with LYS: 85: B and ASP: 
200: B in GSK3B binding pocket. Analogs with 4-(3-hydroxypropyl) phenol at C-7 
demonstrated higher binding affinity and formed a hydrogen bond with LYS:85: B and 
LYS:183: B in the crystal structure of GSK3B (Fig 5.8). Substitution of phenol at C-4 and 
introduction of 4-(3-hydroxypropyl) phenol at the C-7 position of ormeloxifene skeleton 
improved the binding affinity with the crystal structure of GSK3B. The hydroxyl-OH on 
4-(3-hydroxypropyl) phenol such as JA-24 formed two hydrogen bonds with GLU: 97: B 
and PHE: 201: B in the crystal structure of GSK3B (Fig 5.8). 
Molecular docking results in CDK2 binding pocket also showed a significant binding mode 
with ormeloxifene analogs compared to known estrogen receptor modulators. Substitution 
the 4-(3-hydroxypropyl) phenol with (E)-4-(3-hydroxyprop-1-en-1-yl) phenol moiety at C-
7 position such as JA_31 resulted in higher binding affinity in the CDK2 binding pocket 
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(Fig 5.9). Unsubstituted analog demonstrated outstanding binding affinity towards CDK2 
binding site relative to similar analogs such as JA_16, JA_17, JA_18 with halogens 
substituted para to aromatic ring at C-3.  
Analogs such as JA_31, JA_29, JA_30, JA_33, JA-23, JA-35, 34, 22 and JA_24 showed 
higher binding affinity in several receptors (GSK3B, STAT3, mTOR, EGFR, etc.), an 
example is shown in Table 5.1 below. These most promising analogs from molecular 
docking studies will be synthesized and biologically investigated to identify the lead 
compounds.  
 
Table 5.1 Consensus score of FRED docking in GSK3B receptor 
VIDA 
Name 
VIDA 
ID 
PLP Chemgauss
3 
OEChemscor
e 
Screenscor
e 
Consensu
s Score 
JA_33_195 2 -
69.770
6 
-86.6225 -51.6373 -172.291 2 
JA_27_195 3 -
65.517
4 
-85.0519 -48.1456 -169.37 9 
JA_34_195 4 -
65.517
4 
-85.0519 -48.1456 -169.37 13 
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JA_22_109 5 -
63.448
7 
-75.2457 -49.0157 -151.454 23 
ORM_Br_3
1 
6 -
60.467
3 
-78.4293 -44.6155 -151.325 31 
JA_32_15 7 -
60.212 
-76.9438 -46.7599 -152.291 33 
JA_35_48 8 -
62.645
8 
-68.1517 -49.4359 -147.485 37 
JA_17_175 9 -
60.537
9 
-76.6181 -43.6912 -152.825 38 
JA_28_40 10 -
63.748
6 
-74.9482 -47.6724 -143.316 41 
JA_24_48 11 -
60.216
5 
-68.1734 -48.4074 -143.858 47 
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JA_29_4 12 -
60.155
2 
-77.0875 -43.1687 -148.647 49 
ORM_30_4
8 
13 -
60.216
5 
-68.1734 -48.4074 -143.858 51 
ORM _158 14 -
59.385
2 
-75.1556 -48.1866 -136.677 52 
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Figure 5.6 JA_31 forming two hydrogen bonds with THR:291: A and THR:211: A in 
EGFR binding pocket 
 
 
Figure 5.7 JA_28 forming two hydrogen bonds with GLU:97: B and ASP: 200: B in 
GSK3B binding pocket 
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Figure 5.8 JA-24 with nitrogen forming two hydrogen bonding with GLU 
:97: B and PHE:201: B in GSK3B pocket 
 
 
Figure 5.9 JA-31 in GSK3B binding pocket with no hydrogen bonding, the higher 
binding affinity is as a result of hydrophobic interactions with the receptor.  
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5.2.2 Synthesis of ormeloxifene analogs  
 
Following the previous procedure to prepare compound 12 (Scheme 4.1), the second set 
of ormeloxifene analogs (with 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-
en-1-yl) phenol at C-7) were synthesized as shown below (Scheme 5.1).  P-coumaric acid 
was protected with tetrabuthyl dimethyl silyl chloride (TBSCl) in the presence of imidazole 
and DMF to produce compound 13 (Fig 5.10). Esterification21 of 13 using H2SO4/MeOH 
produced 14. Reduction22 of compound 14 by reducing agent diisobythylaluminum hydride 
(DIBAL-H) to give compound 16a. Compound 16a compound 18a undergo mitsunobu 
reaction using triphenylphosphine (PPh3) and DIAD (diethyl azodicarboxylate) in THF to 
produce compound23 19. Deprotection of 19 with TBAF/THF gave JA_36-50. (Scheme 
5.1). Various synthetic analogs are listed in Table 5.1.  
OH
O
TBS
O
OH
HO
O
TBSCl/
Imidazol
DMF
13  
Figure 5.10  TBS Protection of P-coumaric acid 
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Scheme 5.1 Synthesis of ormeloxifene analogs series 2 
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Table 5.2 Synthesized analogs of ormeloxifene series 2 
 
                                                
1
2
3
1`
OO
HO
R
X
2`
3`
1``
2``
3``
4``5``
6``
7``4
 
Compound ∆1` R (X) 
JA_22 - OCF3 H 
JA_23 - OCH3 H 
JA_24 - OH H 
JA_27 - CF3 Br 
JA_28 - OH Br 
JA_29 + OH Br 
JA_31 + OH H 
JA_32 - OCH3 I 
JA_33 - OCF3 I 
JA_34 - OCH3 Br 
JA_35 - NH2 H 
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5.2.3 Biological Evaluation of synthesized analogs  
 
Studying the cytotoxic activities of ormeloxifene analogs JA_31, JA_28, JA_22, JA_23, 
JA_24, and JA_27 inhibits the viability of A2780 cells in a (10-40 mm) dose-dependent 
manner. The IC50 of analogs JA_31, JA_28, JA_22, JA_23, JA_24, and JA_27 showed 
antiproliferation range of cytotoxicity 44.6µM, 17.6µM, 58.9µM, 89.0µM, 65.7µM, and 
63.7µM after 48 hours treatment respectively (Table 5.2), but analogs such as JA_29, 
JA_32, JA_33, JA_34, and JA_35 completely lost their inhibitory cytotoxicity activity to 
(A2780) ovarian cancer cell lines.  
On the other hand, compounds with 4-(3-hydroxypropyl) phenol and (E)-4-(3-
hydroxyprop-1-en-1-yl) phenol at C-7 and phenol, trifluoromethyl benzene at C-4’’ such 
as JA-31, JA_28, and JA_24 exhibited moderate inhibitory activity (IC50 = 44.6, 17.6 and 
65.7 respectively) in ovarian cancer cell lines. Presence of double bonds also played a 
significant inhibitory effect on ovarian cancer cell lines, for instance, the introduction of 
double bound at C-7 position as in JA_31 showed IC50 = 44.6 a higher the inhibitory on 
A2780 cells compared to the similar compound without double bond JA_24 (IC50 = 
65.7µM).  Similar analogs with halogens at the para position of the aromatic ring at C-3’’ 
and aniline, anisole and trifluoromethyl benzene at C-4’’ position such as JA_35, JA_34, 
JA-33, JA_32, and JA_29 exhibited no inhibitory activity on ovarian cancer cell lines.  
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Table 5.3 MTT Cell viability results of ormeloxifene analogs  on the A2780 Cell line 
 
 
Compound IC50  
(µM) 
Compound IC50  
(µM) 
Ormeloxifene 17.5 JA_31 44.6  
JA_28 17.6 JA_22 58.9  
JA_35 NA JA_23 89.0  
JA_33 NA  JA_24 65.7  
JA_29 NA JA_32 NA  
JA_34 NA JA_27 63.7  
 
 
 
 
5.2.4 Cell cycle via modulation of cell-cycle regulatory proteins 
 
The biological studies for the synthesized compounds started with studying the in vitro 
cytotoxic activities to identify their ability to inhibit EGFR and its downstream. The effect 
of ormeloxifene analogs with 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-en-
1-yl) phenol at C-7   on ovarian cancer cell cycle distribution was determined using A2780 
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cells. The cells were synchronized and treated with the most active analogs JA-28 for 24 
hours, with vehicle-control as DMSO.  The cell cycle analysis performed by flow 
cytometry revealed that JA-28 arrest A2780 cells in G2-M phase (Fig 5.11), (Table. 5.4). 
JA-28 showed an increase in the fraction of cells in the G2-M phase with 8.74% compared 
to the control (Ormeloxifene) with 3.52% (Table. 5.4). This result indicates that JA-28 has 
the potential to chemotherapeutic effects because it arrests (A2780) ovarian cell cycle in 
G2-M phase
24’25. The promising antiproliferation activity data of JA_28 demonstrated the 
importance of transposition of 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-
en-1-yl) phenol at C-7 of ormeloxifene skeleton. 
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Control                                                                    ORM (17.2 µM)  
                                                                                                   
 
 JA-28 (17.6 µM) 
 
 
  
 
 
 
 
 
 
Table 5.4 Cell distribution in (A2780) ovarian cancer cells 
Groups  G0 – G1 S G2 - M 
Control 53.42 43.06 3.52 
Orm (17.2 µM/L) 60.69 27.93 11.38 
JA-28 (17.6 µM/L) 50.95 40.31 8.74 
 
Figure 5.11 Effects of Ormeloxifene and JA-28 on cell cycle phase distribution of ovarian cancer cells 
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5.3 Conclusion 
 
In conclusion series of ormeloxifene analogs with 4-(3-hydroxypropyl) phenol at C-7 were 
designed, synthesized and evaluated for their antiproliferation activity against ovarian cancer 
(A2780) cell line.  Ormeloxifene analogs JA-28, JA-35, JA-33, JA-29, JA-34, JA-31, JA-22, JA-
23, JA-24, JA-32, and JA-27, were generated using in-silico drug design strategies to installing 
pharmacophores of various aromatic and heterocyclic substituents at C-4 and C-7. Analogs such as 
JA-33, JA-24, JA-27, and JA-22 showed higher binding affinity in several receptors.  Biological 
studies showed that JA_28 has better cytotoxicity (IC50 of 17.6 µM) than a known EGFR inhibitor 
Ormeloxifene. Other analogs such as JA-31, JA-22, and JA-24 showed moderate cytotoxic activity 
in A2780 human ovarian cancer cell line with IC50 values of 44.6µM, 58.9µM, and 65.7µM 
respectively. However, JA-34, JA-35, JA-32, and JA-29 completely lost their activity in human 
ovarian cancer cell lines. Installation of trifluromethoxybenze at the C-4 position and 4-(3-
hydroxypropyl) phenol at C-7 of Ormeloxifene skeleton improved the cytotoxicity activities 
compared with similar compounds with anisole, aniline and phenol groups at C-4.JA-28 arrests 
cells in the S phase with 8.74% compared to 3.52% for control (Ormeloxifene) which 
indicates that it has the potential to chemotherapeutic effects. 
 
5.4 Experimental section 
 
5.4.1 General 
 
All chemicals and solvents were purchased from Fisher Scientific, Across Chemical or 
Sigma Aldrich and used without further purification. All glassware used was washed, 
cleaned and oven dried overnight before conducting any chemical reaction. Any reaction 
that requires anhydrous condition were performed under argon or nitrogen environment. 
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Pre-coated silica gel plates were used to analyze the progress and completion reaction. UV 
light at 254 or 365 or CAM stain was used to visualize the chemical reaction spot. All 
synthetic intermediates and final compounds were purified by column chromatography 
with 230 x 400 silica gel. Proton (1H) and Carbon (13C) NMR spectra were analyzed by 
Bruker Avance-400 MHz and 600 MHz NMR using D-acetone or CDCl3. NMR chemical 
shifts were presented in σ(PPM) using residual solvent peaks as standard ( CDCl3, 7.26 (H), 
77.16 (C)). High-resolution mass spectrometer (HRMS) was gained using Thermo 
Finnigan MAT 95XL mass spectrometer at the University of Buffalo mass spectroscopy 
facility. All synthetic intermediate and final compounds were purified using column 
chromatography with 230ˣ400 mesh silica gel.  1H and 13C NMR spectra were using Bruker 
AVANCE-400 MHZ and 600 MHZ NMR spectrometer, in CDCl3 and D-acetone. NMR 
chemical shifts were presented in 𝜎(PPM) using residual solvent peaks as standards 
(CDCl3, 7.26 (H), 77.16 (C)). 
5.4.2 3-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-acrylic acid 
 
 
OH
O
TBS
O
OH
HO
O
TBSCl/
Imidazol
DMF
13  
To a solution of (E)-3-(4-hydroxyphenyl) acrylic acid (8.2g, 49.9mmol) in dimethyl 
formamide (DMF) (120 ml), tert-buthylsilylchloride (TBSCl) (11.29g, 74.95mmol) and 
imidazole (9.18g, 134.89mmol) were added sequentially. The reaction was stirred for 24h 
and quenched with saturated NaHCO3 (50ml). The aqueous layer was extracted with ethyl 
acetate (3 x 60ml), dried over anhydrous sodium sulfate (Na2SO4), filtered and the organic 
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layer evaporated under reduced pressure. The crude product was purified by column 
chromatography (10% ethyl acetate: hexane) to give ester 13 (12.7g, 97%). 
1H NMR (400 MHz, Chloroform-d) δ 10.98 (s, 1H), 7.85 (s, 1H), 7.46 (d, J = 15.9 Hz, 1H), 
7.27 (d, J = 8.6 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 6.23 (d, J = 15.8 Hz, 1H), 3.81 (s, 7H), 
2.99 (d, J = 7.3 Hz, 1H), 2.86 – 2.71 (m, 7H), 1.20 – 1.07 (m, 9H), 1.03 – 0.87 (m, 6H). 
13C NMR (400 MHz, CDCl3) δ 162.81, 129.40, 120.06, 77.44, 36.42, 31.40, 25.73, 17.73, 
17.67, 17.62, 12.58, 12.47, 12.33, 8.35.  
 
 
5.4.3 3-(4-triisopropylsilanyloxy-phenyl)-acrylic acid methyl ester 
 
OH
O
Si MeOH
O
O
O
Si
O
H2SO4
15a
16b
 
Compound 15a (5.0g, 16.2mmol) was dissolved in MeOH (33 ml) and concentrated 
hydrochloric acid (HCl) (0.83ml) was added. The reaction mixture was refluxed for 16h, 
cooled to room temperature and the solvent was evaporated under reduced pressure. The 
resulting residue was dissolved in ethyl acetate (25ml) and washed successively with 1M 
NaHCO3 (2 X 17 ml) and water (18ml). The organic phase was dried with over anhydrous 
Na2SO4, filtered and the solvent was removed under reduced pressure to give a colorless 
crystal (5.35g, 97%).  
1H NMR (400 MHz, Chloroform-d) δ 7.55 (d, J = 16.0 Hz, 1H), 7.33 – 7.27 (m, 2H), 6.81 
– 6.75 (m, 2H), 6.19 (d, J = 16.0 Hz, 1H), 3.70 (s, 3H), 1.96 (s, 4H), 0.98 (s, 21H). 13C 
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NMR (400 MHz, CDCl3) δ 171.78, 168.43, 159.02, 145.29, 129.97, 126.23, 115.96, 
114.26, 60.66, 51.67, 20.99, 17.65, 14.08, 12.30. 
 
 
5.4.4 3-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-prop-2-en-1-ol  
  
 
OH
O
TBS
O
O
O
TBS
DIBAL-H
THF
14
16a
 
To a solution of ester (9.0g, 30.1mmol) in toluene (75.0ml), Diisobutylaluminium hydride 
(DIBAL-H) (75ml, 90.1mmol) was added at -78°C dropwise and the reaction was stirred 
for half an hour at 0°C. The temperature was reduced to room temperature after 20min. and 
the reaction cooled back at -78°C before an addition of solution of potassium sodium titrate 
(50ml). The reaction was stirred overnight, and the aqueous layer extracted with ethyl 
acetate (3 x 70ml), dried over anhydrous sodium sulfate (Na2SO4) and the volume reduced 
under vacuum. The extract was purified using column chromatography (20% ethyl acetate: 
hexane) to afford a colorless liquid (6.85g, 86%).    
 1H NMR (400 MHz, Chloroform-d) δ 7.21 – 7.10 (m, 3H), 6.75 – 6.65 (m, 3H), 4.15 (dd, 
J = 5.9, 1.5 Hz, 3H), 3.77 (s, 1H), 0.92 (s, 17H), 0.89 – 0.75 (m, 17H), 0.12 (s, 12H). 13C 
NMR (400 MHz, CDCl3) δ 155.30, 130.67, 130.22, 127.62, 126.56, 120.19, 69.34, 63.33, 
31.64, 30.69, 25.74, 25.71, 22.69, 18.98, 18.22, 18.03, -3.56, -4.41. 
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5.4.5 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-1-ol 
 
 
OH
O
OH
O
MeOH
pd/c 5%
16a
16bTBS
TBS
 
To an oven dry round 25ml round bottom flask under H2 gas, was added a solution of 
unsaturated alcohol 16a (5.4g, 20.4 mmol) in methanol (90 ml) and stirred until the solution 
is completely dissolved. (4.21g, 6.67 mmol) 5% pd/c was added to the mixture and the 
compound was hydrogenated at room temperature for 4 hours. The reaction was quenched 
and concentrated under reduced pressure after completion and purified by column 
chromatography (30% ethyl acetate: hexane) to obtain the desired product alcohol (4.2g, 
96 %) 
1H NMR (400 MHz, Chloroform-d) δ 6.94 – 6.87 (m, 1H), 6.71 – 6.63 (m, 1H), 3.55 (s, 
2H), 2.75 (t, J = 7.8 Hz, 1H), 2.48 (dd, J = 8.4, 7.1 Hz, 1H), 0.92 (s, 17H), 0.89 – 0.75 (m, 
17H), 0.12 (s, 12H). 13C NMR (400 MHz, CDCl3) δ 155.30, 130.67, 130.22, 127.62, 
126.56, 120.19, 69.34, 63.33, 31.64, 30.69, 25.74, 25.71, 22.69, 18.98, 18.22, 18.03, -3.56, 
-4.41. 
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5.4.6 (4-(4-(3-(4-fluorophenyl)-2,2-dimethyl-2H-chromen-7  yloxy)butyl)phenoxy) 
(tert-butyl) dimethylsilane  
 
OO
F
O
TBS
OHO
F
OH
O
TBS
+
DIAD, Pph3
THF, 20OC,rt
16a
10b
16f
 
To a solution of 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-1-ol  (16b) (0.35g, 1.35 
mmol), 10b (0.37g, 1.35 mmol) in Tetrahydrofuran (THF) (10 ml) was cooled to 0°C. 
Triphenylphosphine (Pph3) (0.35g, 2.83 mmol) was added followed by addition of (DIAD 
(0.270ml, 1.20 mmol) in dropwise for 30 min. The mixture was stirred overnight at room 
temperature and quenched with 1N NaOH (85ml) after completion. The aqueous layer was 
extracted with ethyl acetate (3 x 50ml), washed with brine (45ml), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give a yellow oil (0.60g, 84%). 
 
1H NMR (600 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.32 – 7.26 (m, 2H), 7.05 (tdd, J = 8.7, 
5.8, 2.4 Hz, 4H), 6.92 (d, J = 8.1 Hz, 1H), 6.85 (dd, J = 8.3, 5.4 Hz, 2H), 6.53 – 6.48 (m, 
2H), 6.28 (s, 1H), 5.03 (ddt, J = 20.7, 14.4, 7.3 Hz, 1H), 3.65 – 3.54 (m, 1H), 2.61 (t, J = 
7.7 Hz, 1H), 1.93 (p, J = 7.4 Hz, 1H), 1.44 – 1.41 (m, 6H), 1.38 (s, 3H), 1.18 – 1.13 (m, 
11H), 0.95 (s, 9H), 0.20 (s, 6H)  13C NMR (600 MHz, CDCl3) δ 162.93, 161.30, 157.76, 
153.71, 150.29, 137.63, 135.83, 135.81, 129.91, 129.85, 129.20, 127.39, 122.49, 119.77, 
115.67, 115.44, 115.07, 114.93, 108.58, 103.89, 78.73, 72.73, 32.00, 29.78, 29.74, 29.44, 
22.76, 22.04, 21.95, 21.62, 18.08, 17.93, 17.90, 17.83, 17.76, 14.21, -3.41, -4.36 
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5.4.7 (4-(4-(3-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-4-(4-(trifluoromethoxy) 
phenyl) -2H-chromen-7-yloxy)butyl)phenoxy)(tert-butyl)dimethylsilane 
 
AlCl3,
Benzene, 
cyclohexane 
00C, 80%
O CF3
OO
F
O
O
CF3
TBS
19f
OO
F
O
TBS
18f
 
To a stirred solution of 18f (0.28 g, 0.53 mmol) and phenol (0.18 g, 1.10 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 8.0 ml) at 0°C was added anhydrous aluminum chloride 
(0.09g, 0.64 mmol) in portions. A solution of phenol (0.06 g, 0.37 mmol) in benzene- 
cyclohexane mixture (1:1 Ratio, 8.0 ml) was added after 30 min, and the mixture further 
stirred for 8 hrs. The reaction mixture was quenched by adding a mixture of ice and conc. 
Hydrochloric acid (1:1 2.0 ml) and the organic layer was separated. The aqueous layer was 
re-extracted three times with dichloromethane (16.0 ml). The combined extract was washed 
with NaHCO3 (10 %, 10.0ml), dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The semi-solid obtained was purified by column chromatography 
(70% hexane: 30% ethyl acetate) to obtain (0.29g, 80%) 19f. 
 
1H NMR (600 MHz, Chloroform-d) δ 8.09 (dd, J = 8.3, 1.4 Hz, 1H), 7.72 – 7.68 (m, 1H), 
7.65 – 7.61 (m, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.29 (dd, J = 8.5, 7.4 Hz, 2H), 7.17 – 7.11 
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(m, 4H), 7.11 – 7.05 (m, 3H), 6.93 – 6.87 (m, 3H), 6.80 – 6.74 (m, 2H), 6.71 (dt, J = 7.6, 
1.1 Hz, 2H), 6.34 (d, J = 7.4 Hz, 1H), 6.15 – 6.11 (m, 1H), 1.92 (s, 1H), 1.44 – 1.41 (m, 
6H), 1.38 (s, 3H), 1.18 – 1.13 (m, 11H), 0.95 (s, 9H), 0.20 (s, 6H) 13C NMR (600 MHz, 
CDCl3) δ 157.23, 156.16, 153.51, 151.01, 138.31, 135.77, 133.69, 133.03, 130.25, 130.01, 
129.92, 129.86, 129.84, 129.57, 129.41, 129.28, 128.64, 128.36, 128.24, 128.15, 127.03, 
122.46, 121.77, 121.08, 120.96, 120.28, 119.99, 119.73, 116.64, 115.45, 115.38, 115.26, 
115.12, 114.98, 113.12, 108.39, 100.57, 78.69, 67.38, 60.66, 34.74, 32.02, 31.68, 29.80, 
29.46, 27.31, 27.15, 26.89, 25.35, 22.79, 22.74, 18.01, 17.99, 17.89, 17.81, 17.76, 14.20, -
3.44, -4.31. 
 
 
5.4.8 4-{4-[3-(4-Fluoro-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-
chroman-7-yloxy]-butyl}-phenol 
 
 
 
Tetrabutyl ammonium fluoride (TBAF) (0.90 ml, 3.5mmol) was added to a stirred solution 
of (4-(3-(3-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-2H-chromen-7-
yloxy)propyl)phenoxy)(tert-butyl)dimethylsilane ( 0.48g, 0.69 mmol) and stirred for 6h . 
The reaction was quenched with ammonium chloride (NH4Cl) solution and extracted with 
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ethyl acetate (3 x 40ml), dried over anhydrous sodium sulfate (Na2SO4). The solution was 
filtered, and the volume reduced under vacuum. Purification was done by column 
chromatography (10% ethyl acetate: hexane) to give the titled compound.  (0.33g, 82%).  
1H NMR (600 MHz, Chloroform-d) δ 8.09 (dd, J = 8.3, 1.4 Hz, 1H), 7.72 – 7.68 (m, 1H), 
7.65 – 7.61 (m, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.29 (dd, J = 8.5, 7.4 Hz, 2H), 7.17 – 7.11 
(m, 4H), 7.11 – 7.05 (m, 3H), 6.93 – 6.87 (m, 3H), 6.80 – 6.74 (m, 2H), 6.71 (dt, J = 7.6, 
1.1 Hz, 2H), 6.34 (d, J = 7.4 Hz, 1H), 6.15 – 6.11 (m, 1H), 1.92 (s, 1H), 1.44 – 1.41 (m, 
3H), 1.38 (s, 3H), 1.18 – 1.13 (m, 11H), 1.00 (dq, J = 7.9, 4.3, 3.4 Hz, 26H), 0.95 (s, 6H). 
13C NMR (600 MHz, CDCl3) δ 157.23, 156.16, 153.51, 151.01, 138.31, 135.77, 133.69, 
133.03, 130.25, 130.01, 129.92, 129.86, 129.84, 129.57, 129.41, 129.28, 128.64, 128.36, 
128.24, 128.15, 127.03, 122.46, 121.77, 121.08, 120.96, 120.28, 119.99, 119.73, 116.64, 
115.45, 115.38, 115.26, 115.12, 114.98, 113.12, 108.39, 100.57, 78.69, 67.38, 60.66, 
34.74, 32.02, 31.68, 29.80, 29.46, 27.31, 27.15, 26.89, 25.35, 22.79, 22.74, 18.01, 17.99, 
17.89, 17.81, 17.76, 14.20, 12.95, 12.73, 12.72, 12.69, 12.37, 11.51. HR-FT-MS calcd for 
C34H32 F4O4 580.60 found 580.28 
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5.4.9 Tert-butyl(4-(4-((3-(4-iodophenyl)-2,2-dimethyl-2H-chromen-7-yl)oxy)butyl) 
phenoxy)dimethylsilane  
 
OO
I
O
TBS
OHO
I
OH
O
TBS
+
DIAD, Pph3
THF, 20OC,rt
16a
10e
16e
 
To a solution of 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-1-ol  (16a) (0.23g, 1.0 
mmol), 10e (0.33g, 1.0 mmol) in Tetrahydrofuran (THF) (15 ml) was cooled to 0°C. 
Triphenyphospine (Pph3) (0.35g, 2.66 mmol) was added followed by addition of (DIAD 
(0.20ml, 1.0 mmol) in dropwise for 30 min. The mixture was stirred overnight at room 
temperature and quenched with 1N NaOH (85ml) after completion. The aqueous layer was 
extracted with ethyl acetate (3 x 45ml), washed with brine (20ml), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give yellow oil (0.60g, 95%).  
1H NMR (400 MHz, Chloroform-d) δ 8.14 (s, 2H), 7.61 (t, J = 9.7 Hz, 14H), 4.84 (qt, J = 
12.1, 8.4, 6.1 Hz, 4H), 3.99 (dd, J = 10.7, 6.5 Hz, 1H), 3.49 (d, J = 3.3 Hz, 1H), 2.76 (qd, 
J = 15.7, 15.1, 7.5 Hz, 1H), 2.45 (td, J = 15.4, 13.8, 7.5 Hz, 1H), 1.88 (d, J = 3.3 Hz, 1H), 
1.05 (q, J = 14.5 Hz, 51H). 13C NMR (400 MHz, CDCl3) δ 156.69, 153.36, 139.28, 136.99, 
136.88, 133.49, 133.29, 132.50, 131.87, 131.83, 131.73, 131.46, 128.70, 128.54, 128.39, 
128.31, 128.27, 127.93, 127.83, 121.76, 119.55, 116.58, 115.53, 107.97, 78.42, 68.61, 
60.03, 51.11, 21.69, 20.59, 17.73, 17.71, 13.91, 12.40, 12.34, -3.11. 
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5.4.10 4-{3-[3-(4-Iodo-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-
chroman-7-yloxy]-propyl}-phenol 
 
Following the procedure for the preparation of JA_23, (4-(4-(3,4-dihydro-3-(4-
iodophenyl)-2,2-dimethyl-4-(4-(trifluoromethoxy)phenyl)-2H-chromen-7-
yloxy)butyl)phenoxy)(tert-butyl)dimethylsilane (0.39, 0.49 mmol) was reacted with 
tetrabutylammonium fluoride ( 0.64g, 2.45mmol) to give JA_33 (0.27g, 79%). 
1H NMR (600 MHz, Chloroform-d) δ 7.59 (ddt, J = 12.1, 6.9, 1.4 Hz, 5H), 7.50 – 
7.42 (m, 2H), 7.37 (tdd, J = 7.5, 3.1, 1.9 Hz, 5H), 7.20 – 7.11 (m, 1H), 6.98 – 6.86 (m, 1H), 
6.85 – 6.62 (m, 1H), 4.92 – 4.84 (m, 1H), 1.95 (s, 1H), 1.46 – 1.38 (m, 2H), 1.24 – 1.13 
(m, 15H), 1.01 (dd, J = 7.4, 2.0 Hz, 3H), 0.96 (s, 1H), 0.83 – 0.75 (m, 6H). 13C NMR (600 
MHz, CDCl3) δ 157.41, 156.51, 137.32, 137.22, 133.60, 132.64, 132.15, 132.08, 132.04, 
132.03, 131.95, 130.18, 130.08, 129.49, 129.26, 128.59, 128.51, 121.73, 119.18, 115.64, 
69.87, 60.41, 34.68, 31.94, 31.60, 29.72, 29.68, 29.38, 29.07, 22.71, 22.67, 21.96, 21.72, 
17.94, 14.14. HR-FT-MS calcd for C34H32 F3IO4 580.60 found 580.28 
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5.4.11 4-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2,2-dimethyl-3-phenylchroman-7-
ol 
 
OHO
10c
AlCl3,
Benzene, 
cyclohexane 
00C, 78% OHO
O
TBS
12c
O TBS
 
Following the procedure in the preparation of JA_20, 10c (0.73g, 3.48mmol) reacted with 
tert-butyldimethyl(phenoxy)silane (0.35ml, 1.69 mmol) in the presence of AlCl3 (0.52g, 
3.90 mmol) to afford 12c (1.09g, 78%). 
1H NMR (400 MHz, Chloroform-d) δ 7.21 (s, 2H), 7.08 – 7.04 (m, 15H), 6.73 (tt, J = 7.3, 
1.1 Hz, 9H), 6.75 – 6.61 (m, 14H), 6.61 (d, J = 8.5 Hz, 1H), 6.46 – 6.39 (m, 1H), 6.32 (d, 
J = 2.5 Hz, 1H), 6.22 – 6.13 (m, 8H), 2.34 (d, J = 10.9 Hz, 1H), 1.2 – 1.10 (m, 10H), 0.81 
– 0.70 (m, 7H), 0.21 (s, 1H), 0.08 (s, 6H). 13C NMR (400 MHz, CDCl3) δ 158.83, 155.10, 
153.71, 153.49, 138.20, 135.36, 131.01, 130.19, 129.60, 128.22, 120.73, 118.54, 115.47, 
107.79, 101.61, 78.36, 55.34, 43.70, 37.60, 28.50, 26.84,25.8, 24.72 ,17.7, 14.17, 14.02, 
10.87, -6.1 
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5.4.12 (E)-tert-butyl(4-(4-((4-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2,2-dimethyl-
3-phenylchroman-7-yl)oxy)but-1-en-1-yl)phenoxy)dimethylsilane 
 
OHO
O
TBS
12c
OH
O
TBS
+ DIAD, Pph3
THF, 20OC,rt OO
O
O
19c
TBS
TBS
16a
 
 
To a solution of unsaturated alcohol (16a) (0.38g, 1.43 mmol), 12c (0.68g, 1.43 mmol) in 
Tetrahydrofuran (THF) (20 ml) was cooled to 0°C. Triphenylphosphine (Pph3) (0.75g, 2.87 
mmol) was added followed by addition of (DIAD (0.29 ml, 1.43 mmol) in dropwise for 30 
min. The mixture was stirred overnight at room temperature and quenched with 1N NaOH 
(35.0ml) after completion. The aqueous layer was extracted with ethyl acetate (3 x 45ml), 
washed with brine (20.0 ml), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to give yellow oil (0.37g, 35%). 
1H NMR (400 MHz, Chloroform-d) δ 7.47 (dd, J = 12.2, 7.5 Hz, 9H), 7.23 (dt, J = 33.0, 
7.4 Hz, 13H), 7.14 – 6.95 (m, 8H), 6.72 – 6.51 (m, 4H), 4.71 (p, J = 6.2 Hz, 3H), 3.81 (q, 
J = 7.1 Hz, 1H), 1.76 (s, 1H), 0.94 (d, J = 6.3 Hz, 17H), 0.81 (s, 10H), 0.03 (s, 6H). 13C 
NMR (400 MHz, CDCl3) δ 157.60, 156.81, 155.51, 137.20, 137.43, 13315, 133.45, 
132.44, 132.15, 132.13, 132.08, 131.97, 131.39, 129.41, 129.19, 128.73, 128.65, 128.57, 
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128.53, 128.46, 121.37, 120.01, 115.67, 77.88, 69.36, 60.32, 25.86, 25.72, 21.93, 20.90, 
18.15, 14.17, -3.45, -4.39.  
 
 
5.4.13 (E)-4-(4-((4-(4-hydroxyphenyl)-2,2-dimethyl-3-phenylchroman-7-yl)oxy)but-
1-en-1-yl)phenol 
 
OO
OH
HO
OO
O
O
TBS
TBS
TBAF
THF, 80%
JA_31
19c  
Tetrabutyl ammonium fluoride (TBAF) (0.63ml, 2.4mmol) was added to a stirred solution 
of 19C (0.35g, 0.48 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 30ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered, and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_31 (0.19g, 80%).  
1H NMR (400 MHz, Chloroform-d) δ 7.88 (s, 1H), 7.44 (dd, J = 12.0, 7.5 Hz, 6H), 
7.26 – 7.20 (m, 3H), 7.15 (td, J = 7.6, 2.7 Hz, 6H), 7.02 (t, J = 4.7 Hz, 3H), 4.74 – 4.60 (m, 
2H), 3.82 (d, J = 7.1 Hz, 1H), 3.03 (t, J = 8.1 Hz, 1H), 2.50 – 2.16 (m, 1H), 0.90 (d, J = 6.3 
Hz, 6H). 13C NMR (400 MHz, CDCl3) δ 156.67, 137.02, 136.91, 133.53, 133.34, 132.61, 
131.88, 131.86, 131.77, 131.57, 128.57, 128.42, 128.35, 128.29, 128.28, 115.62, 114.33, 
266 
 
 
 
77.99, 68.70, 60.08, 54.19, 53.34, 21.75, 20.69, 13.97, 13.92, 13.49. HR-FT-MS calcd for 
C33H32O4 492.60 found 492.24 
 
 
 
 
5.4.14 Tert-butyl(4-(4-((2,2-dimethyl-3-phenyl-2H-chromen-7yl)oxy)butyl)phenoxy)  
dimethylsilane 
 
OO
O
TBS
OHO
OH
O
TBS
+
DIAD, Pph3
THF, 20OC,rt
16a
10c
16c
 
 
To a solution of 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-1-ol  (16a) (0.25g, 0.96 
mmol), 10c (0.21g, 0.83 mmol) in Tetrahydrofuran (THF) (6.30 ml) was cooled to 0°C. 
Triphenylphosphine (Pph3) (0.54g, 2.1 mmol) was added followed by addition of (DIAD 
(0.16ml, 079 mmol) in dropwise for 30 min. The mixture was stirred overnight at room 
temperature and quenched with 1N NaOH (45ml) after completion. The aqueous layer was 
extracted with ethyl acetate (3 x 40ml), washed with brine (40ml), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give yellow oil (0.38g, 92%). 
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1H NMR (600 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.32 – 7.26 (m, 2H), 7.05 (tdd, J = 8.7, 
5.8, 2.4 Hz, 4H), 6.91 (d, J = 8.1 Hz, 1H), 6.85 (dd, J = 8.3, 5.4 Hz, 2H), 6.53 – 6.48 (m, 
2H), 6.28 (s, 1H), 5.03 (ddt, J = 20.7, 14.4, 7.3 Hz, 1H), 3.64 – 3.55 (m, 1H), 2.21 (t, J = 
7.7 Hz, 1H), 1.93 (p, J = 7.4 Hz, 1H), 1.51 – 1.41 (m, 6H), 1.38 (s, 3H), 1.18 – 1.13 (m, 
11H), 0.98 (s, 9H), 0.21 (s, 6H)  13C NMR (600 MHz, CDCl3) δ 162.91, 161.10, 157.72, 
153.81, 150.19, 137.33, 135.73, 135.84, 129.90, 129.81, 129.20, 127.29, 122.59, 119.72, 
115.66, 115.1, 115.01, 114.94, 108.48, 103.80, 78.73, 72.71, 32.08, 29.88, 29.77, 29.34, 
22.71, 22.04, 21.85, 21.60, 18.07, 17.92, 17.93, 17.80, 17.76, -0.91. 
 
 
5.4.15 Tert-butyl(4-(4-((4-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2,2-dimethyl-3-
phenylchroman-7-yl)oxy)butyl)phenoxy)dimethylsilane 
 
OO
O
TBS
16c
AlCl3,
Benzene, 
cyclohexane 
00C, 80%
O TBS
OO
O
O
TBS
TBS
19c
 
To a stirred solution of 16c (0.36 g, 0.71 mmol) and tert-buthyldimethyl(phenoxy)silane 
(0.31 g, 1.49 mmol) in benzene-cyclohexane mixture (1:1 ratio, 10 ml) at 0°C was added 
anhydrous aluminum chloride (0.13g, 0.85 mmol) in portions and stirred for 30 min and 
the mixture was further stirred for 8 hrs. at room temperature. The reaction mixture was 
quenched by adding a mixture of ice and conc. Hydrochloric acid (1:1 3.0 ml) and the 
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organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (18.0 ml). The combined extract was washed with NaHCO3 (10 %, 
11.0ml), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. 
The semi-solid obtained was purified by column chromatography (70% hexane: 30% ethyl 
acetate) to obtain (0.40g, 80%) 19c. 
1H NMR (600 MHz, Chloroform-d) δ 8.10 (dd, J = 8.3, 1.4 Hz, 1H), 7.71 – 7.67 (m, 1H), 
7.65 – 7.59 (m, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.20 (dd, J = 8.5, 7.4 Hz, 2H), 7.18 – 7.13 
(m, 4H), 7.11 – 7.05 (m, 3H), 6.92 – 6.88 (m, 3H), 6.81 – 6.74 (m, 2H), 6.71 (dt, J = 7.6, 
1.1 Hz, 2H), 6.32 (d, J = 7.4 Hz, 1H), 6.15 – 6.10 (m, 1H), 2.02 (s, 1H), 1.43 – 1.42 (m, 
6H), 1.37 (s, 3H), 0.95 (s, 9H), 0.22 (s, 6H) 13C NMR (600 MHz, CDCl3) δ 157.13, 
156.15, 153.41, 151.78, 138.34, 135.75, 133.62, 133.03, 130.35, 130.00, 129.91, 129.86, 
129.83, 129.55, 129.42, 129.78, 128.62, 128.33, 128.23, 128.14, 127.01, 122.43, 121.77, 
121.09, 120.96, 120.29, 119.98, 119.69, 116.61, 115.45, 115.37, 115.24, 115.10, 114.96, 
113.11, 108.39, 100.51, 78.67, 67.35, 60.69, 34.71, 32.00, 31.68, 29.82, 29.45, 27.32, 
27.14, 26.88, 25.35, 22.77, 22.71, 18.01, 17.98, 17.87, 17.81, 17.73, 14.20, -3.40, -4.32.  
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5.4.16 4-(7-(4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butoxy)-2,2-dimethyl-3-
phenylchroman-4-yl)phenol 
 
OO
OH
HO
OO
O
O
TBS
TBS
TBAF
THF, 75%
JA_30
19c  
 
Tertbutyl ammonium fluoride (TBAF) (0.63ml, 1.94mmol) was added to a stirred solution 
of 19b (0.28g, 0.39 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 25ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered, and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_30 (0.15g, 75%).  
1H NMR (400 MHz, Chloroform-d) δ 7.87 – 7.78 (m, 10H), 7.62 (td, J = 7.4, 1.5 
Hz, 6H), 7.52 (dt, J = 7.6, 3.9 Hz, 12H), 7.47 (d, J = 2.1 Hz, 3H), 7.34 – 7.27 (m, 15H), 
7.22 – 7.18 (m, 2H), 7.11 (dd, J = 7.6, 1.5 Hz, 13H), 7.00 (t, J = 7.3 Hz, 9H), 5.17 – 5.06 
(m, 3H), 4.27 (q, J = 7.1 Hz, 1H), 3.71 (s, 1H), 2.71 (t, J = 7.9 Hz, 1H), 2.10 – 2.00 (m, 
1H), 1.33 (s, 3H), 1.32 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 157.58, 156.53, 156.19, 
154.11, 142.85, 134.03, 133.84, 132.80, 132.78, 132.31, 132.26, 132.20, 131.51, 130.46, 
129.72, 129.66, 129.44, 129.09, 128.96, 128.85, 128.00, 120.27, 120.18, 115.82, 115.19, 
77.89, 70.83, 61.23, 41.71, 31.33, 29.95, 22.11, 21.96, 21.18, 18.20, 18.18, 17.97. HR-FT-
MS calcd for C33H34O4 494.62 found 494.36 
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5.4.17 4-(7-(4-(4-((tert-butyldimethylsilyl)oxy)phenyl)butoxy)-2,2-dimethyl-3-
phenylchroman-4-yl)aniline 
OO
O
TBS
16c
AlCl3,
Benzene, 
cyclohexane 
00C, 85%
NH2
OO
NH2
O
TBS
19g
  
To a stirred solution of 16c (0.40 g, 0.79 mmol) and aniline (0.07 g, 0.75 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 13.0 ml) at 0°C was added anhydrous aluminum chloride 
(0.18g, 1.35 mmol) in portions. A solution of aniline (0.18 g, 1.94 mmol) in benzene- 
cyclohexane mixture (1:1 Ratio, 21.0 ml) was added after 30 min and the mixture further 
stirred for 8 hrs. The reaction mixture was quenched by adding a mixture of ice and conc. 
Hydrochloric acid (1:1 4.0 ml) and the organic layer was separated. The aqueous layer was 
re-extracted three times with dichloromethane (25.0 ml). The combined extract was washed 
with NaHCO3 (10 %, 15.0ml), dried over anhydrous Na2SO4, filtered and concentrated 
under reduced pressure. The semi-solid obtained was purified by column chromatography 
(70% hexane: 30% ethyl acetate) to obtain (0.39g, 85%) 19g. 
1H NMR (400 MHz, Chloroform-d) δ 7.72 (s, 2H), 7.53 (dd, J = 12.1, 7.4 Hz, 11H), 7.32 
(t, J = 7.4 Hz, 6H), 7.20 (td, J = 7.6, 2.8 Hz, 11H), 7.04 (d, J = 4.3 Hz, 4H), 6.85 (t, J = 7.6 
Hz, 1H), 6.79 – 6.70 (m, 1H), 6.43 (d, J = 7.8 Hz, 1H), 4.81 – 4.69 (m, 4H), 3.43 (d, J = 
14.1 Hz, 2H), 2.71 – 2.57 (m, 1H), 2.37 (q, J = 7.8, 6.7 Hz, 1H), 0.98 (d, J = 6.3 Hz, 22H), 
0.28 (d, J = 3.1 Hz, 8H), 0.95 (s,9H), 0.21 (s, 6H). 13C NMR (400 MHz, CDCl3) δ 157.10, 
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156.81, 156.04, 153.51, 146.66, 137.03, 136.91, 133.56, 133.57, 132.49, 132.07, 132.03, 
132.00, 131.91, 131.42, 130.54, 129.11, 128.96, 128.91, 128.68, 128.55, 128.48, 128.44, 
128.41, 128.01, 117.81, 115.62, 115.06, 78.41, 69.09, 51.35, 43.80, 36.08, 30.87, 26.91, 
21.85, 17.87, -3.52, 0-.91. 
 
5.4.18 4-{3-[4-(4-Amino-phenyl)-2,2-dimethyl-3-phenyl-chroman-7-yloxy]-propyl}-
phenol 
 
 
Tertbutyl ammonium fluoride (TBAF) (1.63ml, 4.12mmol) was added to a stirred solution 
of 19g (0.52g, 0.86 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 38ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered, and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_35 (0.29g, 68%).  
1H NMR (400 MHz, Chloroform-d) δ 7.71 (s, 2H), 7.50 (dd, J = 12.1, 7.4 Hz, 11H), 
7.30 (t, J = 7.4 Hz, 6H), 7.22 (td, J = 7.6, 2.8 Hz, 11H), 7.10 (d, J = 4.3 Hz, 4H), 6.86 (t, J 
= 7.6 Hz, 1H), 6.79 – 6.71 (m, 1H), 6.45 (d, J = 7.8 Hz, 1H), 4.83 – 4.67 (m, 4H), 3.42 (d, 
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J = 14.1 Hz, 2H), 2.72 – 2.58 (m, 1H), 2.36 (q, J = 7.8, 6.7 Hz, 1H), 0.98 (d, J = 6.3 Hz, 
22H), 0.89 (d, J = 3.1 Hz, 8H). 13C NMR (400 MHz, CDCl3) δ 159.10, 156.80, 156.06, 
153.58, 146.76, 137.09, 136.99, 133.66, 133.47, 132.49, 132.07, 132.04, 132.00, 131.90, 
131.45, 130.56, 129.10, 128.96, 128.90, 128.69, 128.56, 128.47, 128.44, 128.40, 128.01, 
117.85, 115.62, 115.08, 78.40, 69.09, 51.36, 43.82, 36.08, 30.09, 26.92, 21.85, 17.87, 
17.83, 12.55, 12.42. . HR-FT-MS calcd for C33H35 NO3 493.63 found 493.58 
 
5.4.19 Tert-butyl(4-(4-((4-(4-methoxyphenyl)-2,2-dimethyl-3-phenylchroman-7-
yl)oxy)butyl)) dimethylsilane 
OO
O
TBS
16c
AlCl3,
Benzene, 
cyclohexane 
00C, 91%
O
OO
O
O
TBS
19b
 
To a stirred solution of 18c (0.42 g, 0.83 mmol) and anisole (0.136 g, 1.25 mmol) in 
benzene-cyclohexane mixture (1:1 ratio, 15.0 ml) at 0°C was added anhydrous aluminum 
chloride (0.13g, 0.97 mmol) in portions. A solution of anisole (0.005 g, 0.049 mmol) in 
benzene- cyclohexane mixture (1:1 Ratio, 10.0 ml) was added after 30 min, and the mixture 
further stirred for 8 hrs. The reaction mixture was quenched by adding a mixture of ice and 
conc. Hydrochloric acid (1:1 2.0 ml) and the organic layer was separated. The aqueous 
layer was re-extracted three times with dichloromethane (20.0 ml). The combined extract 
was washed with NaHCO3 (10 %, 5.0ml), dried over anhydrous Na2SO4, filtered and 
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concentrated under reduced pressure. The semi-solid obtained was purified by column 
chromatography (70% hexane: 30% ethyl acetate) to obtain (0.45g, 91%) 19c. 
 
1H NMR (600 MHz, Chloroform-d) δ 7.73 – 7.68 (m, 1H), 7.65 – 7.60 (m, 1H), 7.35 (d, J 
= 7.8 Hz, 1H), 7.28 (dd, J = 8.5, 7.4 Hz, 2H), 7.17 – 7.11 (m, 4H), 7.11 – 7.04 (m, 3H), 
6.91 – 6.86 (m, 3H), 6.80 – 6.74 (m, 2H), 6.72 (dt, J = 7.6, 1.1 Hz, 2H), 6.31 (d, J = 7.4 Hz, 
1H), 6.15 – 6.12 (m, 1H), 1.99 (s, 1H), 1.45 – 1.40 (m, 6H), 1.37 (s, 3H), 1.18 – 1.12 (m, 
11H), 0.98 (s, 9H), 0.23 (s, 6H) 13C NMR (600 MHz, CDCl3) δ 157.22, 156.17, 153.56, 
151.06, 137.91, 135.67, 133.67, 132.73, 130.35, 130.01, 129.91, 129.86, 129.82, 129.59, 
129.43, 129.24, 128.67, 128.36, 128.20, 128.15, 127.1, 122.56, 121.78, 121.05, 120.98, 
120.21, 119.99, 119.72, 116.54, 115.48, 115.35, 115.26, 115.18, 114.97, 113.19, 108.37, 
100.52, 78.63, 67.38, 60.56, 34.84, 32.00, 31.69, 29.81, 29.3, 27.33, 27.15, 26.88, 25.32, 
22.79, 22.75, 18.00, 17.95, 17.88, 17.82, 17.76, 14.24, -0.93. 
 
5.4.20 4-{3-[4-(4-Methoxy-phenyl)-2,2-dimethyl-3-phenyl-chroman-7-yloxy]-
propyl}-phenol 
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Tetrabutyl ammonium fluoride (TBAF) (0.72ml, 2.73mmol) was added to a stirred solution 
of 19b (0.34g, 0.55 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 45ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_23 (0.23g, 82%).  
1H NMR (600 MHz, Chloroform-d) δ 7.37 – 7.32 (m, 2H), 7.01 (tt, J = 7.3, 1.2 Hz, 
4H), 6.99 – 6.95 (m, 2H), 5.04 (p, J = 6.2 Hz, 1H), 3.83 (s, 3H), 1.32 (d, J = 6.8 Hz, 6H). 
13C NMR (400 MHz, CDCl3) δ 159.59, 156.89, 156.82, 129.49, 129.47, 128.39, 120.72, 
119.82, 115.50, 113.95, 77.53, 69.98, 55.06, 37.32, 26.98, 21.97, 17.98, 17.80. . HR-FT-
MS calcd for C34H36O4 508.64 found 508.01 
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5.4.21 4-[3-(4-Bromo-phenyl)-7-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-
chroman-4-yl]-phenol 
 
 
 
Following the procedure in the preparation of JA_20, 10d (3.3g, 9.96mmol) reacted with 
tert-butyldimethyl(phenoxy)silane (2.8ml, 20.9mmol) in the presence of AlCl (1.6g, 
11.95mmol) to afford 12d (4.8g, 90%). 
1H NMR (400 MHz, Chloroform-d) δ 7.24 (s, 2H), 7.12 – 7.04 (m, 15H), 6.79 (tt, J = 7.3, 
1.1 Hz, 9H), 6.75 – 6.68 (m, 14H), 6.65 (d, J = 8.5 Hz, 1H), 6.47 – 6.41 (m, 1H), 6.32 (d, 
J = 2.5 Hz, 1H), 6.24 – 6.12 (m, 8H), 2.36 (d, J = 10.9 Hz, 1H), 1.25 – 1.12 (m, 10H), 0.82 
– 0.72 (m, 7H), 0.20 (s, 1H), -0.00 (s, 1H). 13C NMR (400 MHz, CDCl3) δ 158.86, 155.20, 
153.78, 153.56, 138.26, 135.66, 131.11, 130.20, 129.70, 128.32, 120.83, 118.74, 115.43, 
107.81, 101.67, 78.32, 55.24, 43.76, 30.71, 28.54, 26.87, 22.91, 19.96, 14.15, 14.02, 10.87, 
0.00. 
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5.4.22 3-(4-Bromo-phenyl)-4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-7-{3-[4-
(tert-butyl-dimethyl-silanyloxy)-phenyl]-allyloxy}-2,2-dimethyl-chroman 
 
OHO
O
TBS
12d
Br
OH
O
TBS
+ DIAD, Pph3
THF, 20OC,rt OO
O
O
19d
TBS
TBS Br
16a
 
To a solution of unsaturated alcohol (16a) (0.26g, 1.0 mmol), 12d (0.33, 1.0 mmol) in 
Tetrahydrofuran (THF) (10 ml) was cooled to 0°C. Triphenyphospine (Pph3) (0.35g, 2.66 
mmol) was added followed by addition of (DIAD (0.20ml, 1.0 mmol) in dropwise for 30 
min. The mixture was stirred overnight at room temperature and quenched with 1N NaOH 
(100ml) after completion. The aqueous layer was extracted with ethyl acetate (3 x 50ml), 
washed with brine (50ml), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to give yellow oil (0.75g, 94%). 
1H NMR (400 MHz, Chloroform-d) δ 7.47 (dd, J = 12.2, 7.5 Hz, 9H), 7.23 (dt, J = 33.0, 
7.4 Hz, 13H), 7.14 – 6.97 (m, 8H), 6.79 – 6.53 (m, 4H), 4.73 (p, J = 6.2 Hz, 3H), 3.88 (q, 
J = 7.1 Hz, 1H), 1.78 (s, 1H), 0.97 (d, J = 6.3 Hz, 17H), 0.80 (s, 10H), 0.00 (s, 6H). 13C 
NMR (400 MHz, CDCl3) δ 157.61, 156.85, 155.54, 137.23, 137.12, 133.75, 133.56, 
132.47, 132.15, 132.13, 132.08, 131.98, 131.43, 129.40, 129.19, 128.73, 128.65, 128.57, 
128.53, 128.46, 121.37, 120.06, 115.67, 77.87, 69.30, 60.33, 25.86, 25.72, 21.93, 20.90, 
18.15, 14.17, -3.45, -4.39. 
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5.4.23 4-(4-((3-(4-bromophenyl)-4-(4-hydroxyphenyl)-2,2-dimethylchroman-7-
yl)oxy)butyl)phenol 
 
OO
Br
OH
HO
OO
Br
O
O
TBS
TBS
TBAF
THF, 85%
JA_28
19d  
 
 
 
Tetrabutyl ammonium fluoride (TBAF) (0.99 ml, 3.8mmol) was added to a stirred solution 
of 19d (0.61g, 0.76 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 50ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered, and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_28 (0.37g, 85%).  
1H NMR (400 MHz, Chloroform-d) δ 7.63 (ddt, J = 12.1, 6.8, 1.4 Hz, 5H), 7.49 
(ddt, J = 8.8, 3.0, 1.5 Hz, 3H), 7.41 (ddd, J = 8.5, 6.8, 3.1 Hz, 5H), 7.26 – 7.19 (m, 1H), 
7.12 (d, J = 8.1 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 4.91 (p, J = 6.2 Hz, 2H), 1.18 (s, 3H), 
1.17 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 156.76, 132.31, 132.20, 132.17, 132.11, 
132.01, 131.27, 128.67, 128.55, 127.60, 115.71, 78.52, 69.71, 60.46, 29.66, 22.05, 21.92. 
. HR-FT-MS calcd for C33H33BrO4 571.03 found 571.32 
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5.4.24 (4-(4-((3-(4-bromophenyl)-4-(4-((tert-butyldimethylsilyl)oxy)phenyl)-2,2-
dimethylchroman-7-yl)oxy)butyl)phenoxy)(tert-butyl)dimethylsilane 
OHO
O
TBS
12d
Br
OH
O
TBS
+ DIAD, Pph3
THF, 20OC,rt OO
O
O
28a
TBS
TBS Br
16d
 
To a solution of saturated alcohol (16d) (0.23g, 1.0 mmol), 12d (0.33, 1.0 mmol) in 
Tetrahydrofuran (THF) (10 ml) was cooled to 0°C. Triphenyphospine (Pph3) (0.35g, 2.66 
mmol) was added followed by addition of (DIAD (0.20ml, 1.0 mmol) in dropwise for 30 
min. The mixture was stirred overnight at room temperature and quenched with 1N NaOH 
(100ml) after completion. The aqueous layer was extracted with ethyl acetate (3 x 50ml), 
washed with brine (50ml), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure to give yellow oil (0.71g, 92%). 
1H NMR (400 MHz, Chloroform-d) δ 7.47 (dd, J = 12.2, 7.5 Hz, 9H), 7.23 (dt, J = 33.0, 
7.4 Hz, 13H), 7.14 – 6.97 (m, 8H), 6.79 – 6.53 (m, 4H), 4.73 (p, J = 6.2 Hz, 3H), 3.88 (q, 
J = 7.1 Hz, 1H), 1.78 (s, 1H), 0.97 (d, J = 6.3 Hz, 17H), 0.80 (s, 10H), 0.00 (s, 6H). 13C 
NMR (400 MHz, CDCl3) δ 157.61, 156.85, 155.54, 137.23, 137.12, 133.75, 133.56, 
132.47, 132.15, 132.13, 132.08, 131.98, 131.43, 129.40, 129.19, 128.73, 128.65, 128.57, 
128.53, 128.46, 121.37, 120.06, 115.67, 77.87, 69.30, 60.33, 25.86, 25.88, 21.91, 20.96, 
18.19, 14.11, -3.47, -4.33. 
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5.4.25 4-(4-((3-(4-bromophenyl)-4-(4-hydroxyphenyl)-2,2-dimethylchroman-7-
yl)oxy)butyl)phenol 
OO
Br
OH
HO
OO
Br
O
O
TBS
TBS
TBAF
THF, 81%
JA_28
28a  
Tetrabutyl ammonium fluoride (TBAF) (0.97 ml, 3.8mmol) was added to a stirred solution 
of 28a (0.63g, 0.76 mmol) and stirred for 6h. The reaction was quenched with ammonium 
chloride (NH4Cl) solution and extracted with ethyl acetate (3 x 50ml), dried over anhydrous 
sodium sulfate (Na2SO4). The solution was filtered, and the volume reduced under vacuum. 
Purification was done by column chromatography (10% ethyl acetate: hexane) to give 
JA_28 (0.35g, 81%).  
1H NMR (400 MHz, Chloroform-d) δ 7.63 (ddt, J = 12.1, 6.8, 1.4 Hz, 5H), 7.49 
(ddt, J = 8.8, 3.0, 1.5 Hz, 3H), 7.41 (ddd, J = 8.5, 6.8, 3.1 Hz, 5H), 7.26 – 7.19 (m, 1H), 
7.12 (d, J = 8.1 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 4.91 (p, J = 6.2 Hz, 2H), 1.18 (s, 3H), 
1.17 (s, 3H). 13C NMR (400 MHz, CDCl3) δ 156.76, 132.31, 132.20, 132.17, 132.11, 
132.01, 131.27, 128.67, 128.55, 127.60, 115.71, 78.52, 69.71, 60.46, 29.66, 22.05, 21.92. 
. HR-FT-MS calcd for C33H33BrO4 573.51 found 573.20 
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5.4.26 3-(4-Bromo-phenyl)-2,2-dimethyl-chroman-7-yloxy]-tert-butyl-dimethyl-
silane 
 
 
TBSCl/
Imidazole
DMFOHO
10d
OO
10db
TBS
Br
Br
 
To a solution of 10d (6.43g, 26.9mmol) in dimethyl formamide (DMF) (99.88ml), tert-
buthylsilylchloride (TBSCl) (6.38g, 40.45mmol) and imidazole (5.1g, 74.2mmol) were 
added sequentially. The reaction was stirred for 24h and quenched with saturated NaHCO3 
(30ml). The aqueous layer was extracted with ethyl acetate (3 x 40ml), dried over 
anhydrous sodium sulfate (Na2SO4), filtered and the organic layer evaporated under 
reduced pressure. The crude product was purified by column chromatography (10% ethyl 
acetate: hexane) to give ester 10db (7.31g, 74%). 
1H NMR (400 MHz, Chloroform-d) δ 7.22 (d, J = 8.3 Hz, 2H), 7.08 – 6.98 (m, 2H), 6.86 
– 6.75 (m, 1H), 6.27 (d, J = 2.3 Hz, 1H), 6.22 (dd, J = 8.3, 2.4 Hz, 1H), 6.05 (s, 1H), 3.91 
(q, J = 7.1 Hz, 1H), 3.57 – 3.48 (m, 2H), 1.83 (s, 2H), 1.72 – 1.61 (m, 2H), 1.10 (d, J = 5.7 
Hz, 11H), 0.79 (s, 11H), 0.00 (s, 6H). 13C NMR (400 MHz, CDCl3) δ 156.01, 153.93, 
149.72, 143.06, 130.70, 130.63, 130.45, 126.46, 120.64, 119.01, 112.07, 108.43, 77.50, 
75.38, 73.19, 67.79, 67.54, 60.47, 33.03, 31.96, 25.79, 25.62, 25.54, 14.10, -4.50.  
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5.4.27 3-(4-triisopropylsilanyloxy-phenyl)-acrylic acid methyl ester 
 
OH
O
Si MeOH
O
O
O
Si
O
H2SO4
15a
16b
 
Compound 15a (5.0g, 16.2mmol) was dissolved in MeOH (33 ml) and concentrated 
hydrochloric acid (HCl) (0.83ml) was added. The reaction mixture was refluxed for 16h, 
cooled to room temperature and the solvent was evaporated under reduced pressure. The 
resulting residue was dissolved in ethyl acetate (25ml) and washed successively with 1M 
NaHCO3 (2 X 17 ml) and water (18ml). The organic phase was dried with over anhydrous 
Na2SO4, filtered and the solvent was removed under reduced pressure to give a colorless 
crystal (5.35g, 97%).  
1H NMR (400 MHz, Chloroform-d) δ 7.55 (d, J = 16.0 Hz, 1H), 7.33 – 7.27 (m, 2H), 6.81 
– 6.75 (m, 2H), 6.19 (d, J = 16.0 Hz, 1H), 3.70 (s, 3H), 1.96 (s, 4H), 0.98 (s, 21H). 13C 
NMR (400 MHz, CDCl3) δ 171.78, 168.43, 159.02, 145.29, 129.97, 126.23, 115.96, 
114.26, 60.66, 51.67, 20.99, 17.65, 14.08, 12.30. 
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5.4.28 3-(4-Triisopropylsilanyloxy-phenyl)-propionic acid methyl ester 
 
O
O
Si MeOH
pd/c 5%
O
O
O
Si
O
17
16b  
 
Following the procedure for the preparation of (16), unsaturated alcohol (3.12g, 9.33mmol) 
in methanol (50ml) was reacted with 5% pd/c (1.60g, 1.55mmol) to give the alcohol (2.60g, 
90%). 
1H NMR (400 MHz, Chloroform-d) δ 7.00 – 6.83 (m, 2H), 6.74 – 6.61 (m, 2H), 3.54 (s, 
3H), 2.74 (t, J = 7.8 Hz, 2H), 2.47 (dd, J = 8.4, 7.1 Hz, 2H), 0.96 (s, 18H). 13C NMR (400 
MHz, CDCl3) δ 174.34, 154.69, 131.73, 129.23, 115.51, 51.78, 36.13, 30.10, 17.92, 17.68, 
17.31, 12.91, 12.35, 11.82. 
 
5.4.29 3-(4-Triisopropylsilanyloxy-phenyl)-propan-1-ol 
 
OH
O
Si
OH
O
Si
MeOH
pd/c 5%
16 18  
To an oven dry round 25ml round bottom flask under H2 gas, was added a solution of 
unsaturated alcohol (6.1g, 34mmol) in methanol (100ml) and stirred until the  solution is 
completely dissolved. (3.64g, 5.7mmol) 5% pd/c was added to the mixture and the 
compound was hydrogenated at room temperature for 4 hours. The reaction was quenched 
and concentrated under reduced pressure after completion and purified by column 
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chromatography (30% ethyl acetate: hexane) to obtain the desired product alcohol (5.91g, 
97 %) 
1H NMR (400 MHz, Chloroform-d) δ 6.94 – 6.87 (m, 1H), 6.71 – 6.63 (m, 1H), 3.55 (s, 
2H), 2.75 (t, J = 7.8 Hz, 1H), 2.48 (dd, J = 8.4, 7.1 Hz, 1H), 1.04 – 0.97 (m, 3H), 0.96 (s, 
11H), 0.94 – 0.83 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 174.25, 154.67, 131.77, 
129.23, 115.51, 51.77, 36.13, 30.11, 17.93, 17.68, 17.31, 12.91, 12.34. 
 
5.4.30 3-(4-((tert-butyldimethylsilyl)oxy)phenyl)propan-1-ol 
 
 
OH
O
OH
O
MeOH
pd/c 5%
16a
16bTBS
TBS
 
To an oven dry round 25ml round bottom flask under H2 gas, was added a solution of 
unsaturated alcohol (5.4g, 20.4 mmol) in methanol (90 ml) and stirred until the solution is 
completely dissolved. (4.21g, 6.67 mmol) 5% pd/c was added to the mixture and the 
compound was hydrogenated at room temperature for 4 hours. The reaction was quenched 
and concentrated under reduced pressure after completion and purified by column 
chromatography (30% ethyl acetate: hexane) to obtain the desired product alcohol (4.2g, 
96 %) 
1H NMR (400 MHz, Chloroform-d) δ 6.94 – 6.87 (m, 1H), 6.71 – 6.63 (m, 1H), 3.55 (s, 
2H), 2.75 (t, J = 7.8 Hz, 1H), 2.48 (dd, J = 8.4, 7.1 Hz, 1H), 0.92 (s, 17H), 0.89 – 0.75 (m, 
17H), 0.12 (s, 12H). 13C NMR (400 MHz, CDCl3) δ 155.30, 130.67, 130.22, 127.62, 
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126.56, 120.19, 69.34, 63.33, 31.64, 30.69, 25.74, 25.71, 22.69, 18.98, 18.22, 18.03, -3.56, 
-4.41. 
 
5.5 Alternative synthetic routes for other analogs 
 
5.5.1 3-(4-Triisopropylsilanyloxy-phenyl)-propan-1-ol 
 
 
 
O
O
Si
OH
O
Si
O
DIBAL-H
THF
17 18  
To a solution of ester (3.86g, 11.59mmol) in toluene (23.0ml), Diisobutylaluminium 
hydride (DIBAL-H) (20ml, 24.2mmol) was added at -78°C dropwise and the reaction was 
stirred for half an hour at 0°C. The temperature was reduced to room temperature after 
20min. and the reaction cooled back at -78°C before the addition of a solution of potassium 
sodium titrate (30ml). The reaction was stirred overnight, and the aqueous layer extracted 
with ethyl acetate (3 x 40ml), dried over anhydrous sodium sulfate (Na2SO4) and the 
volume reduced under vacuum. The extract was purified using column chromatography 
(20% ethyl acetate: hexane) to afford a colorless liquid (3.48, 97%).    
1H NMR (400 MHz, Chloroform-d) δ 7.13 – 7.02 (m, 2H), 6.89 – 6.80 (m, 2H), 3.65 (t, J 
= 6.5 Hz, 2H), 3.35 (s, 1H), 2.65 (dd, J = 8.5, 6.8 Hz, 2H), 1.94 – 1.82 (m, 2H), 1.39 – 1.28 
(m, 4H), 1.28 – 1.11 (m, 25H), 1.11 (d, J = 2.8 Hz, 6H). 13C NMR (400 MHz, CDCl3) δ 
154.07, 134.28, 129.21, 119.74, 77.50, 61.89, 34.33, 31.27, 17.96, 17.77, 12.71, 12.44. 
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5.5.2 3-(4-Fluoro-phenyl)-2,2-dimethyl-4-(4-trifluoromethoxy-phenyl)-chroman-7-
ol 
 
 
 
OHO
F
OHO
O
CF3
12b
F
10b
AlCl3,
Benzene, 
cyclohexane 
00C, 72%
O CF3
 
 
To a stirred solution of 3-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-2H-chromen-7-ol 
(0.54g, 2.0 mmol) and 1-(trifluoromethoxy) benzene (0.68 g, 0.37 mmol) in benzene-
cyclohexane mixture (1:1 ratio, 20.0 ml) at 0°C was added anhydrous aluminum chloride 
(0.32 g, 2.41 mmol) in portions and the mixture further stirred for 8 hrs. The reaction 
mixture was quenched by adding a mixture of ice and conc. Hydrochloric acid (1:1 3.0 ml) 
and the organic layer was separated. The aqueous layer was re-extracted three times with 
dichloromethane (8.0 ml). The combined extract was washed with NaHCO3 (10 %, 5.0ml), 
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The semi-
solid obtained was purified by column chromatography (70% hexane: 30% ethyl acetate) 
to obtain (0.87g, 69%) 12b.  
1H NMR (600 MHz, Chloroform-d) δ 7.49 (dd, J = 26.9, 8.1 Hz, 1H), 7.34 – 7.19 (m, 4H), 
7.09 – 6.98 (m, 1H), 6.97 – 6.87 (m, 2H), 4.18 (q, J = 7.2 Hz, 2H), 1.93 (d, J = 1.2 Hz, 2H), 
1.59 (s, 1H), 1.40 – 1.18 (m, 6H). 13C NMR (600 MHz, CDCl3) δ 162.44, 160.81, 160.24, 
156.43, 156.36, 139.34, 138.20, 135.26, 133.12, 131.08, 131.03, 130.21, 129.93, 129.55, 
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128.85, 128.65, 128.50, 128.40, 128.32, 128.24, 126.85, 125.81, 121.75, 121.44, 120.06, 
115.48, 115.27, 115.20, 115.13, 115.10, 111.82, 111.63, 104.80, 102.96, 80.58, 60.74, 
34.52, 27.53, 26.96, 26.21. 
 
5.5.3 4-{3-[3-(4-Fluoro-phenyl)-2,2-dimethyl-2H-chromen-7-yloxy]-propyl}-phenol 
 
 
 
 
Tetrabutyl ammonium fluoride (TBAF) (.15 ml, 5.2mmol) was added to a stirred solution 
of (4-(3-(3-(4-fluorophenyl)-3,4-dihydro-2,2-dimethyl-2H-chromen-7-
yloxy)propyl)phenoxy)(tert-butyl)dimethylsilane ( 0.54g, 1.0mmol) and stirred for 6h . 
The reaction was quenched with ammonium chloride (NH4Cl) solution and extracted with 
ethyl acetate (3 x 30ml), dried over anhydrous sodium sulfate (Na2SO4). The solution was 
filtered and the volume reduced under vacuum. Purification was done by column 
chromatography (10% ethyl acetate: hexane) to give the titled compound.  (0.39g, 95%).  
1H NMR (600 MHz, Chloroform-d) δ 7.51 (s, 1H), 7.32 – 7.26 (m, 2H), 7.05 (tdd, J = 8.7, 
5.8, 2.4 Hz, 4H), 6.92 (d, J = 8.1 Hz, 1H), 6.85 (dd, J = 8.3, 5.4 Hz, 2H), 6.53 – 6.48 (m, 
2H), 6.28 (s, 1H), 5.03 (ddt, J = 20.7, 14.4, 7.3 Hz, 1H), 3.65 – 3.54 (m, 1H), 2.61 (t, J = 
7.7 Hz, 1H), 1.93 (p, J = 7.4 Hz, 1H), 1.55 (d, J = 8.7 Hz, 7H). 13C NMR (151 MHz, 
CDCl3) δ 162.93, 161.30, 157.76, 153.71, 150.29, 137.63, 135.83, 135.81, 129.91, 129.85, 
OO
HO
F
OO
O
F
TBS
TBAF
THF, 86%
17f16f
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129.20, 127.39, 122.49, 119.77, 115.67, 115.44, 115.07, 114.93, 108.58, 103.89, 78.73, 
72.73, 32.00, 29.78, 29.74, 29.44, 22.76, 22.04, 21.95, 21.62. 
5.6 Molecular docking 
 
Molecular docking was conducted to know whether ormeloxifene and its analogs bind to 
various receptor proteins such as EGFR, GSK3B, and CDK2. A virtual library of 800 
ormeloxifene analogs was prepared and structurally modified at C-4, C-7 and C-3 based 
on ormeloxifene scaffold with 4-(3-hydroxypropyl) phenol, trifluoromethoxy benzene side 
chain, including ormeloxifene and known EGFR inhibitors. Energy minimization using 
Chem Office, with MMF94 minimization was performed along with standard drug of 
choice for the treatment of ovarian cancer. These files were converted into *pdb files 
maintaining all heavy atoms and concentrated into single continuous *pdb file to be used 
as an input for Omega. Omega uses the MMF94 force field to generate multiple conformers 
for each input ligand to induce ligand flexibility in a rigid model. Modifications were 
applied to the default settings of OMEGA26. Receptor files (PDB files) were downloaded 
from protein data bank (PDB) website (GSK3B, EGFR, CDK2) were prepared using 
OpenEye,s Fred Receptor program27. This program defines the space in which the search 
algorithm performs and define the shape potential for calculation28. Multiple scoring 
functions such as shapegsuss, chemguass3, Oechemscore, Screen score, and PLP were 
employed to obtain a consensus structure and scores in the final output. 
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5.7 MTT Assay 
 
Cell proliferation was determined by MTT assay. Briefly, 5 X 106 cells of (A2780) were 
plated in 96 well plates and incubated for 24 hours at 37°C containing 5% of CO2. Cells 
were treated with various analogs of ormeloxifene for 24 hours. 20µL of 50 mg/mL MTT 
was added in each well containing 100 mL of cell media. The cells were incubated for a 
further 6 hours, and the media was replaced with 150 mL of DMSO. Plates vigorously 
shaken for 15 minutes and absorbance was taken at 570 nm on a microplate reader. 
 
5.8 Cell Cycle analysis 
 
Cell cycle analysis was conducted using ormeloxifene analogs and A2780 cell lines; the 
cells were seeded as 2.5x105 cells/mL in a 6-well plate (2 mL/well) and allowed to adhere 
overnight at 37 °C and 5% CO2. The cells were incubated with JA-28 (17.6 μM) and 
DMSO (0.001%) as a control for 24 h. The cells were washed twice with ice-cold 1X PBS 
(Hyclone™ Laboratories, Inc) and collected after trypsinization29. The cell pellet was 
washed two times with ice-cold 1X PBS and fixed with ice-cold 70% ethanol overnight at 
-20 °C. After that, the cells were washed once with ice-cold PBS and the second wash with 
ice-cold PBS-2% FBS. The cell pellet was re-suspended in 500μL propidium iodide 
(PI)/RNase staining solution (BD Biosciences) and 0.1% Triton x-100 for 30 min. at room 
temperature in the dark and analyzed within 1 h by flow cytometer (BD Accuri C6, Becton-
Dickinson, Mountain View, CA). Data were analyzed by MFLT32 software, and 10,000 
events with slow flow rate were recorded for each sample30’31. The cells were synchronized 
and treated with the most active analogs JA-28 for 24 hours, with vehicle-control as DMSO 
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Chapter 6 
6 General conclusion 
 
The goals and objectives of this study were achieved based on the drug discovery cycle. 
Various ormeloxifene analogs were studied and reviewed to determine their essential 
pharmacophores responsible for their anticancer activities. Studies have confirmed the 
significant pharmacophores of ormeloxifene including the phenolic group at C-7 of 
ormeloxifene skeleton which is responsible for active binding to estrogen receptors, and 
the pyrrolidine moiety at C-4 of ormeloxifene framework responsible for anti-estrogenic 
activities. The project started using structure base molecular design to assemble the 
ormeloxifene pharmacophores. The concept of bioisosterism was utilized to install various 
functionalities at C-3, C-4, C-7 and para position of the aromatic ring at C-3.  
The first set of analogs were prepared by incorporating moieties such as halogens, electron 
donating and electron withdrawing groups para to 3-phenyl-2H-chromen position without 
altering the rest of ormeloxifene framework. Molecular modeling results revealed that the 
presence of electron donating group at the para position of the aromatic ring at C-3 elevated 
the binding affinity in the crystal structure of EGFR. ORM-CH3 exhibited stronger 
hydrophobic interaction in the EGFR binding pocket. Electron withdrawal moieties at the 
same para position also resulted in significant hydrophobic interaction inside EGFR 
binding pocket. Compounds that exhibited that binding affinity are ORM-F, ORM-Cl, 
ORM-Br, ORM-I, and ORM-CH3 and were identified as most effective EGFR inhibitors. 
Para substituted analogs were predicted to have higher binding affinity in EGFR binding 
site relative to meta and ortho-substituted analogs. 
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Meanwhile, ORM-Br and ORM-F exhibited significant hydrogen bond with Glu-234: A 
in Akt kinase binding pocket via the nitrogen on the pyrrolidine moiety.  Analogs such as 
ORM-Br, ORM-F, and ORM-I formed higher binding affinity in the hydrophobic pocket 
of Akt binding pocket. In the GSK3B structure, ORM-Br and ORM-I formed hydrogen 
bonding with ASP:200: B as well as the formation of hydrophobic interactions compared 
to ormeloxifene. 
Biological assays including, western blot analysis, MTT cell cytotoxicity assay were 
conducted on the analogs to study the mechanism of action of these compounds towards 
ovarian cancer cell lines.  It is interesting to note that, ORM-Br showed stronger 
cytotoxicity on ovarian cancer cell line with an IC50 value of 11.2 µM towards ovarian 
cancer cell line (A2780), a value lower than that of ormeloxifene. But ORM-F and ORM-
CH3 lost their cytotoxicity on ovarian cancer cell lines. There was a complete loss of 
cytotoxicity in analogs such as ORM-Cl, ORM-I, and ORM-OH. These results showed 
that ORM-Br has significant cytotoxic activity on ovarian cancer cell lines. Anti-
proliferation mechanism by western blot analysis on cervical cancer cell lines showed a 
significant decrease in protein levels of β-catenin in CaSki and SiHa cells compared to 
cycloheximide. ORM-Br also suppressed the clonogenic potential, inhibits the migration 
and suppresses the invasion of cervical cancer cell lines. This compound also decreases the 
expression of nuclear β-catenin in the cytoplasm of cervical cancer cell lines after 
subjecting to western blot analysis to determine the protein levels of β-catenin. Further 
investigation revealed that ORM-Br inhibits the EMT associated markers in both CaSki 
and SiHa cell lines.  
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The second set of analogs were designed by switching the pyrrolidine side chain to C-7 of 
ormeloxifene skeleton and substitute electron donating, withdrawing and other functional 
substituents at phenoxy position. The third set of analogs were prepared by introducing 
moieties such as 4-(3-hydroxypropyl) phenol and (E)-4-(3-hydroxyprop-1-en-1-yl) phenol 
at C-7 and phenol, methoxy, aniline, anisole, and trifluoromethoxy benzene at C-4. 
 Docking results revealed such as JA_31, JA_29, JA_30, JA_33, and JA_24 exhibited 
higher binding affinity in EGFR pocket by forming a hydrogen bond with HIS:84: A the 
same amino acid that bond to ormeloxifene in EGFR binding site. Also, analogs with 
(ethyl)pyrrolidine side chain at C-7 of Ormeloxifene scaffold such demonstrated an 
outstanding binding affinity by forming hydrogen bonding with ASP:292: A and 
THR:291: A in EGFR pocket. Analogs with (ethyl) pyrrolidine side chain at C-7 of 
Ormeloxifene skeleton such (JA_20, JA_25 JA_15, JA_18, JA_19, and JA_17) showed 
both hydrophilic and hydrophobic interactions in GSK3B binding site. In GSK3B binding 
pocket, analogs with (ethyl) pyrrolidine side chain at C-7 of Ormeloxifene frameworks 
such as JA_20, JA_25 JA_15, JA_18, JA_19, and JA_17 showed both hydrophilic and 
hydrophobic interactions. Meanwhile, the introduction of trifluoromethoxy benzene at C-
4 of ormeloxifene skeleton showed higher binding affinity by forming hydrogen bonds 
with   LYS:85: B and ASP:200: B in GSK3B binding pocket. The higher binding affinity 
of these analogs is attributed to the direct interaction of fluorine with protein or indirectly 
by influencing the polarity of other moieties that interacts with the protein. Molecular 
modeling results in the CDK2 binding site revealed higher binding mode in analogs with 
trifluoromethoxy moiety C-4 and (ethyl) pyrrolidine groups at C-7. JA_15, JA_16, JA_17, 
and JA_18 exhibited hydrogen bond with HIS:84: A, the same amino acid in CDK2 pocket 
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that ormeloxifene binds to induce its anticancer activity. Considering the overall binding 
affinity in CDK2 binding site, JA_15, an unsubstituted analog showed an outstanding 
binding affinity towards CDK2 binding site compares to similar analogs with halogens 
substituted at the para position of the aromatic ring at C-3.  
Biological evaluation of these analogs was conducted using MTT cell viability assay 
revealed that JA_15, JA_17, JA_31, JA_28, JA_16, JA_20, JA_22, JA_23, JA_24, 
JA_18, JA_19, JA_25, and JA_27 inhibits the viability of A2780 cells in a dose-dependent 
manner. The IC50 of JA_15, JA_17, JA_31, JA_28, JA_16, JA_20, JA_22, JA_23, 
JA_24, JA_18, JA_19, JA_25 and JA_27 were 9.0µM, 20.4µM, 44.6µM, 17.6µM, 
37.6µM, 74.8µM, 58.9µM, 89.0µM, 65.7µM, 74.9µM, 36.2µ, 85.6µM and 63.7µM 
respectively. However, analogs such as JA_29, JA_32, JA_33, JA_34, and JA_35 
completely lost their activities towards (A2780) ovarian cancer cell lines. Among all the 
synthesized analogs, JA_15 exhibited higher inhibitory activity with IC50 of 9.0µM, a value 
twice lower than the reference compound, however, the substitution of halogen at the para 
position of the aromatic ring at C-3 negatively affected the overall inhibitory activity of the 
compound. Introduction of double bonds at the C-7 position of ormeloxifene resulted in 
higher inhibitory activity on ovarian cancer cell lines relative to similar analogs with no 
double bonds. Cell cycle analysis by flow cytometry showed that JA-15 and JA-28 arrest 
A2780 cells in the G0 – G1 phase.  JA-15 exhibited an increased in the fraction of cells in 
the G0-G1 phase with 61.98% compared to the control with 53.42%.   JA-28, however, 
exhibited an increase in the fractions of cells in the G2-M phase with 8.74% relative to 
3.52% for control. The results confirmed that JA-15 has the potential to chemotherapeutic 
effects because it arrests (A2780) ovarian cell cycle in G0-G1 phase 
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This project offered potential analogs of ormeloxifene as a promising drug candidate for 
the treatment of ovarian cancer, however further studies are needed to elucidate the effects 
of these class of compounds in an animal model. 
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Appendix 
  Molecular docking protocol  
7 Design of virtual library 
   
The first step of creating a virtual library was done by drawing all the analogs with 
ChemDraw software, followed by copying all the compounds and paste in the Chem 3-D 
software and minimize their energies using MOPAC application, MMF94 to obtain relative 
crystal structure for each compound. Each file is named saved in pdb format and later 
combined into a single pdb file. Command prompt was used to execute this process by 
selecting start menu > accessories > command prompt then the folder where the pdb file of 
the ligands was copied to be used into single pdb file by writing the following: copy *pdb 
input_ligands_file.pdb (enter). The created pdb file can be opened using notepad as shown 
in fig A-1. 
 
 
 
 
7.1 Generating different conformers for each ligand 
 
Omega Application is a command that uses interface to create fast rigid exhaustive docking 
process. Omega uses the MMF94 force field to create different conformers for each ligand. 
The resultant file now in pdb.gz format was generated using the following inputs:  
1. Copy the combined pdb ligands 
2. Paste in OMEGA application. Application license is located at this place.  
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3. Use the following command to generate the conformers:  omega2.2.1 –in 
name.pdb-out newname.gz.pdb –includeinput –wartz (Enter). This created file is 
used in FRED calculation.  
 
Fig AP-1. Pdb file using the command prompt. 
7.2 Preparation of target receptor/protein  
 
To prepare a target receptor, Fred make receptor was utilized. Click on the file for the 
program to import the pdb file of the receptor downloaded from the protein data bank to 
show chains of proteins, water molecules any endogenous ligands and co-factors that may 
be present. Selection the ligands and proteins are important as it helps to create the grid 
box for docking calculations. The box size should be adjusted to 50,000 – 60,000 
Armstrong. The site shape is generated by choosing the shape mode to create the shape of 
the active site of the receptor that will be used for molecular docking. There are two types 
of active sites, the inner contours, and the outer contours. The receptor file is finally saved 
as oeb.gz (Fig AP-2). 
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Fig AP-2. Sample of the prepared grid box 
 
 
7.3 Fred docking calculations 
 
Fred calculation was performed by navigating through the files where Fred files and 
licensed are located. The following command lines were used to run the program: Fred.exe-
rec receptor.oeb.gz –dbase name.gz.pdb –prefix newname shapegauss –chemguass3 –
oechemscore –screenscore –plp –hitlist_size 5000 (enter). This command results in 
creating a consensus score, which calculates the binding affinity between the ligand and 
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the target receptors. Lower consensus score is an indication of higher binding affinity and 
vice versa (Table AP-3). 
 
Table AP-3. Sample of consensus score of FRED docking 
VIDA Name VIDA ID PLP Chemgauss3 OEChemscore Screenscore 
Consensus 
Score 
JA_15_8 2 
-
62.1912 -98.9223 -50.9355 -161.426 4 
JA_23_65 3 
-
63.1604 -85.4124 -53.3115 -148.521 9 
JA_18_194 4 
-
55.5819 -94.061 -49.7552 -156.399 15 
JA_31_197 5 
-
58.7091 -78.7798 -50.6628 -138.252 31 
ORM_Me_70 6 
-
58.9203 -88.0918 -48.9543 -130.846 31 
JA_17_124 7 
-
60.2571 -82.0704 -46.9993 -151.993 33 
JA_30_136 8 
-
54.9044 -82.1141 -49.7006 -133.778 34 
JA_20_91 9 
-
55.1979 -82.9193 -52.6244 -128.111 34 
JA_29_196 10 
-
56.4896 -74.7738 -51.4356 -136.43 37 
JA_22_18 11 
-
57.7173 -76.0436 -49.6441 -141.795 38 
JA_24_136 12 
-
54.9044 -82.1141 -49.7006 -133.778 38 
JA_16_118 13 
-
50.2681 -89.5709 -47.0727 -145.829 41 
JA_19_43 14 
-
51.9849 -86.1558 -49.8197 -128.74 41 
JA_33_173 15 
-
52.6577 -80.5097 -48.3041 -139.799 43 
JA_35_136 16 
-
49.7391 -81.7393 -46.085 -134.599 58 
JA_25_26 17 -52.629 -76.5679 -47.4447 -128.804 63 
JA_28_130 18 
-
52.1154 -73.6299 -49.4652 -122.123 65 
JA_26_58 19 
-
50.8557 -75.0371 -48.8462 -128.441 65 
JA_32_166 20 
-
49.3175 -79.5876 -48.1438 -121.453 68 
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JA_34_4 21 
-
48.3862 -71.7791 -48.2779 -130.937 69 
ORM_188 22 
-
46.7276 -86.295 -45.0742 -110.072 69 
JA_27_4 23 
-
48.3862 -71.7791 -48.2779 -130.937 73 
ORM_F_106 24 -54.664 -70.7967 -42.5575 -119.368 79 
ORM_Cl_107 25 
-
46.5579 -78.3947 -41.5806 -103.429 86 
ORM_Br_166 26 
-
36.8834 -79.3884 -41.2741 -92.8488 87 
ORM_I_109 27 
-
30.6345 -79.4347 -40.6518 -85.7905 89 
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7.4 Visualization of docking results using VIDA 
  
The final stage of molecular docking is where VIDA application is utilized to visualize 
the 3D structure of all docked analogs and potential binding interactions inside the target 
receptor.  
 
Fig AP-3. VIDA Visualization in 3D 
  
 
